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A B S T R A C T
Background
Increasing numbers of incidental pancreatic lesions are being detected each year. Accurate characterisation of pancreatic lesions into
benign, precancerous, and cancer masses is crucial in deciding whether to use treatment or surveillance. Distinguishing benign lesions
from precancerous and cancerous lesions can prevent patients from undergoing unnecessary major surgery. Despite the importance of
accurately classifying pancreatic lesions, there is no clear algorithm for management of focal pancreatic lesions.
Objectives
To determine and compare the diagnostic accuracy of various imaging modalities in detecting cancerous and precancerous lesions in
people with focal pancreatic lesions.
Search methods
We searched the CENTRAL, MEDLINE, Embase, and Science Citation Index until 19 July 2016. We searched the references of
included studies to identify further studies. We did not restrict studies based on language or publication status, or whether data were
collected prospectively or retrospectively.
Selection criteria
We planned to include studies reporting cross-sectional information on the index test (CT (computed tomography), MRI (magnetic
resonance imaging), PET (positron emission tomography), EUS (endoscopic ultrasound), EUS elastography, and EUS-guided biopsy
or FNA (fine-needle aspiration)) and reference standard (confirmation of the nature of the lesion was obtained by histopathological
examination of the entire lesion by surgical excision, or histopathological examination for confirmation of precancer or cancer by
biopsy and clinical follow-up of at least six months in people with negative index tests) in people with pancreatic lesions irrespective of
language or publication status or whether the data were collected prospectively or retrospectively.
Data collection and analysis
Two review authors independently searched the references to identify relevant studies and extracted the data. We planned to use the
bivariate analysis to calculate the summary sensitivity and specificity with their 95% confidence intervals and the hierarchical summary
receiver operating characteristic (HSROC) to compare the tests and assess heterogeneity, but used simpler models (such as univariate
random-effects model and univariate fixed-effect model) for combining studies when appropriate because of the sparse data. We were
unable to compare the diagnostic performance of the tests using formal statistical methods because of sparse data.
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Main results
We included 54 studies involving a total of 3,196 participants evaluating the diagnostic accuracy of various index tests. In these 54
studies, eight different target conditions were identified with different final diagnoses constituting benign, precancerous, and cancerous
lesions. None of the studies was of high methodological quality. None of the comparisons in which single studies were included was of
sufficiently high methodological quality to warrant highlighting of the results. For differentiation of cancerous lesions from benign or
precancerous lesions, we identified only one study per index test. The second analysis, of studies differentiating cancerous versus benign
lesions, provided three tests in which meta-analysis could be performed. The sensitivities and specificities for diagnosing cancer were:
EUS-FNA: sensitivity 0.79 (95% confidence interval (CI) 0.07 to 1.00), specificity 1.00 (95% CI 0.91 to 1.00); EUS: sensitivity 0.95
(95% CI 0.84 to 0.99), specificity 0.53 (95% CI 0.31 to 0.74); PET: sensitivity 0.92 (95% CI 0.80 to 0.97), specificity 0.65 (95% CI
0.39 to 0.84). The third analysis, of studies differentiating precancerous or cancerous lesions from benign lesions, only provided one
test (EUS-FNA) in which meta-analysis was performed. EUS-FNA had moderate sensitivity for diagnosing precancerous or cancerous
lesions (sensitivity 0.73 (95% CI 0.01 to 1.00) and high specificity 0.94 (95% CI 0.15 to 1.00), the extremely wide confidence intervals
reflecting the heterogeneity between the studies). The fourth analysis, of studies differentiating cancerous (invasive carcinoma) from
precancerous (dysplasia) provided three tests in which meta-analysis was performed. The sensitivities and specificities for diagnosing
invasive carcinoma were: CT: sensitivity 0.72 (95%CI 0.50 to 0.87), specificity 0.92 (95%CI 0.81 to 0.97); EUS: sensitivity 0.78 (95%
CI 0.44 to 0.94), specificity 0.91 (95% CI 0.61 to 0.98); EUS-FNA: sensitivity 0.66 (95% CI 0.03 to 0.99), specificity 0.92 (95% CI
0.73 to 0.98). The fifth analysis, of studies differentiating cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous
(low- or intermediate-grade dysplasia) provided six tests in which meta-analysis was performed. The sensitivities and specificities for
diagnosing cancer (high-grade dysplasia or invasive carcinoma) were: CT: sensitivity 0.87 (95% CI 0.00 to 1.00), specificity 0.96 (95%
CI 0.00 to 1.00); EUS: sensitivity 0.86 (95% CI 0.74 to 0.92), specificity 0.91 (95% CI 0.83 to 0.96); EUS-FNA: sensitivity 0.47
(95% CI 0.24 to 0.70), specificity 0.91 (95% CI 0.32 to 1.00); EUS-FNA carcinoembryonic antigen 200 ng/mL: sensitivity 0.58 (95%
CI 0.28 to 0.83), specificity 0.51 (95% CI 0.19 to 0.81); MRI: sensitivity 0.69 (95% CI 0.44 to 0.86), specificity 0.93 (95% CI 0.43 to
1.00); PET: sensitivity 0.90 (95% CI 0.79 to 0.96), specificity 0.94 (95% CI 0.81 to 0.99). The sixth analysis, of studies differentiating
cancerous (invasive carcinoma) from precancerous (low-grade dysplasia) provided no tests in which meta-analysis was performed. The
seventh analysis, of studies differentiating precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma)
from precancerous (low-grade dysplasia) provided two tests in which meta-analysis was performed. The sensitivity and specificity for
diagnosing cancer were: CT: sensitivity 0.83 (95% CI 0.68 to 0.92), specificity 0.83 (95% CI 0.64 to 0.93) and MRI: sensitivity 0.80
(95% CI 0.58 to 0.92), specificity 0.81 (95% CI 0.53 to 0.95), respectively. The eighth analysis, of studies differentiating precancerous
or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) from precancerous (low-grade dysplasia) or benign lesions
provided no test in which meta-analysis was performed.
There were no major alterations in the subgroup analysis of cystic pancreatic focal lesions (42 studies; 2086 participants). None of the
included studies evaluated EUS elastography or sequential testing.
Authors’ conclusions
Wewere unable to arrive at any firm conclusions because of the differences in the way that study authors classified focal pancreatic lesions
into cancerous, precancerous, and benign lesions; the inclusion of few studies with wide confidence intervals for each comparison; poor
methodological quality in the studies; and heterogeneity in the estimates within comparisons.
P L A I N L A N G U A G E S U M M A R Y
Accuracy of different imaging techniques for determining whether a pancreatic tumour is cancerous
Background
The pancreas is an organ in the abdomen that secretes pancreatic juice, which aids digestion and contains cells that produce important
hormones such as insulin. Increasingly, abnormalities in the pancreas are noted in people undergoing routine scans, such as ultrasound
or computed tomography (CT) scans, in the form of what are known as ’shadows’, which may be described as focal pancreatic lesion,
pancreatic mass, pancreatic tumour, pancreatic cyst, or pancreatic nodule. A significant proportion of focal pancreatic lesions are benign
(non-cancerous) lesions requiring no treatment. Surgical removal of the tumour is the main method of treatment for precancerous (i.e.
focal pancreatic lesions that are not full-blown cancer and do not have the ability to spread like cancer, but can turn into cancer) and
cancerous focal pancreatic lesions. Newmethods are being developed for treating precancerous lesions, such as using heat to destroy the
tumour. Surgical removal remains the only potentially curative treatment for people with limited pancreatic cancer. It is thus important
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to characterise whether a focal pancreatic lesion is non-cancerous, precancerous, or cancerous. A number of scans are available for
characterising the nature of the focal pancreatic lesion, which include the following.
• Computed tomography (CT) scan: a series of X-rays taken from different angles, which are then reconstructed using a computer.
• Magnetic resonance imaging (MRI): the use of a powerful magnet to produce images of different tissues of the body.
• Positron emission tomography (PET): the use of a small amount of radioactive glucose (sugar) to differentiate between different
tissues. It takes advantage of the tendency of cancer cells to use more glucose than normal cells.
• Endoscopic ultrasound (also known as endosonography or EUS): the use of an endoscope, a camera introduced into a body cavity to
view the inside of the body. An ultrasound (high-energy sound waves) probe at the end of the endoscope is used to differentiate tissues.
• EUS elastography: this measures the stiffness of the lesion, which is used to identify whether the lesion is cancerous.
• EUS-guided biopsy: the removal of cells or tissues for examination under a microscope or to perform other tests on the cells or tissue.
At present it is unclear how effective different scans are in characterising focal pancreatic lesions.
Study characteristics
We performed a thorough literature search for studies reporting the accuracy of different scans until 19 July 2016. We identified 54
studies reporting information on 3196 people with focal pancreatic lesions. These studies evaluated one or more of the above tests and
compared these test results with the eventual diagnosis provided by surgical removal of the lesion and examination under microscope.
There were no diagnostic test accuracy studies of EUS elastography or studies that looked at multiple scans rather than single scans.
Key results
Variations in how studies defined precancerous and cancerous lesions meant that we were not able to combine the data to provide the
overall results for many tests. We were unable to arrive at any firm conclusions for the following reasons.
• The way that study authors classified focal pancreatic lesions into cancerous, precancerous, and benign lesions was not consistent in
different studies.
• The studies included few participants, leading to significant uncertainty in the results.
• The studies were of poor methodological quality, which introduced additional uncertainty in the results.
• Even among the studies that classified focal pancreatic lesions into cancerous, precancerous, and benign lesions in a similar manner,
the results were not consistent.
Quality of evidence
All of the studies were of low methodological quality, which may result in arriving at false conclusions.
B A C K G R O U N D
(Please see the glossary in Appendix 1 for terms that have not been
described in the main text.)
A ’shadow’ identified in the pancreas on imaging may be variously
described as a focal pancreatic lesion, pancreatic mass, pancreatic
tumour, pancreatic cyst, or pancreatic nodule. This phrasing refers
to focal lesions, as opposed to diffuse changes of the pancreas, and
includes solid and cystic lesions of the pancreas. In the Western
world, the prevalence of focal pancreatic lesions is approximately
1.2% and is increasing steadily (by approximately 8%) each year,
with smaller and asymptomatic lesions being identified more fre-
quently (Gaujoux 2011; Spinelli 2004). An incidental pancreatic
lesion is one that is detected in the pancreas of a patient who un-
dergoes radiological investigations for an unrelated medical con-
dition (Sachs 2009). Such asymptomatic incidental lesions repre-
sent 55% to 60% of pancreatic tumours (Gaujoux 2011; Spinelli
2004). Some focal pancreatic lesionsmay be associated with symp-
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toms, depending upon their size and nature. The symptoms of
pancreatic cancer, which generally refers to pancreatic adenocarci-
noma, can include obstructive jaundice (yellowish discolouration
of the skin and the whites of the eyes with dark urine and pale stool
due to blockage of bile duct (National Cancer Institute 2011a), a
tube that transports the bile from the liver), loss of appetite, and
abdominal pain (Holly 2004). The symptoms of pancreatic neu-
roendocrine tumours (tumours arising from cells that secrete hor-
mones), some of which may be cancer, are related to the excessive
secretion of hormones (by the tumour) such as insulin, glucagon,
gastrin, somatostatin, and vasoactive peptide resulting in hypogly-
caemia (decreased blood sugar), hyperglycaemia (increased blood
sugar, a rare cause of diabetes), and gastrointestinal disturbances
such as peptic ulcer and diarrhoea (Batcher 2011). The symptoms
of chronic pancreatitis (chronic inflammation of the pancreas that
can result in alteration in the structure and function of the pan-
creas) are abdominal and back pain and those symptoms related to
pancreatic insufficiency, which include steatorrhoea, malabsorp-
tion, vitamin deficiency, diabetes, or weight loss (Braganza 2011;
Nair 2007). About 40% of people with focal pancreatic lesions
have chronic pancreatitis (Spinelli 2004). In the remaining 60%
of people with focal pancreatic lesions, the remaining pancreas is
normal.
Focal pancreatic lesions can be benign (serous pancreatic cys-
tadenoma, acinar cell cystadenoma, papillary cysts, lymphoep-
ithelial cysts, simple cysts), precancerous (intraductal papillary
mucinous neoplasm (IPMN) with dysplasia but without inva-
sive cancer, mucinous cystic neoplasm (MCN), benign neuroen-
docrine tumours), or cancer (ductal adenocarcinoma, acinar cell
carcinoma, IPMN with invasive carcinoma, cystadenocarcinoma,
pancreatoblastoma, solid pseudo-papillary neoplasm, cancer neu-
roendocrine tumours) (Luttges 2011; Sachs 2009; Spinelli 2004;
WHO 2016). Dysplasia can be low grade, intermediate grade, or
high grade (WHO 2016). About 80% of benign lesions, 50% of
precancerous lesions, and 20% of cancerous lesions are asymp-
tomatic (Spinelli 2004). Focal pancreatic lesions can be solid or
cystic or mixed solid and cystic tumours (Cho 2011).
Surgical resection is generally considered to be the only curative
treatment for pancreatic cancer. Worldwide, only 15% to 20% of
people with pancreatic cancer undergo potentially curative resec-
tion (Conlon 1996; Engelken 2003; Katz 2009; Michelassi 1989;
Shahrudin 1997; Smith 2008). In the remaining patients, the can-
cers are not resected because of infiltration of local structures or
disseminated disease. Early diagnosis of pancreatic cancer might
enable resection of the pancreatic cancer before it is too late to
resect. Pancreatic resection is a major surgery, with an approxi-
mately 1% to 25% risk of perioperative death reported worldwide
(Conlon 1996; Katz 2009;Michelassi 1989; Shahrudin 1997; van
Oost 2006).High-volume centres show a lower perioperativemor-
tality of less than 5% compared to low-volume centres, which are
associated with a perioperative mortality of up to 25% (Gurusamy
2013; van Oost 2006). Pancreatic resection is also associated with
an about 40% morbidity rate (Gurusamy 2013; van der Gaag
2010). Only 5% to 25% of patients survive for five years (Conlon
1996; Katz 2009; Michelassi 1989; Shahrudin 1997). Surgery is
generally offered if there are features suggestive of precancerous
or cancerous lesions (Lee 2005c), although some clinicians pre-
fer sequential follow-up (by imaging) of precancerous lesions to
surgical resection (Irie 2004). Surgery is offered when there is an
increase in the size or morphology (the way the lesion appears) of
the lesion in sequential imaging (Gaujoux 2011). Surgery is also
offered when there is considerable uncertainty as to the nature of
the lesion. In some ways, surgery can be considered as a diagnostic
test for characterisation of the lesion and as a treatment for peo-
ple with cancerous and precancerous lesions. Histological confir-
mation of the lesion by percutaneous biopsy is generally not per-
formed because of difficulty in accessing the lesion percutaneously
and because of dissemination of cancer cells.
Target condition being diagnosed
1. Cancerous versus benign or precancerous lesions.
2. Precancerous or cancerous (including the type of cancerous
lesion) versus benign lesions.
Index test(s)
Computed tomography (CT) scan
This involves a series of X-rays taken from different angles,
which are then reconstructed using a computer (National Cancer
Institute 2011a).Morphological features of the lesion, such as den-
sity, regularity of margins, vascularity, and the diameter of the pan-
creatic duct, are taken into account to characterise the lesion. The
main side effect of CT scan is the ionising radiation (radioactivity)
associated with it. Everyone is exposed to very small amounts of
radiation (background radiation). One CT scan of the abdomen
is equivalent to approximately three years of background radiation
(Fred 2004). In addition, the contrast material (dye used to view
the structures better) can cause allergic reactions, such as difficulty
breathing, or kidney damage, particularly in people with pre-ex-
isting kidney disease (Namasivayam 2006).
Magnetic resonance imaging (MRI)
This involves the use of a powerful magnet to produce images of
different tissues of the body. Magnetic resonance imaging is also
known as nuclear magnetic resonance imaging (NMRI) (National
Cancer Institute 2011b). Similar features as those employed inCT
scan are used to characterise the lesion. While MRI does not use
radiation, it is contraindicated in people with metallic implants
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such as artificial joints, those with cardiac pacemakers (devices
used to control heart rhythm), and those with claustrophobia (fear
of closed spaces) (Dill 2008). Some of the contrasts used can also
cause kidney damage (Dill 2008).
Positron emission tomography (PET)
This involves the use of a small amount of radioactive glucose
(sugar) to differentiate between different tissues. It takes advantage
of the tendency of cancer cells to use more glucose than normal
cells. Positron emission tomography is also known as PET scan
(National Cancer Institute 2011c). Cancerous lesions appear as
areas of increased uptake. Positron emission tomography also uses
ionising radiation (Leide-Svegborn 2010). The radiation exposure
to one PET scan is similar to that in one CT scan of abdomen
(Fred 2004; Leide-Svegborn 2010).
Endoscopic ultrasound (EUS)
This involves the use of an endoscope, a camera introduced into
a body cavity to view the inside of the body. An ultrasound (high-
energy sound waves) probe at the end of the endoscope is used
to differentiate tissues. Endoscopic ultrasound is also known as
endosonography (National Cancer Institute 2011d). Features such
as echogenicity and regularity of margins are taken into account
and used to characterise the lesion. Complications following EUS
are rare and include perforation (Benson 2010; Niv 2011).
EUS elastography
This measures the stiffness of the lesion, which can be used to
identify whether the lesion is benign or cancerous (Iglesias-Garcia
2010). The complications associated with EUS elastography are
the same as with EUS.
EUS-guided biopsy
This is the removal of cells or tissues for examination by a pathol-
ogist. The pathologist may study the tissue under a microscope or
perform other tests on the cells or tissue. There are many different
types of biopsy procedures. The most common types include:
1. incisional biopsy, in which only a sample of tissue is
removed;
2. excisional biopsy, in which an entire lump or suspicious
area is removed; and
3. needle biopsy, in which a sample of tissue or fluid is
removed with a needle. When a wide needle is used the
procedure is called a core biopsy. When a thin needle is used the
procedure is called a fine-needle aspiration biopsy (FNAB)
(National Cancer Institute 2011e).
Because of the risk of dissemination from cancer, EUS-guided
biopsy is preferable to percutaneous (image-guided) biopsy (
Micames 2003). The examinations under the microscope used
may include the routine haemotoxylin and eosin stain for core
biopsy and special staining for FNAB (Mehta 2010). Immuno-
cytochemistry and proteomic profiling to identify the presence of
biomarkers in the tissue may also be used in the diagnosis (Cui
2009; Mehta 2010). A positive core biopsy can confirm cancer,
but a negative core biopsy cannot rule out cancer. Cytology results
are not quite as reliable as core biopsy as false-positive cytology
has been reported (Hancke 1984).
Complications associated with EUS-guided biopsy include those
associated with EUS as well as bleeding (Benson 2010; Niv 2011).
Of these index tests, the commonly available tests are CT scan
andMRI. The remaining tests (PET, EUS, EUS elastography, and
EUS-guided biopsy) are available in major tertiary centres only.
Clinical pathway
There is no standard algorithm in the diagnosis or management
of focal pancreatic lesions. The algorithm may vary from one cen-
tre to another and even within the same centre (Gaujoux 2011;
Goh 2006b). One possible diagnostic clinical pathway is shown in
Figure 1. As noted in Figure 1, an increase in the size of or change
of morphological features is one of the reasons that surgeons rec-
ommend surgical excision, as this may indicate that the lesion was
malignant in the first instance (without features suggestive of ma-
lignancy in the original scan) or has transformed into a malig-
nant lesion. The interval for sequential scans is variable. Our local
protocol advises sequential scanning in one year in the absence
of malignant features. It is important to distinguish whether the
focal pancreatic lesion is benign with no cancer potential so that
unnecessary surgery and anxiety can be avoided. It is also impor-
tant to know whether the lesion is precancerous or cancerous so
that an informed decision about surgery can be made after weigh-
ing the potential benefits and harms. In addition, new alternative
treatments such as radiofrequency ablation (destruction of tissue
using radiofrequency waves) are being evaluated for precancerous
lesions (Pereira 2015). It is also necessary to differentiate the dif-
ferent types of cancer, since different malignancies carry different
prognoses (Klempnauer 1995). Some surgeons follow the single-
test strategy, that is making decisions based on the features of the
lesion in a single test, while others follow repeated testing (repeat-
ing the imaging modality or using a different imaging modality),
particularly if the nature of the lesion is indeterminate. The op-
timal interval between the tests in the repeated-testing strategy is
unknown.
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Figure 1. Clinical pathway.Abbreviations:Ca 19-9: carbohydrate antigen 19-9CT: computed
tomographyEUS: endoscopic ultrasoundMRI: magnetic resonance imagingPET: positron emission tomography
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Prior test(s)
The tests that occur prior to pancreatic imaging depend on how
the patient presents. The investigation may be targeted if the pa-
tient presents with abdominal symptoms, however it is equally
possible that the pancreatic lesion is an incidental finding on an
abdominal scan for an alternative reason. As pancreatic cancer is
relatively late presenting (Porta 2005), the number of incidental
lesions found will be high comparative to other cancers where
symptoms will primarily drive discovery. Whilst CT, MRI, and
PET may identify incidental lesions, EUS and EUS-guided fine-
needle aspiration (EUS-FNA) are the likely second test for known
lesions of symptomatic individuals.
Role of index test(s)
All of the index tests described are used primarily to characterise
pancreatic lesions as either benign or cancerous, or more impor-
tantly as needing significant or more conservative treatment. The
location of the pancreas makes percutaneous biopsy dangerous
because of the risk of cancer spread, therefore determination of
cancer stage and consequently required treatment must be made
non-invasively by the imaging techniques and by EUS-FNA.
Alternative test(s)
Computed tomography is usually part of a standard algorithm for
assessing focal pancreatic lesions (Gaujoux 2011). If the incidental
lesion is detected on CT scan, then CT scan can be the only in-
vestigation, since the added value of the other tests is not known.
One or more of the above tests may be used in addition to, or in-
stead of, CT scan. Diagnostic laparoscopy and laparoscopic ultra-
sound are other tests that may be used in the differential diagnosis
of focal pancreatic lesions; however, these tests are not used rou-
tinely. Serum carbohydrate antigen 19-9 (CA 19-9) is a substance
released into the bloodstream by both cancer cells and normal cells
and is used as a type of tumour marker (National Cancer Institute
2011f). Excessive CA 19-9 in the blood can be a sign of pancreatic
cancer or other types of cancer or conditions. The amount of CA
19-9 in the blood can be used to measure how effective cancer
treatments are or if cancer has returned. It can be used in conjunc-
tion with other imaging modalities in the assessment of the focal
pancreatic lesion.
Rationale
The various imaging modalities use different methods to differen-
tiate normal and diseased tissues. Endoscopic ultrasound is closer
to the tissues and therefore high-frequency ultrasound waves can
be used, which have better resolution but poorer penetration than
an external ultrasound. Image-guided biopsy can be performed
and the tissue can be examined under the microscope to differen-
tiate between types of focal pancreatic lesion.
Accurate characterisation of lesions will help in patient manage-
ment. Patients with cancerous lesions will be offered surgery if
there is no distant spread of cancer and assuming they are fit for
major surgery. Patients with cancerous lesions who are not eligible
for surgery because of distant spread of cancer or lack of fitness for
major surgery will be offered other treatments such as chemother-
apy. Patients with precancerous lesions may also undergo surgery
or ablation depending upon the clinician and patient preferences.
Unnecessary major surgery can be avoided in patients with benign
lesions.
There is currently no Cochrane review of studies assessing the di-
agnostic accuracy of different imagingmodalities in the assessment
of focal pancreatic lesions.
O B J E C T I V E S
To determine and compare the diagnostic accuracy of various
imaging modalities in detecting cancerous and precancerous le-
sions in people with focal pancreatic lesions.
Secondary objectives
We planned to explore the following sources of heterogeneity.
1. Studies at low risk of bias versus those at unclear or high
risk of bias (as assessed by the revised Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) tool as recommended
by the Cochrane Screening and Diagnostic Tests Methods
Group) (Whiting 2006). In particular, we considered the studies
classified as ’yes’ for the items differential verification, un-
interpretable results, and withdrawals as the most important
sources of heterogeneity.
2. Full-text publications versus abstracts (this might be
indicative of publication bias, since there may be an association
between the results of the study and the study reaching full
publication) (Eloubeidi 2001).
3. Prospective studies versus retrospective studies.
4. Different types of reference standard.
5. Symptomatic versus asymptomatic lesions (the presence of
symptoms may increase the pre-test probability).
6. Solid versus cystic lesions (as the diagnostic accuracy of the
imaging modalities may vary depending upon whether the lesion
is solid or cystic).
7. Participants with chronic pancreatitis versus those without
chronic pancreatitis.
8. Different criteria used by the authors to classify the lesions.
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9. Single imaging versus sequential imaging (repeated
imaging).
10. Different intervals of sequential imaging (e.g. imaging every
six months versus annual review).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies reporting on cross-sectional information of
the index test and reference test in the appropriate patient pop-
ulation (see below), irrespective of language or publication status
or whether the data were collected prospectively or retrospectively.
However, we excluded case series in which only true-positive re-
sults or true-negative results were reported without any informa-
tion on the other participants who underwent the test.
Participants
Adults with focal pancreatic lesions.
Index tests
CT scan, MRI scan, PET scan, EUS, EUS elastography, and EUS-
guided biopsy either alone or in combination as replacement for
major surgery for diagnostic purposes.
We accepted the criteria stated by the authors to classify the le-
sion as benign, precancerous, and cancerous for different imaging
modalities.
There is no standard algorithm in the diagnosis or management
of focal pancreatic lesions. Other tests that may be used in the di-
agnosis of focal pancreatic lesions include diagnostic laparoscopy,
laparoscopic ultrasound, serum levels of CA 19-9, and surgical
resection (surgical resection may be considered diagnostic when
the diagnosis is uncertain after all other diagnostic modalities have
been attempted).
Target conditions
1. Benign versus precancerous and cancerous lesions
(including the type of cancerous lesion).
2. Benign and precancerous versus cancerous lesions.
Reference standards
We accepted the following reference standards.
• Histopathological examination of the entire lesion by
surgical resection (gold standard). This classified the lesion as
benign, precancerous, or cancerous.
• Histopathological examination (irrespective of how the
tissues were obtained for histopathological examination) in
people with positive test (for cancerous or precancerous lesions)
and clinical follow-up by a doctor (with or without sequential
follow-up with imaging but using appropriate criteria such as
metastases or confirmation of cancer by biopsy or death of
participants due to cancer) of all participants with negative test
for a period of at least six months and for a maximum period of
24 months. Until a definitive diagnosis is available, percutaneous
biopsy is generally avoided because of the fear of seeding of
cancer cells in potentially resectable cancers. As anticipated, the
tissues obtained for histopathological examination were obtained
from surgical resection. It is unlikely that patients with a low
likelihood for cancer based on clinical symptoms and signs and
test results (may include the results of index test) are subject to
surgery or biopsy. Even if a biopsy is performed in such patients,
a cancerous or precancerous lesion cannot be ruled out because
of sampling error. Consequently, such patients are usually
followed up clinically with sequential imaging. Pancreatic
adenocarcinoma will cause clinical deterioration or increase in
tumour size during a period of six months, and so we accepted
clinical follow-up or sequential follow-up imaging (irrespective
of the modality of the imaging) of all participants with a negative
biopsy or no biopsy for at least six months as one of the reference
standards. However, we accepted clinical follow-up as a reference
standard only when the criteria used for diagnosis were
appropriate (e.g. identification of metastases, later biopsy of the
lesion confirming the nature of the lesion, and death of
participants due to cancer). The choice of a maximum period of
24 months was an arbitrary choice based on the low probability
of precancerous lesions becoming cancerous during 24 months.
Clinical follow-up of patients is unlikely to classify precancerous
lesions correctly since patients are unlikely to develop metastases
or die within this interval.
Search methods for identification of studies
Electronic searches
We searched the following databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library (Issue 7, 2016) (Appendix
2).
2. MEDLINE via PubMed (January 1946 to 19 July 2016)
(Appendix 3).
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3. Embase via OvidSP (January 1947 to 19 July 2016)
(Appendix 4).
4. Science Citation Index Expanded via ISI Web of
Knowledge (January 1980 to 19 July 2016) (Appendix 5).
Searching other resources
We searched the references of included studies to identify further
studies (Horsley 2011). We also searched for additional articles
related to the included studies by performing the ’related search’
function inMEDLINE (PubMed) and Embase (OvidSP) and ’cit-
ing reference’ search (search the articles that cited the included ar-
ticles) in Science Citation Index Expanded and Embase (OvidSP)
(Sampson 2008).
Data collection and analysis
Selection of studies
Two review authors independently searched the references to iden-
tify relevant studies. We obtained the full text of references that
at least one of the review authors consider relevant and used these
full texts to further exclude irrelevant references.We selected refer-
ences to studies that met the inclusion criteria for data extraction.
Any differences in study selection were arbitrated by review author
BR Davidson.
Data extraction and management
Two review authors independently extracted the following data
from each included study.
• First author of report.
• Year of publication of report.
• Study design (prospective or retrospective; cross-sectional
studies or randomised clinical trials).
• Inclusion and exclusion criteria for individual studies.
• Total number of participants.
• Number of females.
• Mean age of the participants.
• Criteria used for classification of lesions.
• Preoperative tests carried out prior to index test.
• Index test.
• Reference standard.
• True positive (TP), false positive (FP), true negative (TN),
and false negative (FN) data.
Main analysis
The unit of analysis was the participant. We extracted the TP, FP,
TN, and FN information for each index test for the following
situations (when data were available).
1. Precancerous or cancerous lesions (positive test) versus
benign lesions with no cancer potential (negative test) (this helps
determine whether the patient needs further follow-up).
2. Cancerous lesions (positive test) versus non-cancerous
lesions (negative test) (this helps determine whether the patient
needs immediate surgery).
3. In the group of participants with precancerous or cancerous
lesions (i.e. those with positive test in the analysis of benign
lesions with no cancer potential (negative test) versus
precancerous or cancerous lesions (positive test)), we extracted
the TP, FP, TN, and FN information for cancerous lesions
(positive test) versus precancerous lesions (negative test) (this
helps in assessing whether or not surgery is appropriate; surgery
is the only curative option for cancerous lesions, while follow-up
may be an option for precancerous lesions).
We extracted the information on indeterminate results separately
from the TP, FP, TN, and FN data. There is no standard algo-
rithm of management of patients with indeterminate results in the
first scan. Some surgeons may recommend surgical resection for
indeterminate lesions, while others may advise additional scans or
sequential follow-up imaging. We therefore planned to perform a
sensitivity analysis as described in Sensitivity analyses.
For tests performed for sequential follow-up imaging (repeated-
testing strategy), we planned to extract the TP, FP, TN, and FN
data for the strategy as a whole. We considered increase in size or
change in the lesion on sequential follow-up imaging (performed
within 12 months) a positive index test. If the lesion remained
static (or decreased in size) without any change in the character-
istics of the lesion, we considered this a negative index test. The
majority of surgeons will recommend further follow-up imaging
or no follow-up if the sequential follow-up image shows no change
in the lesion, and there is no clinical deterioration for the com-
parison between precancerous and cancerous lesions.We therefore
considered indeterminate results on sequential follow-up imaging
as negative results for this comparison.
We sought further information from study authors where neces-
sary. Any differences between the review authors were resolved by
discussion.
Assessment of methodological quality
Two review authors independently assessed the quality of the
studies using the QUADAS-2 assessment tool (Whiting 2006;
Whiting 2011). We resolved any differences in assessment using
the QUADAS-2 assessment algorithm published in the protocol.
We sought further information from the authors of the studies in
order to accurately assess themethodological quality of the studies.
We assessed the quality items derived from the QUADAS-2 tool
using the methodology stated in Table 1.
Statistical analysis and data synthesis
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We have plotted study estimates of sensitivity and specificity on
forest plots and in receiver operating characteristic (ROC) space to
explore between-study variation in the performance of each test.
To estimate the summary sensitivity and specificity of each test,
we planned to perform the meta-analysis by fitting the bivariate
model (Chu 2006; Reitsma 2005), which accounts for between-
study variability in estimates of sensitivity and specificity through
the inclusion of random effects for the logit sensitivity and logit
specificity parameters of the bivariate model. As there was lack of
convergence due to sparse data, we tried other alternate models
suggested by Takwoingi 2015 and colleagues. These included the
random-effects model, ignoring the inverse correlation between
sensitivities and specificities in the different studies due to intrinsic
threshold effect, and the fixed-effect model for either sensitivity
or specificity or both after visualising the forest plots and sum-
mary receiver operating characteristics (SROC) plots (Takwoingi
2015). We based our choice between the different models on the
distribution of sensitivities and specificities as noted in the forest
plots or ROC space. We also used the model fit as indicated by
the -2 log likelihood and considered the model with the lower -2
log likelihood to be the better model.
We planned to compare the diagnostic accuracy of the tests by
including covariate terms for test type (CT scan, MRI, PET, EUS,
EUS-FNA, EUS elastography) in the bivariate model to estimate
differences in the sensitivity and specificity of the tests.We planned
to allow both the sensitivity and specificity to vary by covariate. In
addition, we planned to permit the variances of the random effects
and their covariance to also depend on test type, thus allowing the
variances to differ between tests.Weplanned touse likelihood ratio
tests to compare the model with and without covariate (test type).
We planned to use a P value of less than 0.05 for the likelihood
ratio test to indicate differences in the diagnostic accuracy between
the tests. If studies that reported different tests in the same study
population were available from at least four studies, we planned
to perform a direct head-to-head comparison by limiting the test
comparison to such studies. We planned to calculate the relative
sensitivities and specificities for each pair-wise comparison of tests.
We performed the meta-analysis using the NLMIXED command
in SAS version 9.4 (SAS Institute Inc, Cary, NorthCarolina, USA)
(Takwoingi 2012). The post-test probabilities were calculated us-
ing these pre-test probabilities and the summary positive and nega-
tive likelihood ratios. We calculated the summary likelihood ratios
and their confidence intervals from the functions of the parameter
estimates from the model that we fitted to estimate the summary
sensitivities and specificities. Post-test probability associated with
a positive test is the probability of having the target condition (e.g.
precancer or cancer) on the basis of a positive test result (e.g. pos-
itive CT) and is the same as the term ’positive predictive value’
used in a single diagnostic accuracy study. Post-test probability
associated with a negative test is the probability of having the tar-
get condition (e.g. precancer or cancer) on the basis of a negative
test result (e.g. negative CT) and is 1 - ’negative predictive value’.
’Negative predictive value’ is the term used in a single diagnostic
accuracy study to indicate the chance that the participant has no
target condition when the test is negative. We have reported the
summary sensitivity, specificity, and post-test probabilities for the
median pre-test probabilities whenever possible.
Investigations of heterogeneity
We visually inspected forest plots of sensitivity and specificity and
the ROC curve to identify heterogeneity. We planned to explore
heterogeneity by using the different sources of heterogeneity as
covariates in the METADASmacro (Takwoingi 2012), but due to
the sparseness of the data wewere unable to do this.We planned to
assess whether there was a statistically significant difference in the
likelihood ratios in order to identify heterogeneity. Although we
did not formally compare the diagnostic test accuracy of different
index tests between solid and cystic lesions, we have presented a
subgroup analysis of solid and cystic lesions, since some clinicians
consider the diagnostic test accuracies to differ between the two.
Sensitivity analyses
In the presence of indeterminate results (for any reason) for the
initial test, we planned to consider two scenarios: the participants
with indeterminate results as positive for the test, as some surgeons
will recommend surgical resection for indeterminate lesions; and
the indeterminate results as negative for the test, as some surgeons
will recommend sequential follow-up imaging. We planned to
assess the diagnostic accuracy in both of these scenarios. However,
due to sparse data and few studies reporting indeterminate results
we did not perform the above.
We also planned to assess the comparative performance of tests
by direct comparison (i.e. the tests performed in the same partici-
pant) versus indirect comparison (the tests performed in different
participants across studies).
R E S U L T S
Results of the search
We identified 33,795 references through electronic searches of
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, and Science Citation Index. We were left
with 24,799 references after removing duplicate references. We
excluded 23,879 clearly irrelevant references through reading the
abstracts. We sought the full text for 920 references for further as-
sessment. We did not identify any additional references to studies
through other searches.We excluded 866 references for the reasons
described in the Characteristics of excluded studies tables. Fifty-
two studies (54 references) met the inclusion criteria. Two studies
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reported the diagnostic test data on solid and cystic lesions sepa-
rately (Brandwein 2001 - Cystic; Brandwein 2001 - Solid; Fischer
2009 - Cystic; Fischer 2009 - Solid)therefore, we considered them
as separate studies. We thus included a total of 54 studies in the
review (Brand 2000; Brandwein 2001 - Cystic; Brandwein 2001
- Solid; Cellier 1998; Choi 2003; Correa-Gallego 2009; de Jong
2012; Doi 2002; Erkan 2012; Fischer 2009 - Cystic; Fischer 2009
- Solid; Fisher 2008; Grieser 2010; Harrison 1999; Higashi 1997;
Hong 2010; Hu 2013; Jafarimehr 2010; Jang 2014a; Jang 2014b;
Jin 2013a; Jin 2015; Kalha 2003; Kamata 2016a; Kato 1995; Kim
2015; Klau 2011; Kobayashi 2012; Kubo 2001; Kucera 2012; Le
Baleur 2011a; Lee 2014; Maire 2008; McHenry 2002; Nakagawa
2009; Nara 2009; Ogawa 2008; Ogawa 2014; Otomi 2014; Pais
2007; Sahani 2006; Saito 2013; Salla 2007; Sedlack 2002; Smith
2016; Takanami 2011; Takeshita 2008; Tan 2009; Taouli 2000;
Tomimaru 2010; Yamao 2001; Zhan 2011; Zhan 2013). The ref-
erence flow diagram is shown in Figure 2.
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Figure 2. Study flow diagram.
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Characteristics of included studies
For a summary of the characteristics of included studies see the
Characteristics of included studies table.
We included a total of 54 studies involving 31,196 participants in
this systematic review. The studies reported investigation of eight
different target conditions:
• cancerous versus benign or precancerous lesions;
• cancerous versus benign lesions;
• precancerous or cancerous lesions versus benign lesions;
• cancerous (invasive carcinoma) versus precancerous
(dysplasia) lesions;
• cancerous (high-grade dysplasia or invasive carcinoma)
versus precancerous (low- or intermediate-grade dysplasia)
lesions;
• cancerous (invasive carcinoma) versus precancerous (low-
grade dysplasia) lesions;
• precancerous or cancerous (intermediate- or high-grade
dysplasia or invasive carcinoma) versus precancerous (low-grade
dysplasia) lesions; and
• precancerous or cancerous (intermediate- or high-grade
dysplasia or invasive carcinoma) versus precancerous (low-grade
dysplasia) or benign lesions.
The variation in target condition was due to different definitions
of what constitutes a benign, precancerous, and cancerous lesion.
For example, the World Health Organization pancreatic tumour
classification system classifies intraductal papillary mucinous neo-
plasms’ (IPMNs) as precancerous tumours regardless of dysplasia
(Luttges 2011). However, many of the included studies consid-
ered IPMNs to be benign lesions or even classified them as be-
nign or cancerous based on the grade of dysplasia. This meant
that the index tests were actually used for differentiating between
very different populations of cancerous and benign tumours, and
therefore the combination of all studies as simply cancer versus
benign would have been inappropriate. In addition, different sur-
geons will have different thresholds for recommending surgery.
Consequently, we have presented the results for all of the various
definitions used by authors to classify a lesion as benign, precan-
cerous, or cancerous.
Three studies reported data on tests differentiating cancerous from
benign or precancerous lesions. Of these three studies, one re-
ported the performance of EUS-FNA using cytology (McHenry
2002); another reported the performance of EUS-FNA using a
carcinoembryonic antigen (CEA) threshold of 500 ng/mL (Kalha
2003); and the third reported the performance of PET to dif-
ferentiate between benign or precancerous and cancerous lesions
(Jafarimehr 2010). The median pre-test probability of a cancer-
ous lesion in these studies was 0.625 or 62.5% (minimum 0.533,
maximum 0.711).
Twelve studies reported data on tests differentiating cancerous
from benign lesions. Of these 12 studies, two reported the perfor-
mance of EUS (Brand 2000; Harrison 1999); three reported the
performance of EUS-FNA (Brandwein 2001 - Cystic; Brandwein
2001 - Solid; Cherian 2010); three reported the performance of
PET (Erkan 2012; Higashi 1997; Kato 1995); one reported the
performance of PET with a standard uptake value (SUV) maxi-
mum of greater than 3.5 as its threshold for positivity (Hu 2013);
two reported the performance of CT (Grieser 2010; Harrison
1999); and one reported the performance of MRI to differentiate
between cancerous and benign lesions (Klau 2011). The median
pre-test probability of a cancerous lesion in these studies was 0.697
or 69.7% (minimum 0.231, maximum 0.889).
Six studies reported data on tests differentiating precancerous or
cancerous from benign lesions, with one study providing data for
multiple imaging modalities (Sedlack 2002). One study reported
the performance of EUS (Sedlack 2002); three studies reported the
performance of EUS-FNA (Fischer 2009 - Cystic; Fischer 2009 -
Solid; Sedlack 2002); one study reported the performance of EUS-
FNA using a CEA threshold of 50 ng/mL (Sedlack 2002); one
study reported the performance of PET with an SUV maximum
threshold of greater than 2.4 as its threshold for positivity (Otomi
2014); one study reported the performance of CT (Fisher 2008);
andone study reported the performance ofMRI (Jang 2014a). The
median pre-test probability of a precancerous or cancerous lesion
in these studies was 0.706 or 70.6% (minimum 0.519, maximum
0.75).
Twelve studies reported data on tests differentiating cancerous in-
vasive carcinomas from precancerous dysplastic lesions, with some
studies reporting the diagnostic test accuracy or more than one
index test. Five studies reported the performance of EUS (Cellier
1998; de Jong 2012; Nakagawa 2009; Yamao 2001; Zhan 2011);
three studies reported the performance of EUS-FNA (Jin 2015;
Pais 2007; Salla 2007); and one study reported the performance of
EUS-FNAusing a CEA threshold of 200 ng/mL (Maire 2008). Six
studies reported the performance of CT (Cellier 1998; Nakagawa
2009; Nara 2009; Ogawa 2008; Taouli 2000; Yamao 2001), and
one study reported the performance of MRI (de Jong 2012). The
median pre-test probability of a cancerous invasive carcinoma was
0.270 or 27% (minimum 0.122, maximum 0.618).
Eighteen studies reported data on tests differentiating cancerous
lesions defined by high-grade dysplasia or invasive carcinoma from
precancerous lesions with a low or intermediate grade of dysplasia,
with some studies reporting the diagnostic test accuracy or more
than one index test. Four studies reported the performance of
EUS (Doi 2002; Kobayashi 2012; Lee 2014; Yamao 2001). Three
studies reported the performance of EUS-FNA (Jin 2013a; Smith
2016; Zhan 2013). Three studies reported the performance of
EUS-FNA using a CEA threshold of 200 ng/mL (Correa-Gallego
2009; Kucera 2012; Maire 2008). One study reported the perfor-
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mance of EUS-FNA using a carbohydrate antigen 19-9 threshold
of greater than 1000 U/mL (Maire 2008). One study reported the
performance of EUS-FNA using a CEA threshold of 692.8 ng/mL
(Zhan 2013). Four studies reported the performance of PET with
an SUVmax value between 2 and 2.5 as their threshold for positiv-
ity (Hong 2010; Saito 2013; Takanami 2011; Tomimaru 2010).
Three studies reported the performance of CT (Hong 2010; Le
Baleur 2011a; Yamao 2001). Three studies reported the perfor-
mance of MRI (Jang 2014b; Kim 2015; Ogawa 2014). The me-
dian pre-test probability of a cancerous lesion defined by high-
grade dysplasia or invasive carcinoma in these studies was 0.449
or 44.9% (minimum 0.167, maximum 0.875).
Two studies reported data on tests differentiating cancerous inva-
sive carcinomas from precancerous lesions with a low grade of dys-
plasia. One study reported the performance of EUS (Kubo 2001),
and one study reported the performance of CT (Takeshita 2008).
The median pre-test probability of cancerous invasive carcinoma
in these studies was 0.214 or 21.4% (minimum 0.174, maximum
0.255).
Five studies reported data on tests differentiating precancerous or
cancerous lesions that may be moderately or highly dysplastic or
invasive carcinomas from precancerous lesions with a low grade of
dysplasia. Three studies reported the performance of CT (Ogawa
2008; Sahani 2006; Tan 2009), and two studies reported the per-
formance of MRI (Choi 2003; Sahani 2006). None of the studies
reported the diagnostic accuracy of EUS elastography or sequential
testing. The median pre-test probability of a cancerous lesion that
may be moderately or highly dysplastic or an invasive carcinoma
in these studies was 0.593 or 59.3% (minimum 0.574, maximum
0.68).
One study reported data on tests differentiating precancerous or
cancerous lesions that may be moderately or highly dysplastic or
invasive carcinomas from benign or precancerous lesions with a
low grade of dysplasia. This study reported the performance of
EUS. The median pre-test probability of a cancerous lesion that
may be moderately or highly dysplastic or an invasive carcinoma
in this study was 0.429 or 42.9%.
Forty-six studies were full-text publications (Brand 2000;
Brandwein 2001 - Cystic; Brandwein 2001 - Solid; Cellier 1998;
Cherian 2010; Choi 2003; Correa-Gallego 2009; de Jong 2012;
Doi 2002; Fisher 2008; Grieser 2010; Harrison 1999; Higashi
1997; Hong 2010; Hu 2013; Jang 2014a; Jang 2014b; Jin 2015;
Kamata 2016a; Kato 1995; Kim 2015; Klau 2011; Kobayashi
2012;Kubo 2001;Kucera2012; LeBaleur 2011a; Lee 2014;Maire
2008; Nakagawa 2009; Nara 2009; Ogawa 2008; Ogawa 2014;
Otomi 2014; Pais 2007; Sahani 2006; Saito 2013; Salla 2007;
Sedlack 2002; Smith 2016; Takanami 2011; Takeshita 2008; Tan
2009; Taouli 2000; Tomimaru 2010; Yamao 2001; Zhan 2013).
The remaining studies were abstracts (Erkan 2012; Fischer 2009
- Cystic; Fischer 2009 - Solid; Jafarimehr 2010; Jin 2013a; Kalha
2003; McHenry 2002; Zhan 2011). Three studies were prospec-
tive (Brand 2000; de Jong 2012; Erkan 2012); 39 were retro-
spective (Brandwein 2001 - Cystic; Brandwein 2001 - Solid;
Cellier 1998; Cherian 2010; Correa-Gallego 2009; Doi 2002;
Fisher 2008; Grieser 2010; Harrison 1999; Hong 2010; Hu 2013;
Jafarimehr 2010; Jang 2014a; Jang 2014b; Jin 2013a; Jin 2015;
Kalha 2003; Kamata 2016a; Kim 2015; Klau 2011; Kobayashi
2012; Kubo 2001; Kucera 2012; Lee 2014;Maire 2008;McHenry
2002; Nakagawa 2009; Ogawa 2008; Otomi 2014; Pais 2007;
Sahani 2006; Saito 2013; Salla 2007; Sedlack 2002; Smith 2016;
Takanami 2011; Taouli 2000; Zhan 2011; Zhan 2013); and 12
did not state whether they were prospective or retrospective (Choi
2003; Fischer 2009 - Cystic; Fischer 2009 - Solid; Higashi 1997;
Kato 1995; Le Baleur 2011a; Nara 2009; Ogawa 2014; Takeshita
2008; Tan 2009; Tomimaru 2010; Yamao 2001).
None of the studies reported data on symptomatic and asymp-
tomatic participants separately. Forty-two studies (2086 partici-
pants) reported on cystic pancreatic lesions (Brandwein 2001 -
Cystic; Cellier 1998; Choi 2003; Correa-Gallego 2009; de Jong
2012; Doi 2002; Fischer 2009 - Cystic; Fisher 2008; Hong 2010;
Hu 2013; Jang 2014a; Jang 2014b; Jin 2013a; Jin 2015; Kalha
2003; Kamata 2016a; Kim 2015; Kobayashi 2012; Kubo 2001;
Kucera 2012; Le Baleur 2011a; Lee 2014; Maire 2008; McHenry
2002; Nakagawa 2009; Nara 2009; Ogawa 2008; Ogawa 2014;
Pais 2007; Sahani 2006; Saito 2013; Salla 2007; Sedlack 2002;
Smith 2016; Takanami 2011; Takeshita 2008; Tan 2009; Taouli
2000; Tomimaru 2010; Yamao 2001; Zhan 2011; Zhan 2013).
Four studies reported on solid pancreatic lesions (Brandwein 2001
- Solid; Cherian 2010; Fischer 2009 - Solid; Klau 2011). The re-
maining eight studies either did not mention whether the lesions
were cystic or solid, or did not report this information separately
(Brand 2000; Erkan 2012; Grieser 2010; Harrison 1999; Higashi
1997; Jafarimehr 2010; Kato 1995; Otomi 2014). None of the
studies reported data on people with chronic pancreatitis sepa-
rately.
Overall, 12 studies reported data on EUS results (Brand 2000;
Cellier 1998; de Jong 2012; Doi 2002; Harrison 1999; Kamata
2016a; Kobayashi 2012; Kubo 2001; Lee 2014; Nakagawa 2009;
Sedlack 2002; Yamao 2001); 19 studies reported data on EUS-
FNA (Brandwein 2001 - Cystic; Brandwein 2001 - Solid; Cherian
2010; Correa-Gallego 2009; Fischer 2009 - Cystic; Fischer 2009
- Solid; Fisher 2008; Jin 2013a; Jin 2015; Kalha 2003; Kucera
2012;Maire 2008;McHenry 2002; Pais 2007; Salla 2007; Sedlack
2002; Smith 2016; Zhan 2011; Zhan 2013); 10 studies reported
data on PET (Erkan 2012; Higashi 1997; Hong 2010; Hu 2013;
Jafarimehr 2010; Kato 1995; Otomi 2014; Saito 2013; Takanami
2011; Tomimaru 2010); 13 studies reported data on CT (Cellier
1998;Grieser 2010;Harrison 1999;Hong 2010; Le Baleur 2011a;
Nakagawa 2009;Nara 2009;Ogawa 2008; Sahani 2006; Takeshita
2008; Tan 2009; Taouli 2000; Yamao 2001); and eight studies
reported data on MRI (Choi 2003; de Jong 2012; Jang 2014a;
Jang 2014b; Kim 2015; Klau 2011; Ogawa 2014; Sahani 2006).
The criteria for a positive test result varied widely by study and
are described in detail in Characteristics of included studies. The
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reference standards in all of the included studies was surgical ex-
cision.
Methodological quality of included studies
The methodological quality of the included studies is summarised
in Figure 3 and Figure 4. None of the included studies was of high
methodological quality.
Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 4. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Participant selection domain
In the participant selection domain, nine studies had a low risk of
bias (Cherian 2010; Correa-Gallego 2009; Fisher 2008; Kamata
2016a; Klau 2011; Nara 2009; Otomi 2014; Saito 2013; Salla
2007). All of the studies had high applicability concerns because of
concerns that the participants did not match the review question.
The review question was to find out the diagnostic accuracy of
these index tests in people with focal lesions. However, all of the
studiesmeeting the inclusion criteria for this review exceptCherian
2010 used surgical excision as the reference standard, suggesting
that the surgeons considered these patients to be at high risk of
malignancy based on the results of the index tests or the tests that
patients had prior to or subsequent to the index test. Cherian 2010
was also at high risk of applicability concern because it excluded
participants with resectable lesions on CT scan and included only
those equivocal lesions on CT scan.
Index test domain
In the index test domain, nine studies were at low risk of bias
(Correa-Gallego 2009;Hong 2010; Jang 2014b; Kim 2015; Kubo
2001; Nara 2009; Ogawa 2014; Tan 2009; Taouli 2000). Of the
remaining studies, 31 were at unclear risk of bias because it was
unclear whether the index test results were interpreted without
knowledge of the results of the reference standard (Brand 2000;
Brandwein 2001 - Cystic; Brandwein 2001 - Solid; Cellier 1998;
Choi 2003; Cherian 2010; de Jong 2012; Doi 2002; Erkan 2012;
Fischer 2009 - Cystic; Fischer 2009 - Solid; Fisher 2008; Harrison
1999; Jafarimehr 2010; Jin 2013a; Jin 2015; Kalha 2003; Kamata
2016a; Kato 1995; Kobayashi 2012; Kucera 2012; Le Baleur
2011a; McHenry 2002; Ogawa 2008; Pais 2007; Salla 2007;
Sedlack 2002; Smith 2016; Yamao 2001; Zhan 2011; Zhan 2013).
Fifteen studieswere at high risk of bias because the threshold for the
index test was not prespecified (Grieser 2010; Higashi 1997; Hu
2013; Jang 2014a; Klau 2011; Lee 2014; Maire 2008; Nakagawa
2009; Otomi 2014; Sahani 2006; Saito 2013; Takanami 2011;
Takeshita 2008;Tomimaru 2010;Zhan2013). Twenty-eight stud-
ies had low applicability concerns (Brand 2000; Brandwein 2001 -
Cystic; Brandwein 2001 - Solid; Cellier 1998; Choi 2003; Cherian
2010; Correa-Gallego 2009; de Jong 2012;Doi 2002;Hong 2010;
Hu 2013; Jang 2014b; Jin 2013a; Jin 2015; Kalha 2003; Kamata
2016a; Kim 2015; Kubo 2001; Le Baleur 2011a; Nara 2009;
Ogawa 2008;Ogawa 2014; Pais 2007; Sahani 2006; Sedlack 2002;
Smith 2016; Yamao 2001; Zhan 2013), and the remaining 27
studies had high applicability concerns because of concerns that
the index test, its conduct, or interpretation differed from the re-
view question (Erkan 2012; Fischer 2009 - Cystic; Fischer 2009 -
Solid; Fisher 2008; Grieser 2010; Harrison 1999; Higashi 1997;
Jafarimehr 2010; Jang 2014a; Kato 1995; Klau 2011; Kobayashi
2012; Kucera 2012; Lee 2014; Maire 2008; McHenry 2002;
Nakagawa 2009; Otomi 2014; Saito 2013; Salla 2007; Sedlack
2002; Takanami 2011; Takeshita 2008; Tan 2009; Taouli 2000;
Tomimaru 2010; Zhan 2011).
Reference standard domain
In the reference standard domain, three studies were at low risk of
bias (Correa-Gallego 2009; Grieser 2010; Hu 2013). Two studies
were at high risk of bias because the reference standard results
were not interpreted without knowledge of the index test results
(Pais 2007), or because radiological and clinical follow-up was
used in some of the participants as the reference standard. The
remaining 49 studies were at unclear risk of bias as it was unclear
if the reference standard was interpreted without knowledge of
the results of index tests (Brand 2000; Brandwein 2001 - Cystic;
Brandwein 2001 - Solid; Cellier 1998; Choi 2003; de Jong 2012;
Doi 2002; Erkan 2012; Fischer 2009 - Cystic; Fischer 2009 -
Solid; Fisher 2008; Harrison 1999; Higashi 1997; Hong 2010;
Jafarimehr 2010; Jang 2014a; Jang 2014b; Jin 2013a; Jin 2015;
Kalha 2003; Kamata 2016a; Kato 1995; Kim 2015; Klau 2011;
Kobayashi 2012; Kubo 2001; Kucera 2012; Le Baleur 2011a; Lee
2014; Maire 2008; McHenry 2002; Nakagawa 2009; Nara 2009;
Ogawa 2008; Ogawa 2014; Otomi 2014; Sahani 2006; Saito
2013; Salla 2007; Sedlack 2002; Smith 2016; Takanami 2011;
Takeshita 2008; Tan 2009; Taouli 2000; Tomimaru 2010; Yamao
2001; Zhan 2011; Zhan 2013). All studies were at low concern for
applicability, aswe considered the definitionof the target condition
by the reference standard to match the review question.
Flow and timing domain
None of the studies were at low risk of bias in the flow and timing
domain. Thirty studies were at high risk of bias because not all of
the participants were included in the analysis, or there was an in-
appropriate interval between the index test and reference standard
(Brand 2000; Brandwein 2001 - Cystic; Cellier 1998; Choi 2003;
Correa-Gallego2009; de Jong 2012;Doi 2002; Erkan2012;Hong
2010; Jang 2014a; Jang 2014b; Jin 2015; Kalha 2003; Kamata
2016a; Kato 1995; Kim 2015; Kobayashi 2012; Kucera 2012; Lee
2014; Nakagawa 2009; Ogawa 2008; Ogawa 2014; Pais 2007;
Sedlack 2002; Smith 2016; Takanami 2011; Tan 2009; Taouli
2000; Tomimaru 2010; Yamao 2001). One study was at high risk
of bias because the reference standards that participants received
were dependent on the index test results. The remaining 23 studies
were at unclear risk of bias because it was either unclear if there
was an appropriate interval between the index test and reference
standard or if all participants were included in the analysis, or both
(Brandwein 2001 - Solid; Fischer 2009 - Cystic; Fischer 2009 -
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Solid; Fisher 2008; Grieser 2010; Harrison 1999; Higashi 1997;
Hu 2013; Jafarimehr 2010; Jin 2013a; Klau 2011; Kubo 2001; Le
Baleur 2011a; Maire 2008; McHenry 2002; Nara 2009; Otomi
2014; Sahani 2006; Saito 2013; Salla 2007; Takeshita 2008; Zhan
2011; Zhan 2013).
Findings
The results are summarised in the Summary of findings. The over-
all sensitivities and specificities for different tests for different tar-
get conditions are tabulated in Table 2. A detailed description is
given below.
Cancerous versus benign or precancerous
EUS-FNA cytology: We included one study reporting data on
45 participants for this test (McHenry 2002). The sensitivity and
specificity for diagnosing cancer were 0.79 (95% confidence in-
terval (CI) 0.60 to 0.91) and 1.00 (95% CI 0.85 to 1.00), respec-
tively.
EUS-FNA (CEA > 500 ng/mL):We included one study reporting
data on 24 participants for this test (Kalha 2003). The sensitivity
and specificity for diagnosing cancer were 0.93 (95% CI 0.70 to
0.99) and 0.33 (95% CI 0.12 to 0.65), respectively.
PET (criteria: not specified): We included one study reporting
data on 76 participants for this test (Jafarimehr 2010). The sen-
sitivity and specificity for diagnosing cancer were 0.85 (95% CI
0.73 to 0.92) and 0.91 (95% CI 0.72 to 0.97), respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sensi-
tivity and specificity data for the ’cancerous versus benign or pre-
cancerous’ studies is shown in Figure 5.
Figure 5. Forest plot - Cancerous versus benign or precancerous.
Cancerous versus benign
EUS: Two studies reporting data on 133 participants were in-
cluded for this test, allowingmeta-analysis to be performed (Brand
2000; Harrison 1999). The summary sensitivity and summary
specificity for diagnosing cancer were 0.95 (95% CI 0.84 to 0.99)
and 0.53 (95% CI 0.31 to 0.74), respectively.
EUS-FNA cytology: Three studies reporting data on 147 par-
ticipants were included for this test (Brandwein 2001 - Cystic;
Brandwein 2001 - Solid; Cherian 2010). The sensitivity and speci-
ficity for diagnosing cancer were 0.79 (95% CI 0.07 to 1.00) and
1.00 (95% CI 0.91 to 1.00), respectively.
PET (criteria: not specified): Three studies reporting data on
99 participants were included for this test, allowing meta-analysis
to be performed (Erkan 2012; Higashi 1997; Kato 1995). The
summary sensitivity and summary specificity for diagnosing cancer
were 0.92 (95%CI 0.80 to 0.97) and 0.65 (95% CI 0.39 to 0.85),
respectively.
PET (SUVmax > 3.5): We included one study reporting data
on 80 participants for this test (Hu 2013). The sensitivity and
specificity for diagnosing cancer were 0.96 (95% CI 0.87 to 0.99)
and 0.62 (95% CI 0.43 to 0.78), respectively.
CT: Two studies reporting data on 123 participants were included
for this test, allowingmeta-analysis to be performed (Grieser 2010;
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Harrison 1999). The summary sensitivity and summary specificity
for diagnosing cancer were 0.98 (95% CI 0.00 to 1.00) and 0.76
(95% CI 0.02 to 1.00), respectively.
MRI:We included one study reporting data on 29 participants for
this test (Klau 2011). The sensitivity and specificity for diagnosing
cancer were 0.80 (95% CI 0.58 to 0.92) and 0.89 (95% CI 0.57
to 0.98), respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sensi-
tivity and specificity data for the ’cancerous versus benign’ studies
is shown in Figure 6.
Figure 6. Forest plot - Cancerous versus benign.
Precancerous or cancerous versus benign
EUS: We included one study reporting data on 34 participants
for this test (Sedlack 2002). The sensitivity and specificity for
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diagnosing cancer or precancer were 0.92 (95% CI 0.74 to 0.98)
and 0.60 (95% CI 0.31 to 0.83), respectively.
EUS-FNA cytology:We included three studies, reporting data on
52 participants for this test (Fischer 2009 - Cystic; Fischer 2009
- Solid; Sedlack 2002). The summary sensitivity and summary
specificity for diagnosing cancer or precancer were 0.73 (95% CI
0.01 to 1.00) and 0.94 (95% CI 0.15 to 1.00), respectively.
EUS-FNA (CEA > 50 ng/mL):We included one study reporting
data on 11 participants for this test (Sedlack 2002). The sensitivity
and specificity for diagnosing cancer or precancer were 0.29 (95%
CI 0.08 to 0.64) and 0.25 (95% CI 0.05 to 0.70), respectively.
PET (SUVmax > 2.4): We included one study reporting data on
32 participants for this test (Otomi 2014). The sensitivity and
specificity for diagnosing cancer or precancer were 0.94 (95% CI
0.74 to 0.99) and 0.93 (95% CI 0.69 to 0.99), respectively.
CT:We included one study reporting data on 48 participants for
this test (Fisher 2008). The sensitivity and specificity for diagnos-
ing cancer or precancer were 0.62 (95% CI 0.45 to 0.76) and 0.64
(95% CI 0.39 to 0.84), respectively.
MRI:We included one study reporting data on 27 participants for
this test (Jang 2014a). The sensitivity and specificity for diagnosing
cancer or precancer were 0.93 (95% CI 0.69 to 0.99) and 0.85
(95% CI 0.58 to 0.96), respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sensi-
tivity and specificity data for the ’precancerous or cancerous versus
benign’ studies is shown in Figure 7.
Figure 7. Forest plot - Precancerous or cancerous versus benign.
Cancerous (invasive carcinoma) versus precancerous
(dysplasia)
EUS:Five studies reportingdata on156 participantswere included
20Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for this test, allowing meta-analysis to be performed (Cellier 1998;
de Jong 2012; Nakagawa 2009; Yamao 2001; Zhan 2011). The
summary sensitivity and summary specificity for diagnosing inva-
sive cancer were 0.78 (95% CI 0.45 to 0.94) and 0.91 (95% CI
0.61 to 0.98), respectively.
EUS-FNA cytology: Three studies reporting data on 158 partici-
pants were included for this test, allowing meta-analysis to be per-
formed (Jin 2013a; Pais 2007; Salla 2007). The summary sensi-
tivity and summary specificity for diagnosing invasive cancer were
0.66 (95% CI 0.03 to 0.99) and 0.92 (95% CI 0.73 to 0.98),
respectively.
EUS-FNA (CEA > 200 ng/mL):We included one study reporting
data on 41 participants for this test (Maire 2008). The sensitivity
and specificity for diagnosing invasive cancer were 1.00 (95% CI
0.57 to 1.00) and 0.64 (95% CI 0.48 to 0.78), respectively.
CT: Six studies reporting data on 326 participants were included
for this test, allowing meta-analysis to be performed (Cellier 1998;
Nakagawa 2009; Nara 2009; Ogawa 2008; Taouli 2000; Yamao
2001). The summary sensitivity and summary specificity for diag-
nosing invasive cancer were 0.72 (95% CI 0.50 to 0.87) and 0.92
(95% CI 0.81 to 0.97), respectively.
MRI: We included one study reporting data on 32 participants
for this test (de Jong 2012). The sensitivity and specificity for
diagnosing invasive cancer were 0.75 (95% CI 0.30 to 0.95) and
0.93 (95% CI 0.77 to 0.98), respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sensitiv-
ity and specificity data for the ’cancer (invasive carcinoma) versus
precancerous (dysplasia)’ studies is shown in Figure 8.
Figure 8. Forest plot - Cancerous (invasive carcinoma) versus precancerous (dysplasia).
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Cancerous (high-grade dysplasia or invasive
carcinoma) versus precancerous (low- or
intermediate-grade dysplasia)
EUS: Four studies reporting data on 196 participants were in-
cluded for this test, allowing meta-analysis to be performed (Doi
2002; Kobayashi 2012; Lee 2014; Yamao 2001). The summary
sensitivity and summary specificity for diagnosing high-grade dys-
plasia or invasive cancer were 0.86 (95% CI 0.74 to 0.92) and
0.91 (95% CI 0.83 to 0.96), respectively.
EUS-FNA cytology: Three studies reporting data on 310 par-
ticipants were included for this test, allowing meta-analysis to be
performed (Jin 2013a; Smith 2016; Zhan 2013). The summary
sensitivity and summary specificity for diagnosing high-grade dys-
plasia or invasive cancer were 0.47 (95% CI 0.24 to 0.70) and
0.91 (95% CI 0.32 to 1.00), respectively.
EUS-FNA (CEA > 200 ng/mL): Three studies reporting data
on 160 participants were included for this test, allowing meta-
analysis to be performed (Correa-Gallego 2009; Kucera 2012;
Maire 2008). The summary sensitivity and summary specificity for
diagnosing high-grade dysplasia or invasive cancer were 0.58 (95%
CI 0.28 to 0.83) and 0.51 (95% CI 0.19 to 0.81), respectively.
EUS-FNA (carbohydrate antigen 19-9 > 1000 U/mL): We in-
cluded one study reporting data on 41 participants for this test
(Maire 2008). The sensitivity and specificity for diagnosing high-
grade dysplasia or invasive cancer were 0.90 (95%CI 0.60 to 0.98)
and 0.42 (95% CI 0.26 to 0.59), respectively.
EUS-FNA (CEA > 692.8 ng/mL): We included one study re-
porting data on 20 participants for this test (Zhan 2013). The
sensitivity and specificity for diagnosing high-grade dysplasia or
invasive cancer were 0.80 (95% CI 0.49 to 0.94) and 0.90 (95%
CI 0.60 to 0.98), respectively.
PET (SUVmax 2 to 2.5): Four studies reporting data on 124 par-
ticipants were included for this test, allowing meta-analysis to be
performed (Hong 2010; Saito 2013; Takanami 2011; Tomimaru
2010). The summary sensitivity and summary specificity for di-
agnosing high-grade dysplasia or invasive cancer were 0.90 (95%
CI 0.79 to 0.96) and 0.94 (95% CI 0.81 to 0.99), respectively.
CT: Three studies reporting data on 139 participants were in-
cluded for this test, allowing meta-analysis to be performed (Hong
2010; Le Baleur 2011a; Yamao 2001). The summary sensitivity
and summary specificity for diagnosing high-grade dysplasia or
invasive cancer were 0.87 (95% CI 0.00 to 1.00) and 0.96 (95%
CI 0.00 to 1.00), respectively.
MRI: Three studies reporting data on 189 participants were in-
cluded for this test, allowing meta-analysis to be performed (Jang
2014b; Kim 2015; Ogawa 2014). The summary sensitivity and
summary specificity for diagnosing high-grade dysplasia or inva-
sive cancer were 0.69 (95% CI 0.44 to 0.86) and 0.93 (95% CI
0.43 to 1.00), respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sen-
sitivity and specificity data for the ’cancer (high-grade dysplasia
or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia)’ studies is shown in Figure 9.
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Figure 9. Forest plot - Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or
intermediate-grade dysplasia).
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Cancerous (invasive carcinoma) versus precancerous
(low-grade dysplasia)
EUS:We included one study reporting data on 51 participants for
this test (Kubo 2001). The sensitivity and specificity for diagnosing
invasive cancer were 0.77 (95% CI 0.50 to 0.92) and 0.89 (95%
CI 0.76 to 0.96), respectively.
CT: We included one study reporting data on 46 participants
for this test (Takeshita 2008). The sensitivity and specificity for
diagnosing invasive cancer were 0.50 (95% CI 0.22 to 0.78) and
0.95 (95% CI 0.83 to 0.99), respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sensitiv-
ity and specificity data for the ’cancer (invasive carcinoma) versus
precancerous (low-grade dysplasia)’ studies is shown in Figure 10.
Figure 10. Forest plot - Cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia).
Precancerous or cancer (intermediate- or high-grade
dysplasia or invasive carcinoma) versus precancerous
(low-grade dysplasia)
CT: Three studies reporting data on 106 participants were in-
cluded for this test, allowing meta-analysis to be performed
(Ogawa 2008; Sahani 2006; Tan 2009). The summary sensitiv-
ity and summary specificity for diagnosing intermediate- or high-
grade dysplasia or invasive cancer were 0.83 (95%CI 0.68 to 0.92)
and 0.83 (95% CI 0.64 to 0.93), respectively.
MRI:Two studies reporting data on 71 participants were included
for this test, allowing meta-analysis to be performed (Choi 2003;
Takeshita 2008). The summary sensitivity and specificity for di-
agnosing intermediate- or high-grade dysplasia or invasive cancer
were 0.80 (95%CI 0.58 to 0.92) and 0.81 (95% CI 0.53 to 0.95),
respectively.
The results including sensitivities and specificities and post-test
probabilities at median pre-test probabilities are summarised in
Summary of findings. A forest plot summarising all of the sen-
sitivity and specificity data for the ’precancerous or cancer (in-
termediate- or high-grade dysplasia or invasive carcinoma) versus
precancerous (low-grade dysplasia)’ studies is shown in Figure 11.
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Figure 11. Forest plot - Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive
carcinoma) versus precancerous (low-grade dysplasia).
Precancerous or cancerous (intermediate- or high-
grade dysplasia or invasive carcinoma) versus
precancerous (low-grade dysplasia) or benign
EUS: We included one study reporting data on 70 participants
for this test (Kamata 2016a). The sensitivity and specificity for
diagnosing intermediate- or high-grade dysplasia or invasive car-
cinoma were 0.97 (95% CI 0.83 to 0.99) and 0.40 (95% CI 0.26
to 0.55), respectively.
The results including sensitivity and specificity and post-test prob-
ability at median pre-test probability are summarised in Summary
of findings. A forest plot summarising the sensitivity and speci-
ficity data for the ’precancerous or cancerous (intermediate- or
high-grade dysplasia or invasive carcinoma) versus precancerous
(low-grade dysplasia) or benign’ study is shown in Figure 12.
Figure 12. Forest plot of 33 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous
(low- or intermediate-grade dysplasia) or benign - EUS.
Subgroup analyses
We assessed the performance of the tests excluding any studies in-
vestigating participants with solid lesions and those inwhich infor-
mation for solid and cystic lesions was not reported separately. All
of the studies assessing the ability of different imaging modalities
to differentiate precancerous versus cancerous lesions regardless of
the definitions used by authors for precancer and cancer (Analysis
4 to Analysis 8) included participants with cystic focal pancreatic
lesions only, therefore all the results reported are for cystic focal
pancreatic lesions only.
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In the analysis assessing the ability of different imaging modalities
to differentiate benign or precancerous versus cancerous lesions,
we excluded one study because if did not specify the type (solid or
cystic) of lesions for which included participants were investigated
(Jafarimehr 2010). However, as this study did not contribute to a
meta-analysis, there were no changes to the analysis.
Cancerous versus benign
In the analysis assessing the ability of different imaging modalities
to differentiate benign versus cancerous lesions, we excluded eight
studies because they did not explicitly include participants with
cystic lesions (Brand 2000; Erkan 2012; Grieser 2010; Harrison
1999; Higashi 1997; Hu 2013; Kato 1995; Klau 2011), and one
study that only had one component included (Brandwein 2001 -
Cystic; Brandwein 2001 - Solid). This left two remaining studies,
which did not contribute to a meta-analysis due to the exclusion
of the other studies (Brandwein 2001 - Cystic; Hu 2013). We
therefore performed no meta-analyses for this group. The new
findings for benign versus cancerous lesions are described below.
EUS-FNA: We included one study reporting data on 26 partici-
pants for this test (Brandwein 2001 - Cystic). The sensitivity and
specificity for diagnosing cancer were 0.50 (95% CI 0.19 to 0.81)
and 1.00 (95% CI 0.84 to 1.00), respectively.
PET:We included one study reporting data on 80 participants for
this test (Hu 2013). The sensitivity and specificity for diagnosing
cancer were 0.96 (95% CI 0.87 to 0.99) and 0.62 (95% CI 0.43
to 0.78), respectively.
A forest plot summarising all the sensitivity and specificity data
for the cystic subgroup analysis of ’cancerous versus benign lesion’
studies is shown in Figure 13.
Figure 13. Forest plot - Cystic lesion subgroup analysis: Cancerous versus benign.
Precancerous or cancerous versus benign
In the analysis assessing the ability of different imaging modalities
to differentiate precancerous or cancerous versus benign lesions,
we excluded a component of one study because the participants
had solid pancreatic lesions (Fischer 2009 - Solid).We therefore re-
performed the meta-analysis for precancerous or cancerous versus
benign lesions - EUS-FNA without these data. The remaining
tests for this target condition did not have any studies excluded
and were therefore not redone. The new findings are described
below.
EUS-FNA: Two studies reporting data on 34 participants were
included for this test, allowing meta-analysis to be performed (
Fischer 2009 - Cystic; Sedlack 2002). The summary sensitivity
and summary specificity for diagnosing precancer or cancer were
0.43 (95% CI 0.19 to 0.71) and 1.00 (95% CI 0.74 to 1.00),
respectively.
A forest plot summarising the sensitivity and specificity data for
the cystic subgroup analysis of ’precancerous or cancerous versus
benign lesion’ study is shown in Figure 14.
Figure 14. Forest plot - Cystic lesion subgroup analysis: Precancerous or cancerous versus benign - EUS-
FNA.
26Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
27Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Summary of findings
Name of test Number of
studies (num-
ber of partici-
pants)
Sensitivity
(95% CI)
Specificity
(95% CI)
Post-
test probabil-
ity of positive
test* (95% CI)
Post-
test probabil-
ity of negative
test* (95% CI)
Num-
ber of false
positives per
100 positive
index test re-
sults (95% CI)
Num-
ber of false
negatives per
100 negative
index test re-
sults (95% CI)
Risk of bias Applicability
concerns
Uncertainty
(due to incon-
sistency or in-
ability to as-
sess incon-
sistency, and
random errors
because of
overall small
sample size)
Cancerous versus benign or precancerous (median pre- test probability: 63%)
EUS-FNA (cy-
tology)
1 (45) 0.79 (0.60 to
0.91)
1.00 (0.85 to
1.00)
98% (79% to
100%)
26% (14% to
43%)
2 (0 to 21) 26 (14 to 43) Unclear High High
EUS-
FNA (CEA >
500 ng/ mL)
1 (24) 0.93 (0.70 to
0.99)
0.33 (0.12 to
0.65)
70% (59% to
79%)
25% (4% to
73%)
30 (21 to 41) 25 (4 to 73) High High High
PET (criteria
unspecif ied)
1 (76) 0.85 (0.73 to
0.92)
0.91 (0.72 to
0.97)
94% (81% to
98%)
21% (12% to
34%)
6 (2 to 19) 21 (12 to 34) Unclear High High
Cancerous versus benign (median pre- test probability: 70%)
EUS 2 (133) 0.95 (0.84 to
0.99)
0.53 (0.31 to
0.74)
82% (74% to
88%)
18% (6% to
45%)
18 (12 to 26) 18 (6 to 45) Unclear or
high
High High
EUS-FNA (cy-
tology)
3 (147) 0.79 (0.07 to
1.00)
1.00 (0.91 to
1.00)
99% (90% to
100%)
32% (2% to
92%)
0 (0 to 9) 32 (2 to 92) High High High
PET (criteria
unspecif ied)
3 (99) 0.92 (0.80 to
0.97)
0.65 (0.39 to
0.85)
86% (75% to
92%)
22% (9% to
44%)
14 (8 to 25) 22 (9 to 44) High High High
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PET (SUVmax
> 3.5)
1 (80) 0.96 (0.87 to
0.99)
0.62 (0.43 to
0.78)
85% (78% to
90%)
12% (3% to
36%)
15 (10 to 22) 12 (3 to 36) High High High
CT 2 (123) 0.98 (0.00 to
1.00)
0.76 (0.02 to
1.00)
90% (17% to
100%)
6% (0% to
100%)
10 (0 to 83) 6 (0 to 100) Unclear or
high
High High
M RI 1 (29) 0.80 (0.58 to
0.92)
0.89 (0.57 to
0.98)
94% (72% to
99%)
34% (17% to
56%)
6 (1 to 28) 34 (17 to 56) High High High
Precancerous or cancerous versus benign (median pre- test probability: 71%)
EUS 1 (34) 0.92 (0.74 to
0.98)
0.60 (0.31 to
0.83)
85% (72% to
92%)
25% (7% to
58%)
15 (8 to 28) 25 (7 to 58) High High High
EUS-FNA (cy-
tology)
2 (52) 0.73 (0.01 to
1.00)
0.94 (0.15 to
1.00)
97% (25% to
100%)
41% (1% to
98%)
3 (0 to 75) 41 (1 to 98) Unclear or
high
High High
EUS-FNA
(CEA > 50 ng/
mL)
1 (11) 0.29 (0.08 to
0.64)
0.25 (0.05 to
0.70)
48% (20% to
77%)
87% (54% to
98%)
52 (23 to 80) 87 (54 to 98) High High High
PET (SUVmax
2.4)
1 (32) 0.94 (0.74 to
0.99)
0.93 (0.69 to
0.99)
97% (83% to
100%)
13% (2% to
49%)
3 (0 to 17) 13 (2 to 49) High High High
CT 1 (48) 0.62 (0.45 to
0.76)
0.64 (0.39 to
0.84)
81% (66% to
90%)
59% (44% to
72%)
19 (10 to 34) 59 (44 to 72) Unclear High High
M RI 1 (27) 0.93 (0.69 to
0.99)
0.85 (0.58 to
0.96)
94% (80% to
98%)
17% (3% to
58%)
6 (2 to 20) 17 (3 to 58) High High High
Cancerous (invasive carcinoma) versus precancerous (dysplasia) (median pre- test probability: 27%)
EUS 5 (156) 0.78 (0.45 to
0.94)
0.91 (0.61 to
0.98)
75% (37% to
94%)
8% (3% to
22%)
25 (6 to 63) 8 (3 to 22) Unclear or
high
High High
2
9
Im
a
g
in
g
m
o
d
a
litie
s
fo
r
c
h
a
ra
c
te
risin
g
fo
c
a
l
p
a
n
c
re
a
tic
le
sio
n
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
EUS-FNA (cy-
tology)
3 (158) 0.66 (0.03 to
0.99)
0.92 (0.73 to
0.98)
75% (29% to
95%)
12% (1% to
69%)
25 (5 to 71) 12 (1 to 69) Unclear or
high
High High
EUS-
FNA (CEA >
200 ng/ mL)
1 (41) 1.00 (0.57 to
1.00)
0.64 (0.48 to
0.78)
51% (40% to
61%)
Not estimable 49 (39 to 60) Not estimable High High High
CT 6 (326) 0.72 (0.50 to
0.87)
0.92 (0.81 to
0.97)
78% (57% to
91%)
10% (5% to
18%)
22 (9 to 43) 10 (5 to 18) Unclear or
high
High High
M RI 1 (32) 0.75 (0.30 to
0.95)
0.93 (0.77 to
0.98)
80% (48% to
94%)
9% (2% to
35%)
20 (6 to 52) 9 (2 to 35) High High High
Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) (median pre- test probability: 45%)
EUS 4 (196) 0.86 (0.74 to
0.92)
0.91 (0.83 to
0.96)
89% (80% to
94%)
11% (7% to
19%)
11 (6 to 20) 11 (7 to 19) High High High
EUS-FNA (cy-
tology)
3 (310) 0.47 (0.24 to
0.70)
0.91 (0.32 to
1.00)
81% (19% to
99%)
32% (22% to
45%)
19 (1 to 81) 32 (22 to 45) Unclear or
high
High High
EUS-
FNA (CEA >
200 ng/ mL)
3 (160) 0.58 (0.28 to
0.83)
0.51 (0.19 to
0.81)
49% (28% to
70%)
40% (19% to
65%)
51 (30 to 72) 40 (19 to 65) High High High
EUS-FNA (CA
19-9 > 1000 U/
mL)
1 (41) 0.90 (0.60 to
0.98)
0.42 (0.26 to
0.59)
56% (47% to
65%)
16% (3% to
57%)
44 (35 to 53) 16 (3 to 57) High High High
EUS-FNA
(CEA > 692.8
ng/ mL)
1 (20) 0.80 (0.49 to
0.94)
0.90 (0.60 to
0.98)
87% (50% to
98%)
15% (5% to
39%)
13 (2 to 50) 15 (5 to 39) Unclear High High
PET (SUVmax
> 2 to 2.5)
4 (124) 0.90 (0.79 to
0.96)
0.94 (0.81 to
0.99)
93% (78% to
98%)
8% (4% to
16%)
7 (2 to 22) 8 (4 to 16) High High High
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CT 3 (139) 0.87 (0.00 to
1.00)
0.96 (0.00 to
1.00)
95% (0% to
100%)
10% (0% to
100%)
5 (0 to 100) 10 (0 to 100) Unclear or
high
High High
M RI 3 (189) 0.69 (0.44 to
0.86)
0.93 (0.43 to
1.00)
89% (35% to
99%)
21% (12% to
36%)
11 (1 to 65) 21 (12 to 36) High High High
Cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia) (median pre- test probability: 21%)
EUS 1 (51) 0.77 (0.50 to
0.92)
0.89 (0.76 to
0.96)
67% (43% to
84%)
7% (3% to
16%)
33 (16 to 57) 7 (3 to 16) Unclear High High
CT 1 (46) 0.50 (0.22 to
0.78)
0.95 (0.83 to
0.99)
72% (36% to
92%)
13% (7% to
22%)
28 (8 to 64) 13 (7 to 22) High High High
Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) versus precancerous (low-grade dysplasia) (median pre- test probability: 59%)
CT 3 (106) 0.83 (0.68 to
0.92)
0.83 (0.64 to
0.93)
89% (56% to
98%)
33% (18% to
52%)
11 (2 to 44) 33 (18 to 52) High High High
M RI 2 (71) 0.80 (0.58 to
0.92)
0.81 (0.53 to
0.95)
86% (67% to
95%)
27% (13% to
47%)
14 (5 to 33) 27 (13 to 47) High High High
Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) versus precancerous (low-grade dysplasia) or benign (median pre- test probability:
43%)
EUS 1 (70) 0.97 (0.83 to
0.99)
0.40 (0.26 to
0.55)
55% (48% to
61%)
6% (1% to
31%)
45 (39 to 52) 6 (1 to 31) High High High
* Post-test probability was calculated at the median pre-test probability.
Abbreviat ions:
CA 19-9: carbohydrate ant igen 19-9
CEA: carcinoembryonic ant igen
CI: conf idence interval
CT: computed tomography
EUS: endoscopic ultrasound
FNA: f ine-needle aspirat ion
MRI: magnetic resonance imaging31
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PET: positron emission tomography
SUVmax: maximum standardised uptake values
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D I S C U S S I O N
Summary of main results
The results are summarised in Summary of findings.
We included 54 studies involving a total of 3196 participants that
evaluated the diagnostic accuracy of various imaging modalities
(EUS, EUS-FNA, PET, CT, and MRI) for characterising focal
pancreatic lesions. We identified eight different target conditions
in these studies, with the studies using imagingmodalities to differ-
entiate: cancerous versus benign or precancerous lesions; cancer-
ous versus benign lesions; precancerous or cancerous lesions versus
benign lesions; cancerous (invasive carcinoma) versus precancer-
ous (dysplasia) lesions; cancerous (high-grade dysplasia or invasive
carcinoma) versus precancerous (low- or intermediate-grade dys-
plasia) lesions; cancerous (invasive carcinoma) versus precancer-
ous (low-grade dysplasia) lesions; precancerous or cancerous (in-
termediate- or high-grade dysplasia or invasive carcinoma) versus
precancerous (low-grade dysplasia) lesions; and precancerous or
cancerous (intermediate- or high-grade dysplasia or invasive car-
cinoma) versus precancerous (low-grade dysplasia) or benign le-
sions. The wide variety of tumour types that constituted benign
and cancerous lesions within the studies meant that only a few
meaningful meta-analyses could be performed. None of the com-
parisons in which single studies were included were of sufficiently
high methodological quality to warrant highlighting of the results.
For differentiation of cancerous lesions from benign or precancer-
ous lesions, only single studies were included and therefore meta-
analysis was not performed. Overall, EUS-FNA (cytology) had a
sensitivity of 0.79 (95% CI 0.60 to 0.91) and specificity of 1.00
(95% CI 0.85 to 1.00); EUS-FNA (CEA > 500 ng/mL) had a
sensitivity of 0.93 (95% CI 0.70 to 0.99) and specificity of 0.33
(95% CI 0.12 to 0.65); and PET had a sensitivity of 0.85 (95%
CI 0.73 to 0.92) and specificity of 0.91 (95% CI 0.72 to 0.97).
The second analysis, of studies differentiating cancerous versus be-
nign lesions, provided three tests in which meta-analysis could be
performed, however the data were sparse: one of these tests con-
tained three studies, and the remaining two tests contained two
studies, meaning the meta-analysis was of limited value. There
was little difference in the diagnostic test accuracy between the
imaging techniques. EUS-FNA achieved very high specificity (of
1.00, i.e. no false negatives) but modest sensitivity (0.79; 95% CI
0.07 to 1.00). A high specificity of EUS-FNA can be expected,
since this involves physically sampling the lesion. However, the
modest sensitivity may reflect that the sampling methods were
inadequate. Additional guidance such as identifying the location
most likely to yield the correct results or additional guidance us-
ing optical endoscopy techniques such as confocal laser microen-
doscopy may overcome this problem and improve the sensitivity
of EUS (Giovannini 2012), but there are major challenges, such
as knowing the area within the lesion that is being examined by
confocal lasermicroendoscopy, that must be addressed before such
methods can be used routinely.
The third analysis, of studies differentiating precancerous or can-
cerous and benign lesions, only provided one test (EUS-FNA) for
which meta-analysis was performed. The results were unreliable
due to significant heterogeneity in the results between the studies.
The fourth analysis, of studies differentiating cancerous (invasive
carcinoma) versus precancerous (dysplasia) lesions, provided three
tests in which meta-analysis was performed, with one test con-
taining five studies (EUS), one test containing three studies (EUS-
FNA), and the third test containing six studies (CT). All five of
the tests included in the analysis had a similar level of accuracy ac-
cording to their respective ROC curves. EUS and CT showed the
highest (and similar) accuracy estimates (EUS = sensitivity 0.78
and specificity 0.91; CT = sensitivity 0.72 and specificity 0.92)
and included the largest number of studies (five and six, respec-
tively) among all comparisons.
The fifth analysis, of studies differentiating cancerous (high-grade
dysplasia or invasive carcinoma) versus precancerous (low- or in-
termediate-grade dysplasia) lesions, provided six tests in which
meta-analysis was performed, with two tests containing four stud-
ies (EUS and PET SUVmax 2 to 2.5), one test containing two
studies (EUS-FNA), three tests containing three studies (EUS-
FNA > 200, CT, andMRI), and the remaining two tests providing
single studies. PET performed with the highest accuracy (sensitiv-
ity 0.90 (95% CI 0.79 to 0.96) and specificity 0.94 (95% CI 0.81
to 0.99)).
The sixth analysis, of studies differentiating cancerous (invasive
carcinoma) versus precancerous (low-grade dysplasia) lesions, pro-
vided no tests in which meta-analysis was performed.
The seventh analysis, of studies differentiating precancerous or
cancerous (intermediate- or high-grade dysplasia or invasive carci-
noma) versus precancerous (low-grade dysplasia) lesions, provided
two tests in which meta-analysis was performed. The meta-anal-
ysis results for CT (sensitivity 0.83 (95% CI 0.68 to 0.92) and
specificity 0.83 (95% CI 0.64 to 0.93)) were similar to those of
MRI (sensitivity 0.80 (95% CI 0.58 to 0.92) and specificity 0.81
(95% CI 0.53 to 0.95)), however lack of significant data means
little can be inferred from this.
The eighth analysis, of studies differentiating precancerous or can-
cerous (intermediate- or high-grade dysplasia or invasive carci-
noma) versus precancerous (low-grade dysplasia) or benign lesions,
provided no tests in which meta-analysis was performed.
We performed a subgroup analysis to investigate the performance
of imaging modalities for cystic pancreatic lesions. This only re-
sulted in alterations to the ’cancerous versus benign or precan-
cerous’, ’cancerous versus benign’, and ’precancerous or cancer-
ous versus benign’ groups, however when re-performed in these
groups, the analysis did not result in any significant changes.
Overall, none of the tests assessed had sufficient overall diagnostic
accuracy to be considered a definitive diagnostic modality. High
sensitivity of the test is required so that precancer or cancer is not
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missed. High specificity is required to avoid major surgery. Sensi-
tivity and specificity in excess of 90% are required to recommend
the particular modality over other modalities. Only PET in differ-
entiating precancerous (low- or intermediate-grade dysplasia) ver-
sus cancer (high-grade dysplasia or invasive carcinoma) approaches
this level of accuracy. Overall, modalities other than EUS-FNA
had moderate to high sensitivity but moderate specificity, while
EUS-FNA had high specificity with moderate sensitivity in dis-
tinguishing the nature of focal pancreatic lesions.
Strengths and weaknesses of the review
We conducted a thorough literature search and included full-text
publications and abstracts without any language restrictions. Two
review authors independently identified and extracted data from
the studies, potentially reducing the chance of error that would
be associated with one person performing the data extraction. We
used strict reference standards that are likely to diagnose the target
condition with a high degree of accuracy. These were the major
strengths of the review.
We included EUS-FNA as part of the review. Strictly speaking,
EUS-FNA cannot be considered an imaging modality since it uses
cytology criteria or levels of tumour markers in the aspirate rather
than imaging features to make the diagnosis. We had mentioned
at the protocol stage that we would include EUS-FNA in this re-
view, as the searches for EUS return EUS-FNA as well and be-
cause EUS-FNA along with the imaging modalities included in
this review are the most widely used tests for characterising focal
pancreatic lesions. Our review provides the most important infor-
mation about the tests performed to characterise focal lesions in
one location and hence is probably more useful for clinicians, who
would otherwise have to search for another review for information
on EUS-FNA.
The major limitation in the review process was the diverse na-
ture of the collected data, with a wide variety of definitions of be-
nign, precancerous, and cancerous lesions. This limited the pos-
sible analysis of the data and the conclusions that could be made
from our analyses. While some authors defined precancerous le-
sions as lesions with low- and intermediate-grade dysplasia, oth-
ers defined it as low-grade dysplasia only, while yet others consid-
ered any form of dysplasia as precancerous lesions. In the com-
parison ’cancer versus benign’, it is unclear how the study authors
dealt with precancerous lesions, that is whether they included pre-
cancerous lesions in the ’cancer’ group or the ’benign’ group, or
whether they simply excluded them, consequently undermining
any conclusions that could be made for this comparison.
We could not perform a bivariate random-effects model that takes
correlation between sensitivity and specificity into account and
were unable to compare the diagnostic test accuracy of index tests
using formal statistical methods due to the sparseness of data for
each comparison. As a result, we performed the analysis using
simpler models suggested by Takwoingi 2015 and colleagues. We
reported the model with the lowest -2 log likelihood and also vi-
sualised the forest plots and ROC plots in deciding the model
to be reported. The confidence intervals were extremely wide for
the following analyses: benign versus cancer: CT; benign versus
cancer: EUS-FNA; benign versus precancer or cancer: EUS-FNA;
and precancer (low- or intermediate-grade dysplasia) versus cancer
(high-grade dysplasia or invasive carcinoma): CT. While fixed-ef-
fect model provided narrower confidence intervals for some of the
above analyses, such models were inappropriate for these data be-
cause of the poor overlap of confidence intervals on the forest plot.
This observation (i.e. that fixed-effect models were not appropri-
ate) was supported by the -2 log likelihoods, which were higher
for the univariate fixed-effect model than those of the models pre-
sented. The alternative was not to perform a meta-analysis at all,
which is evenmore difficult to interpret. At least the current results
allowed us to interpret that the sensitivity or specificity or both
could not be estimated reliably. There was reasonable overlap of
confidence intervals in the other meta-analyses performed. With
regard to the tests for whichmeta-analysis could not be performed,
the diagnostic test accuracy from single studies needs confirma-
tion by other studies to assess whether the results are reproducible.
Hence, we are unable to arrive at any major conclusions based on
information by a single study.
A high proportion of studies were at high risk of bias and with
high concern regarding applicability in all four domains of the
QUADAS-2 tool. This makes the validity of the results question-
able. Of particular concern was the type of people who underwent
these tests. Because of the strict but appropriate reference stan-
dard, all of the participants in all of the studies included in this
review except Cherian 2010 underwent surgical resection. This
suggested that the surgeons thought that these participants had
high probability of having high-grade dysplasia or cancer, either
because of the results of this test or other tests performed along-
side the index tests. Since most of the studies were retrospective
studies, if participants were operated on on the basis of the index
test, and only participants who underwent surgery were included,
participants with negative index tests but who had cancer would
have been excluded inappropriately. This would have resulted in
overestimation of sensitivity. The studies did not report the pro-
portion of people in whom the different tests were feasible. This is
particularly important for EUS and EUS-FNA, since the partici-
pants may have been selected to undergo EUS or EUS-FNA based
on the proximity to the stomach or duodenum. This increases
the concern regarding applicability. The studies did not report the
complications associated with the index test. While this is unlikely
to influence the diagnostic accuracy of the index test, it may have
implications in determining the balance of benefits and harms in
choosing a test.
Another limitation of this review was that we have included sensi-
tivity-maximising diagnostic filters for searching MEDLINE and
Embase databases (Haynes 2004;Wilczynski 2005), and also used
terms to limit the searches in Science Citation Index. We did this
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because the original searches without the filters retrieved more
than 60,000 references. We had to balance the possibility of miss-
ing some studies against the risk of not being able to complete
the review. We decided that it is useful to have evidence from ma-
jor studies rather than having no information at all. However, it
must be noted that the diagnostic filters we used have a sensitivity
of 98.6% for MEDLINE and 100% for Embase. Consequently,
the chances that we missed some relevant diagnostic studies are
extremely low. This was further reduced by performing a ’related
search’ and ’citing reference search’, in which we found no studies
that could be included in this review.
We identified six other systematic reviews on the topics included
in this systematic review (Banafea 2016; Chen 2012; Fuccio 2013;
Gillis 2015; Hewitt 2012; Mei 2013). These included the role
of EUS-FNA (cytology), K-ras gene mutation analysis of FNA
aspirate, and EUS elastography in focal pancreatic lesions. The
diagnostic test accuracy in four of the studies showed that EUS
cytology and K-ras gene mutation analysis of FNA aspirate had a
reasonably high sensitivity (0.80 to 0.86) and very high specificity
(96% to 98%) in solid pancreatic lesions (Banafea 2016; Chen
2012; Fuccio 2013; Hewitt 2012). These studies accepted cytol-
ogy and clinical follow-up (without specifying the exact nature
of acceptable clinical follow-up) in addition to histopathology as
reference standards (Chen 2012; Fuccio 2013; Hewitt 2012). It is
likely that this methodological difference was responsible for the
major differences between our observations and these systematic
reviews. In addition, these systematic reviews restricted partici-
pants to those with solid pancreatic lesions (Banafea 2016; Chen
2012; Fuccio 2013; Hewitt 2012), which could be another ex-
planation for the differences between our observations and these
systematic reviews. One systematic review evaluated EUS elastog-
raphy in focal pancreatic lesions and reported a high sensitivity of
0.95 and a specificity of 0.67 (Mei 2013). We did not identify any
study evaluating EUS elastography that met our inclusion criteria
with respect to our reference standard, therefore we are unable to
comment on the observation by Mei 2013. The last systematic
review evaluated the role of EUS-FNA and EUS-FNA molecu-
lar analysis (i.e. check for abnormal genes) in people with cystic
pancreatic lesions. The authors found poor sensitivity and high
specificity of EUS-FNA, which is similar to our findings (Gillis
2015).
Applicability of findings to the review question
All studies had high applicability concerns, making the applica-
bility of findings to the target patient population of all incidental
lesions questionable. The findings are applicable only for people
who are suspected to be at high risk of high-grade dysplasia or
cancer. The review question was to find out the diagnostic accu-
racy of these index tests in people with focal pancreatic lesions,
usually detected incidentally. However, all of the studies that met
the inclusion criteria for this review used surgical excision as the
reference standard, suggesting that the surgeons considered these
patients to have a high risk of malignancy based on the results of
the index tests or any additional tests. In terms of current avail-
ability of these tests, CT scan and MRI are likely to be available
in most secondary centres. EUS is likely to be available in limited
secondary centres and most tertiary centres that treat pancreatic
lesions. PET is likely to be available only in limited tertiary centres,
although the tertiary centres are likely to have access to a PET scan.
However, based on the observations in this review, there do not
appear to be any major differences between the different imaging
modalities. The improved sensitivity of EUS-FNA compared to
other imaging modalities is compensated by a corresponding de-
crease in sensitivity, consequently there do not appear to be major
advantages to using EUS for characterising focal pancreatic lesions
compared to other non-invasive methodologies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We were unable to arrive at any firm conclusions because of the
differences in the way that study authors classified focal pancre-
atic lesions into cancerous, precancerous, and benign lesions; the
inclusion of few studies with wide confidence intervals for each
comparison; poor methodological quality in the studies; and het-
erogeneity in the estimates within comparisons.
Implications for research
Further studies of high methodological quality are necessary. Fu-
ture research should be conducted in a prospective manner, how-
ever most importantly the definition of benign and cancerous le-
sions in the analysis of studies should be standardised according to
World Health Organization (WHO) classification. The threshold
for positivity of endoscopic ultrasound-guided fine-needle aspira-
tion cancer markers should be prespecified. Future studies should
avoid any inappropriate exclusions to ensure that true diagnostic
accuracy can be determined. Long-term follow-up of participants
with negative tests will help in understanding the implications of
false-negative results and will aid clinical decision-making.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brand 2000
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 179.
Females: 47 (26.3%).
Age: 61 years.
Presentation:
Patients with pancreatic lesions who had undergone EUS and surgical resection with histological
confirmation.
Setting: secondary care, Germany.
Index tests Index test: EUS.
Further details:
Technical specifications: Olympus GF-UM 3, GF-UM 20, and GF-UM 200.
Performed by: gastroenterologist.
Criteria for positive diagnosis: a mass lesion with irregular borders, non-homogeneous echotexture,
and/or loss of vascular interface or obvious vascular involvement, without any signs of chronic
pancreatitis in the lesion or the rest of the gland. However, in the presence of obvious chronic
pancreatitis, an associated malignancy was suspected if the EUS morphology of the focal lesion
suggested involvement of the adjacent structures
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 64 (35.8%)
Comparative
Notes Possible overlap with Binmoeller 1998a and Binmoeller 1998b; out of 179 patients, only 115
patients with histologically confirmed diagnosis were included
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
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Brand 2000 (Continued)
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous versus benign - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
88Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brand 2000 (Continued)
High
Brandwein 2001 - Cystic
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 26.
Females: not stated.
Age: not stated.
Presentation:
Patients with cystic and solid pancreatic lesions who had undergone surgical resection; only patients
with cystic lesions included in our analysis.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: Pentax echoendoscope (model not stated); 22-gauge needle.
Performed by: endoscopist and cytologist.
Criteria for positive diagnosis: a malignant mass was defined as a focal hypoechoic heterogeneous
lesion within the pancreatic parenchyma and cytology reported stated malignancy
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
89Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brandwein 2001 - Cystic (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cystic lesion subgroup analysis - Cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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Brandwein 2001 - Cystic (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Brandwein 2001 - Solid
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 43.
Females: not stated.
Age: not stated.
Presentation:
Patients with cystic and solid pancreatic lesions who had undergone surgical resection.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: Pentax echoendoscope (model not stated); 22-gauge needle.
Performed by: endoscopist and cytologist.
Criteria for positive diagnosis: a malignant mass was defined as a focal hypoechoic heterogeneous
lesion within the pancreatic parenchyma and cytology reported stated malignancy
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
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Brandwein 2001 - Solid (Continued)
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Brandwein 2001 - Solid (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Cellier 1998
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 46.
Females: not stated.
Age: not stated.
Presentation:
Patients with IPMN undergoing surgery.
Setting: secondary care, France.
Index tests Index test: EUS.
Further details:
Technical specifications: Olympus GFUM3 or GF UM20.
Performed by: endoscopist.
Criteria for positive diagnosis:
• Rupture of main pancreatic duct wall with tumoural intrapancreatic spread.
• Intrapancreatic mass.
• Tumour invasion of duodenum or common bile duct.
• Metastatic peripancreatic lymph nodes.
• Extrapancreatic spread.
Index test: CT.
Further details:
Technical specifications: conventional CT (further details not available).
Performed by: not stated.
Criteria for positive diagnosis:
• Intraductal proliferation.
• Intrapancreatic tumoural mass.
• Extrapancreatic tumoural spread.
• Metastatic peripancreatic nodes.
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
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Cellier 1998 (Continued)
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 22 (46.8%)
Comparative
Notes A number of patients were excluded from the analysis. The reasons were not reported
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
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Cellier 1998 (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Cherian 2010
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 78.
Females: not stated.
Age: not stated.
Presentation:
1. Patients with solid pancreatic lesions and suspected pancreatic cancer who required definitive
diagnosis.
2. Atypical histories and symptoms.
3. Equivocal CT findings.
4. Deemed unresectable or unfit for surgery.
Setting: secondary care, UK.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: Olympus GF-UCT240-AL5.
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Cherian 2010 (Continued)
Performed by: endoscopist and cytologist.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: benign versus malignant.
Reference standard: surgical excision and histology in people who had undergone surgery and
clinical follow-up, defined as serial imaging at 12 months that demonstrated progression of disease
or patients had clinical deterioration or death.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
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Cherian 2010 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Choi 2003
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 64.
Females: 14 (21.9%).
Age: 61 years.
Presentation:
Patients with IPMN undergoing surgical resection.
Setting: secondary care, Korea.
Index tests Index test: MRI.
Further details:
Technical specifications: 1.5-T MR system (Magnetom Vision; Siemens, Erlangen, Germany).
Performed by: radiologist.
Criteria for positive diagnosis: presence of mural nodules.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous (intermediate- or high-grade dysplasia or invasive
carcinoma) versus precancerous (low-grade dysplasia).
Reference standard: surgical excision.
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Choi 2003 (Continued)
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 0 (0%).
Number of patients who were excluded from the analysis: 18 (28.1%)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
High High
DOMAIN 2: Index Test Precancerous or cancerous (intermediate or high grade dysplasia or invasive carcinoma) versus
precancerous (low grade dysplasia) - MRI
DOMAIN 2: Index
invasive carcinoma)
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Choi 2003 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Correa-Gallego 2009
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 72.
Females: not stated.
Age: not stated.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: cyst CEA fluid >= 200 ng/mL
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
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Correa-Gallego 2009 (Continued)
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA (CEA > 200 ng/ml)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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Correa-Gallego 2009 (Continued)
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
High
de Jong 2012
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 32.
Females: 19 (59.4%).
Age: 62 years.
Presentation:
Inclusion criteria
• Patients above 18 years of age with a pancreatic cystic lesion of unknown aetiology detected
on cross-sectional imaging (transabdominal ultrasound, CT, MRI).
• Patients undergoing surgical resection.
Exclusion criteria
• Patients with a recent episode of acute pancreatitis or with known chronic pancreatitis.
• Clotting disorders.
• Acute pancreatitis or a synchronic malignancy elsewhere in the body.
Setting: secondary care, Netherlands.
Index tests Index test: EUS.
Further details:
Technical specifications: Olympus GF-UC(T)140(P).
Performed by: endoscopists.
Criteria for positive diagnosis: diffuse main duct dilatation (> 10 mm), and/or mural nodes were
present, and/or a solid component was seen outside the cyst
Index test: MRI.
Further details:
Technical specifications: Avanto 1.5 Tesla MR.
Performed by: radiologist.
Criteria for positive diagnosis: diffuse main duct dilatation (> 10 mm), and/or mural nodes were
present, and/or a solid component was seen outside the cyst
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de Jong 2012 (Continued)
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Interval between index test and reference standard varied, with a median of 78 days
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - MRI DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
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de Jong 2012 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Doi 2002
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 38.
Females: 12 (31.6%).
Age: 60 years.
Presentation:
Patients with IPMN who had undergone a pancreatic resection.
Setting: secondary care, Japan.
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Doi 2002 (Continued)
Index tests Index test: EUS.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: presence of mural nodule or papillary projection
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Out of 38 participants included in the study, only 28 underwent EUS. We obtained diagnostic
accuracy information from the discussion. The tables provide information on the number of par-
ticipants who underwent EUS and the diagnostic accuracy of EUS in identifying the presence of
the lesion
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
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Doi 2002 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Erkan 2012
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 46.
Females: not stated.
Age: not stated.
Presentation:
Patients undergoing PET/CT scan for suspected pancreatic lesions and surgical resection.
Setting: secondary care, Germany.
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Erkan 2012 (Continued)
Index tests Index test: PET.
Further details:
Technical specifications: model and manufacturer not stated.
Performed by: radiologist.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 5 (10.9%)
Comparative
Notes FLT-PET was also available.
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous versus benign - PET DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
106Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Erkan 2012 (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Fischer 2009 - Cystic
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 33.
Females: not stated.
Age: not stated.
Presentation:
Patients with pancreatic lesions undergoing EUS-FNA.
Setting: secondary care, country not stated.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
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Fischer 2009 - Cystic (Continued)
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Precancerous or cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 2: Index Test Cystic lesion subgroup analysis - Precancerous or cancerous versus benign - EUS FNA DOMAIN 2: Index
- EUS FNA
If a threshold was used, was it
pre-specified?
Yes
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Fischer 2009 - Cystic (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Fischer 2009 - Solid
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 33.
Females: not stated.
Age: not stated.
Presentation:
Patients with pancreatic lesions undergoing EUS-FNA.
Setting: secondary care, country not stated.
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Fischer 2009 - Solid (Continued)
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Precancerous or cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
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Fischer 2009 - Solid (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Fisher 2008
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 48.
Females: 33 (68.8%).
Age: 60 years.
Presentation:
Inclusion criteria
• Patients with cystic pancreatic lesions who had undergone surgical resection.
Exclusion criteria
• Patients with a clear history of acute pancreatitis and subsequent development of a
pseudocyst were excluded from the study.
Setting: secondary care, USA.
Index tests Index test: CT.
Further details:
Technical specifications: not stated.
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Fisher 2008 (Continued)
Performed by: radiologist.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Precancerous or cancerous versus benign - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
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Fisher 2008 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Grieser 2010
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 105.
Females: 32 (30.5%).
Age: 58 years.
Presentation:
Patients undergoing surgical exploration or resection for pancreatic mass and CT scan.
Setting: secondary care, Germany.
Index tests Index test: CT.
Further details:
Technical specifications: Siemens Somatom Plus 4; GE Healthcare LightSpeed Ultra, LightSpeed
16/Pro16, LightSpeed VCT.
Performed by: radiologist.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision or biopsy during exploratory laparotomy for non-resectable
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Grieser 2010 (Continued)
cancers.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Another radiologist has a lower specificity.
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous versus benign - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Grieser 2010 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Harrison 1999
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 18.
Females: 10 (55.6%).
Age: 62 years.
Presentation:
Patients undergoing surgery for suspected pancreatic cancer.
Setting: secondary care, USA.
Index tests Index test: EUS.
Further details:
Technical specifications: Olympus UM20.
Performed by: endoscopist.
Criteria for positive diagnosis: not stated.
Index test: CT.
Further details:
Technical specifications: not stated.
Performed by: endoscopist.
Criteria for positive diagnosis: not stated.
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Harrison 1999 (Continued)
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous versus benign - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous versus benign - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
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Harrison 1999 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Higashi 1997
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 34.
Females: 16 (47.1%).
Age: 61 years.
Presentation:
Patients with suspected pancreatic tumours undergoing PET and surgery.
Setting: secondary care, Japan.
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Higashi 1997 (Continued)
Index tests Index test: PET.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous versus benign - PET DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
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Higashi 1997 (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Hong 2010
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 31.
Females: 16 (51.6%).
Age: 65 years.
Presentation:
Patients with IPMN who had undergone CT/PET.
Setting: secondary care, Korea.
Index tests Index test: PET.
Further details:
Technical specifications: DSTe (GE Healthcare).
Performed by: radiologist.
Criteria for positive diagnosis: SUVmax > 2.5.
Index test: CT.
Further details:
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Hong 2010 (Continued)
Technical specifications: LightSpeed Plus (GE Healthcare) or Somatom Sensation 64 (Siemens
Healthcare).
Performed by: radiologist.
Criteria for positive diagnosis:
• Main duct-type.
• Marked dilatation of the main pancreatic duct (> 10 mm).
• Large mural nodule (> 1 cm).
• Large cyst size (> 3 cm).
• Irregular or septate cyst.
• Calcification.
• Patulous duodenal papilla.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision, open laparotomy biopsy or biopsy of metastases.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - PET (SUV max 2-2.5)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
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Hong 2010 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - CT
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Unclear
High
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Hu 2013
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 80.
Females: 36 (45.0%).
Age: 57 years.
Presentation:
Inclusion criteria
• Patients with solitary pancreatic lesions who had undergone PET scan and surgical resection.
Exclusion criteria
• Patients with suspected malignancies in other areas of the body.
Setting: secondary care, China.
Index tests Index test: PET.
Further details:
Technical specifications: Biograph 16 HR PET/CT scanner (Siemens).
Performed by: radiologist.
Criteria for positive diagnosis: SUVmax > 3.5.
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Hu 2013 (Continued)
Unclear High
DOMAIN 2: Index Test Cystic lesion subgroup analysis - Cancerous versus benign - PET DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High Low
DOMAIN 2: Index Test Cancerous versus benign - PET (SUV max > 3.5) DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Hu 2013 (Continued)
Were all patients included in the
analysis?
Unclear
Unclear
Jafarimehr 2010
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 76.
Females: 40 (52.6%).
Age: not stated.
Presentation:
Patients with pancreatic lesions with PET or PET/CT.
Setting: secondary care, USA.
Index tests Index test: PET.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: cancerous versus benign or precancerous.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
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Jafarimehr 2010 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous versus benign or precancerous - PET DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
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Jang 2014a
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 34.
Females: 21 (61.8%).
Age: 52 years.
Presentation:
Patients with neuroendocrine pancreatic lesions who had undergone MRI and surgery.
Setting: secondary care, Korea.
Index tests Index test: MRI.
Further details:
Technical specifications: Intera Achieva 3.0-T.
Performed by: radiologist.
Criteria for positive diagnosis: apparent diffusion coefficient: 1.09 x 103 mm2/s.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 7 (20.6%)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
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Jang 2014a (Continued)
DOMAIN 2: Index Test Precancerous or cancerous versus benign - MRI DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Jang 2014b
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
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Jang 2014b (Continued)
Patient characteristics and set-
ting
Sample size: 65.
Females: 27 (41.5%).
Age: not stated.
Presentation:
Patients with IPMN undergoing MRI and surgery.
Setting: secondary care, Korea.
Index tests Index test: MRI.
Further details:
Technical specifications: Intera Achieva 3.0-T.
Performed by: radiologist.
Criteria for positive diagnosis: signal intensity of normal pancreatic parenchyma at themural nodule,
septum, cystic wall, ductal wall, and solid lesion of the IPMNs
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 4 (6.2%)
Comparative
Notes A second observer with 1 more false positive (with correspondingly 1 less true negative) was also
available. The sensitivity and specificity are for combined conventional- and diffusion-weighted
scan. The accuracy was lower with conventional scan
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
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Jang 2014b (Continued)
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - MRI
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Jin 2013a
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
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Jin 2013a (Continued)
Patient characteristics and set-
ting
Sample size: 162.
Females: 99 (61.1%).
Age: 64 years.
Presentation:
Patients with pancreatic cysts who underwent surgery.
Setting: secondary care, further details not available.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: model and manufacturer not stated.
Performed by: endoscopist.
Criteria for positive diagnosis: cellular atypia.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA
DOMAIN 2: Index
cerous (low or inter
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Jin 2013a (Continued)
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Jin 2015
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 86.
Females: not stated.
Age: not stated.
Presentation:
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Jin 2015 (Continued)
Patients with mucinous pancreatic cysts undergoing operative resection.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: EUS model not stated; 22-gauge needle.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 1 (1.3%).
Number of patients who were excluded from the analysis: 9 (10.6%)
Comparative
Notes Results were reported for only 76 out of 77 participants with mucinous cysts. The final results were
possible only for these participants
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS FNA DOMAIN 2: Index
FNA
If a threshold was used, was it
pre-specified?
Yes
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Jin 2015 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Kalha 2003
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 24.
Females: not stated.
Age: not stated.
Presentation:
Patients undergoing EUS-FNA and surgery for cystic pancreatic lesions.
Setting: secondary care, USA.
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Kalha 2003 (Continued)
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: EUS model or needle size not stated.
Performed by: not stated.
Criteria for positive diagnosis: cyst CEA fluid >= 500 ng/mL
Target condition and reference
standard(s)
Target condition: cancerous versus benign or precancerous.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Of 84 participants, 60 who were observed were excluded because the reference standard was not
adequate for these participants
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous versus benign or precancerous - EUS FNA (cytology) DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Kalha 2003 (Continued)
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Kamata 2016a
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 70.
Females: 39 (55.7%).
Age: 62 years.
Presentation:
Inclusion criteria
• People with pancreatic cyst.
Exclusion criteria
• People with multiple cysts.
• People with intraductal pancreatic cancer foci.
Setting: secondary care, Japan.
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Kamata 2016a (Continued)
Index tests Index test: EUS.
Further details:
Technical specifications: GF-UCT260; Olympus Medical Systems, Tokyo, Japan.
Performed by: endoscopist.
Criteria for positive diagnosis: presence of mural nodules.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia) or benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 0 (0%).
Number of patients who were excluded from the analysis: 419 (85.7%)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) or benign - EUS
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Kamata 2016a (Continued)
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Kato 1995
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 24.
Females: not stated.
Age: not stated.
Presentation:
Patients with pancreatic masses.
Setting: secondary care, Japan.
Index tests Index test: PET.
Further details:
Technical specifications: HEADTOME-IV (Shimadzu Corporation).
Performed by: not stated.
Criteria for positive diagnosis: not stated.
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Kato 1995 (Continued)
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision, open laparotomy biopsy or clinical follow-up for at least 3
years.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous versus benign - PET DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
Unclear
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Kato 1995 (Continued)
condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Unclear
High
Kim 2015
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 123.
Females: not stated.
Age: not stated.
Presentation:
Patients with surgically proven and histopathologically confirmed IPMN and who had undergone
MRI examinations with diffusion-weighted imaging before surgery.
Setting: secondary care, Korea.
Index tests Index test: MRI.
Further details:
Technical specifications: Verio or Trio (Siemens Medical Solutions), Signa HDTx (GE Medical
Systems), Achieva (Philips Healthcare).
Performed by: radiologist.
Criteria for positive diagnosis: signal intensity of normal pancreatic parenchyma at themural nodule,
septum, cystic wall, ductal wall, and solid lesion of the IPMNs
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
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Kim 2015 (Continued)
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 30 (24.4%)
Comparative
Notes 25 participants were excluded due to lack of diffusion-weighed MRI or subquality MRI. The
sensitivities and specificities reported by other radiologists were lower
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - MRI
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Klau 2011
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 29.
Females: 10 (34.5%).
Age: 61 years.
Presentation:
Patients with solid focal pancreatic lesions who had undergone surgery.
Setting: secondary care, Germany.
Index tests Index test: MRI.
Further details:
Technical specifications: 1.5 T Magnetom Avanto, Siemens.
Performed by: radiologist.
Criteria for positive diagnosis: perfusion fraction < 0.1105
Target condition and reference
standard(s)
Target condition: cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
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Klau 2011 (Continued)
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Sensitivities and specificities for other cut-off values were lower
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Cancerous versus benign - MRI DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
142Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Klau 2011 (Continued)
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Kobayashi 2012
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 36.
Females: 15 (41.7%).
Age: 66 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, Japan.
Index tests Index test: EUS.
Further details:
Technical specifications: UM20, UM2000; Olympus.
Performed by: endoscopists.
Criteria for positive diagnosis: lateral spread of the nodule > 15 mm
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
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Kobayashi 2012 (Continued)
Notes Of 238 participants with IPMN, only 46 who had undergone surgical resection were included in
the analysis; another criterion for diagnosis with lower diagnostic test accuracy was also available
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Kubo 2001
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 51.
Females: 19 (37.3%).
Age: 67 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, Japan.
Index tests Index test: EUS.
Further details:
Technical specifications: GF-UM2, UM3, UM20; Olympus.
Performed by: endoscopists.
Criteria for positive diagnosis:
• in main duct type, tumour > 10 mm dilated MPD;
• in branch duct type, large cystic tumour (> 40 mm) with irregular thick septum; or
• large mural nodule (> 10 mm).
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
145Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kubo 2001 (Continued)
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (low grade dysplasia) - EUS DOMAIN 2: Index
- EUS
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Kubo 2001 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Kucera 2012
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 47.
Females: 15 (31.9%).
Age: 66 years.
Presentation:
Patients with IPMN who had undergone EUS-FNA with cyst fluid analysis and surgical resection.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: GF-UC30P and GF-UC140P, Olympus.
Performed by: endoscopist and cytologist.
Criteria for positive diagnosis: CEA > 200 ng/mL.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Of 87 participants who had undergone surgical resection for IPMN, 40 were excluded because they
had not undergone EUS-FNA
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA (CEA > 200 ng/ml)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Kucera 2012 (Continued)
Were all patients included in the
analysis?
No
High
Le Baleur 2011a
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 60.
Females: 59 (98.3%).
Age: 43 years.
Presentation:
Patients with MCN who had undergone surgical resection.
Setting: secondary care, France.
Index tests Index test: CT.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: presence of mural nodule.
Target condition and reference
standard(s)
Target condition: pre-malignant (low- or intermediate-grade dysplasia) versus malignant (high-
grade dysplasia or invasive carcinoma).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Sensitivity and specificity for other parameters related to size of tumour were available and were
lower
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
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Le Baleur 2011a (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - CT
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
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Unclear
Lee 2014
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 84.
Females: 29 (34.5%).
Age: 65 years.
Presentation:
Patients with branch duct IPMN who had undergone surgical resection.
Setting: secondary care, Korea.
Index tests Index test: EUS.
Further details:
Technical specifications: not stated.
Performed by: endoscopists.
Criteria for positive diagnosis: an EUS score composed of cyst size, mural nodule height, associated
main pancreatic duct dilation, thick septum, and patulous papilla >= 7
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
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Lee 2014 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
High
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Maire 2008
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 41.
Females: 27 (65.9%).
Age: 64 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, France.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: Pentax-FG 32 UA 120°.
Performed by: endoscopists.
Criteria for positive diagnosis: CEA > 200 ng/mL.
Second criteria for positive diagnosis: carbohydrate antigen 19-9 > 1000 U/mL
Target condition and reference
standard(s)
Target conditions:
1. Cancerous (invasive carcinoma) versus precancerous (dysplasia).
2. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or
intermediate-grade dysplasia)
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes 6 different criteria for diagnosis were used. All 6 are listed
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Maire 2008 (Continued)
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS FNA (CEA > 200 ng/ml) DOMAIN 2: Index
FNA (CEA > 200
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA (CEA > 200 ng/ml)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA (Ca 19.9 > 1000 U/ml)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
Yes
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Maire 2008 (Continued)
condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
McHenry 2002
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 45.
Females: not stated.
Age: not stated.
Presentation:
Patients with cystic pancreatic lesion who had undergone surgical resection.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: Pentax echoendoscope.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
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Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cystic lesion subgroup analysis - Precancerous or cancerous versus benign - EUS FNA DOMAIN 2: Index
- EUS FNA
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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McHenry 2002 (Continued)
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Nakagawa 2009
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 34.
Females: not stated.
Age: not stated.
Presentation:
Patients with cystic pancreatic lesion who had undergone surgical resection and EUS.
Setting: secondary care, Japan.
Index tests Index test: EUS.
Further details:
Technical specifications: GF-UMP230 or GF-UC2000P (Olympus).
Performed by: endoscopists.
Criteria for positive diagnosis: height of protruding lesion > 4.1 mm
Index test: CT.
Further details:
Technical specifications: GE LightSpeed Ultra, GE LightSpeed 16; GE Medical Systems.
Performed by: radiologists.
Criteria for positive diagnosis: height of protruding lesion > 4.1 mm
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
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Nakagawa 2009 (Continued)
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High High
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Nakagawa 2009 (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Nara 2009
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 123.
Females: 53 (43.1%).
Age: 65 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, Japan.
Index tests Index test: CT.
Further details:
Technical specifications: single-slice helical CT or MDCT.
Performed by: radiologist.
Criteria for positive diagnosis: irregularly shaped hypoattenuating solid mass detected adjacent to
or surrounding an IPMN on contrast-enhanced CT
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Nara 2009 (Continued)
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Ogawa 2008
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 64.
Females: 20 (31.3%).
Age: 65 years.
Presentation:
Patients with surgically proven and histopathologically confirmed IPMN.
Setting: secondary care, Japan.
Index tests Index test: CT.
Further details:
Technical specifications: Aquilion; Toshiba.
Performed by: radiologist.
Criteria for positive diagnosis: main pancreatic duct - the maximum diameter, the presence of a
septum, and the presence of a mural nodule and its maximum size (length of major axis); the type
(unilocular or multilocular) of lesion, the maximum size of the lesion, the presence of wall thickness
Target condition and reference
standard(s)
Target conditions:
1. Cancerous (invasive carcinoma) versus precancerous (dysplasia).
2. Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma)
versus precancerous (low-grade dysplasia).
Reference standard: surgical excision.
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Ogawa 2008 (Continued)
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 5 (7.8%)
Comparative
Notes Only analysis at lesion level was available.
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Unclear Low
DOMAIN 2: Index Test Precancerous or cancerous (intermediate or high grade dysplasia or invasive carcinoma) versus
precancerous (low grade dysplasia) - CT
DOMAIN 2: Index
invasive carcinoma)
If a threshold was used, was it
pre-specified?
Unclear
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Ogawa 2014
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 38.
Females: 12 (31.6%).
Age: 68 years.
Presentation:
Patients with IPMN undergoing surgery and MRI.
Setting: secondary care, Japan.
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Ogawa 2014 (Continued)
Index tests Index test: MRI.
Further details:
Technical specifications: EXCELART Vantage, Toshiba.
Performed by: radiologist.
Criteria for positive diagnosis: presence of positive signal in diffusion-weighted imaging
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 3 (7.9%)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - MRI
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Ogawa 2014 (Continued)
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Otomi 2014
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 32.
Females: 17 (53.1%).
Age: 63 years.
Presentation:
Patients with pancreatic lesions undergoing PET/CT prior to surgery other than pancreatic adeno-
carcinoma.
Setting: secondary care, Japan.
Index tests Index test: PET.
Further details:
Technical specifications: F100 &CYPRIS (Sumitomo Heavy Industries) and Aquido (Toshiba) CT
scanner.
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Otomi 2014 (Continued)
Performed by: radiologist.
Criteria for positive diagnosis: SUVmax > 2.4.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Sensitivity and specificity for other parameters such as visualisation and SUVmean were available
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Precancerous or cancerous versus benign - PET (SUV max > 2.4) DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
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Otomi 2014 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Pais 2007
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 74.
Females: 36 (48.6%).
Age: 65 years.
Presentation:
Patients with IPMN undergoing surgery and EUS-FNA.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: Olympus GF-UM20, GF-UM130, or GF-UM160; 22-gauge needle.
Performed by: endoscopist and cytologist.
Criteria for positive diagnosis: presence of hyperchromasia, nuclear crowding, and loss of nuclear
uniformity, nucleolar prominence, or chromatin abnormalities
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
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Pais 2007 (Continued)
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS FNA DOMAIN 2: Index
FNA
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
High
Sahani 2006
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 25.
Females: 12 (48.0%).
Age: 69 years.
Presentation:
Patients with IPMN undergoing surgery.
Setting: secondary care, USA.
Index tests Index test: CT.
Further details:
Technical specifications: LightSpeed QX/I (GE Medical Systems).
Performed by: radiologist.
Criteria for positive diagnosis: presence of mural nodules, papillary projections, or a solid mass in
the dilated duct or within the cystic lesion
Index test: MRI.
Further details:
Technical specifications: 1.5-T system Signa (GE Medical Systems).
Performed by: radiologist.
Criteria for positive diagnosis: presence of mural nodules, papillary projections, or a solid mass in
the dilated duct or within the cystic lesion
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Target condition and reference
standard(s)
Target condition: precancerous or cancerous (intermediate- or high-grade dysplasia or invasive
carcinoma) versus precancerous (low-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Precancerous or cancerous (intermediate or high grade dysplasia or invasive carcinoma) versus
precancerous (low grade dysplasia) - CT
DOMAIN 2: Index
invasive carcinoma)
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High Low
DOMAIN 2: Index Test Precancerous or cancerous (intermediate or high grade dysplasia or invasive carcinoma) versus
precancerous (low grade dysplasia) - MRI
DOMAIN 2: Index
invasive carcinoma)
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If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Saito 2013
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 48.
Females: 16 (33.3%).
Age: 69 years.
Presentation:
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Saito 2013 (Continued)
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, Japan.
Index tests Index test: PET.
Further details:
Technical specifications: Aquiduo (Toshiba Medical Systems), Advance NXi (GE Healthcare), and
Discovery ST (GE Healthcare).
Performed by: radiologist.
Criteria for positive diagnosis: SUVmax > 2 and retention index < -10
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Sensitivity and specificity for SUVmax > 2 are also available
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - PET (SUV max 2-2.5)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
No
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Salla 2007
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: consecutive patients.
Patient characteristics and set-
ting
Sample size: 8.
Females: 3 (37.5%).
Age: 63 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, Greece.
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Index tests Index test: EUS-FNA.
Further details:
Technical specifications: equipment not stated; 22-gauge needle.
Performed by: endoscopist.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS FNA DOMAIN 2: Index
FNA
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Salla 2007 (Continued)
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Sedlack 2002
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 34.
Females: 18 (52.9%).
Age: 55 years.
Presentation:
Patients with cystic lesions of pancreas who had undergone EUS and surgical resection.
Setting: secondary care, USA.
Index tests Index test: EUS.
Further details:
Technical specifications: GFU-130, Olympus.
Performed by: endoscopist.
Criteria for positive diagnosis: If 1 or more of the following EUS criteria were met
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Sedlack 2002 (Continued)
• Wall thickness of 3 mm or greater, macroseptation (all cyst compartments > 10 mm
diameter).
• Presence of a mass or intramural growth.
• Cystic dilation of the main pancreatic duct.
Index test: EUS-FNA.
Further details:
Technical specifications: GFUC-30P, Olympus; 22-gauge needle.
Performed by: endoscopist.
Criteria for positive diagnosis: CEA >= 50 ng/mL.
Second criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous versus benign.
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Precancerous or cancerous versus benign - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Precancerous or cancerous versus benign - EUS FNA DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Precancerous or cancerous versus benign - EUS FNA (CEA > 50 ng/ml) DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear High
DOMAIN 2: Index Test Cystic lesion subgroup analysis - Precancerous or cancerous versus benign - EUS FNA DOMAIN 2: Index
- EUS FNA
If a threshold was used, was it
pre-specified?
Unclear
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Smith 2016
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 138.
Females: 99 (71.7%).
Age: 62 years.
Presentation:
Patients with IPMN or MCN.
Setting: secondary care, USA.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: high-grade atypia or worse.
Second criteria for positive diagnosis: abnormal cytology.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
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Smith 2016 (Continued)
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 0 (0%).
Number of patients who were excluded from the analysis: 11 (8%)
Comparative
Notes Diagnostic accuracy was also available for another threshold (abnormal cytology) with lower diag-
nostic accuracy
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
Unclear
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Smith 2016 (Continued)
of the results of the index tests?
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Takanami 2011
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 59.
Females: 3 (5.1%).
Age: 66 years.
Presentation:
Patients with IPMN with mural nodules who had undergone PET/CT and surgical resection.
Setting: secondary care, Japan.
Index tests Index test: PET.
Further details:
Technical specifications: Biograph LSO DUO PET/CT scanner, Siemens.
Performed by: radiologist.
Criteria for positive diagnosis: SUVmax > 2.3.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 43 (72.9%)
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Takanami 2011 (Continued)
Comparative
Notes Only 16 of 43 people with IPMN were included in the analysis. Sensitivity was also available for
SUVmax 2.0 and 2.5
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - PET (SUV max 2-2.5)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
181Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Takanami 2011 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Takeshita 2008
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 53.
Females: 25 (47.2%).
Age: 65 years.
Presentation:
Patients with IPMN who had undergone surgery.
Setting: secondary care, Japan.
Index tests Index test: CT.
Further details:
Technical specifications: LightSpeed QX/I; GE Medical Systems.
Performed by: radiologist.
Criteria for positive diagnosis: presence of mural nodule and main ductal dilatation (> 5 mm) or
presence of mural nodule and cystic tumour size > 3 cm
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: 7 (13.2%)
Comparative
Notes Sensitivity and specificity for other parameters were available
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Takeshita 2008 (Continued)
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (low grade dysplasia) - CT DOMAIN 2: Index
- CT
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Takeshita 2008 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Tan 2009
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 20.
Females: 9 (45.0%).
Age: 62 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, China.
Index tests Index test: CT.
Further details:
Technical specifications: LightSpeed QX/I or LightSpeed 16; GE Medical Systems.
Performed by: radiologist.
Criteria for positive diagnosis: not stated.
Target condition and reference
standard(s)
Target condition: precancerous or cancerous (intermediate- or high-grade dysplasia or invasive
carcinoma) versus precancerous (low-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
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Tan 2009 (Continued)
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Precancerous or cancerous (intermediate or high grade dysplasia or invasive carcinoma) versus
precancerous (low grade dysplasia) - CT
DOMAIN 2: Index
invasive carcinoma)
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Tan 2009 (Continued)
High
Taouli 2000
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 36.
Females: 17 (47.2%).
Age: 61 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, France.
Index tests Index test: CT.
Further details:
Technical specifications: Elscint CT Twin; Elscint.
Performed by: radiologist.
Criteria for positive diagnosis: dilatation of MPD > 10 mm.
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Sensitivity and specificity for other parameters were available
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
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Taouli 2000 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
Low High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Tomimaru 2010
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: neither.
Patient characteristics and set-
ting
Sample size: 29.
Females: 13 (44.8%).
Age: 65 years.
Presentation:
Patients with IPMN who had undergone surgical resection.
Setting: secondary care, Japan.
Index tests Index test: PET.
Further details:
Technical specifications: Headtome/Set 2400W; Shimadzu Corporation.
Performed by: radiologist.
Criteria for positive diagnosis: SUVmax > 2.5.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
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Tomimaru 2010 (Continued)
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - PET (SUV max 2-2.5)
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Yamao 2001
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: neither.
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Yamao 2001 (Continued)
Patient characteristics and set-
ting
Sample size: 49.
Females: 18 (36.7%).
Age: 63 years.
Presentation:
Patients with IPMN undergoing surgical resection.
Setting: secondary care, Japan.
Index tests Index test: CT.
Further details:
Technical specifications: CT9200 (Yokogawa), HiSpeed Advantage (GE).
Performed by: radiologist.
Criteria for positive diagnosis: wall-thickening, presence of nodule, and heterogenous pattern
Index test: EUS.
Further details:
Technical specifications: JF-UM20 and GF-UM240 (Olympus).
Performed by: endoscopist.
Criteria for positive diagnosis: wall-thickening, presence of nodule, and heterogenous pattern
Target condition and reference
standard(s)
Target conditions:
1. Cancerous (invasive carcinoma) versus precancerous (dysplasia).
2. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or
intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 1 (2%).
Number of patients who were excluded from the analysis: not stated
Comparative
Notes The study reported 3 x 3 table for CT scan and EUS. 1 patient was excluded from analysis, but this
differed between CT and EUS
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
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Yamao 2001 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - CT
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
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Yamao 2001 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Zhan 2011
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 21.
Females: 3 (14.3%).
Age: not stated.
Presentation:
Patients with MCN undergoing operative resection.
Setting: secondary care, China.
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Zhan 2011 (Continued)
Index tests Index test: EUS.
Further details:
Technical specifications: model and manufacturer not stated.
Performed by: endoscopist.
Criteria for positive diagnosis: different criteria were reported for IPMN and MCN without any
information on how these were distinguished prior to FNA
Target condition and reference
standard(s)
Target condition: cancerous (invasive carcinoma) versus precancerous (dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes Other criteria with lower sensitivity and specificity were available
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS DOMAIN 2: Index
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Zhan 2011 (Continued)
Unclear High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
Zhan 2013
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 20.
Females: 6 (30.0%).
Age: 59 years.
Presentation:
Patients with MCN undergoing operative resection.
Setting: secondary care, China.
Index tests Index test: EUS-FNA.
Further details:
Technical specifications: GF-UCT-2000-OL5 (Olympus).
Performed by: endoscopist.
Criteria for positive diagnosis: cytology
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Zhan 2013 (Continued)
Second criteria for positive diagnosis: CEA > 692.8 ng/mL.
Target condition and reference
standard(s)
Target condition: cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low-
or intermediate-grade dysplasia).
Reference standard: surgical excision.
Further details:
Technical specifications: not applicable.
Performed by: clinicians.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: not stated.
Number of patients who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA
DOMAIN 2: Index
cerous (low or inter
If a threshold was used, was it
pre-specified?
Yes
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
Unclear Low
DOMAIN 2: Index Test Cancerous (high grade dysplasia or invasive carcinoma) versus precancerous (low or intermediate
grade dysplasia) - EUS FNA (CEA > 692.8 ng/ml)
DOMAIN 2: Index
cerous (low or inter
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Zhan 2013 (Continued)
If a threshold was used, was it
pre-specified?
No
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
Unclear
CEA: carcinoembryonic antigen
CT: computed tomography
EUS: endoscopic ultrasound
FNA: fine-needle aspiration
IPMN: intraductal pancreatic mucinous neoplasm
MCN: mucinous cystic neoplasm
MDCT: multidetector computed tomography
MPD: main pancreatic duct
MRI: magnetic resonance imaging
PET: positron emission tomography
SUV: standard uptake value
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aburime 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Adamek 2000 This study was not included as no pancreatic mass was present in the patient(s) tested
Adimoolam 2011 There was no comparison of whether cancer was present or not
Afify 2003 There was no comparison of whether cancer was present or not
Agarwal 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
Agarwal 2008a This study was not included as no pancreatic mass was present in the patient(s) tested
Agarwal 2008b This study was not included as no pancreatic mass was present in the patient(s) tested
Agarwal 2008c This study was not included as no pancreatic mass was present in the patient(s) tested
Aguilar-Saavedra 2011 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Ahmad 2001 There was no comparison of whether cancer was present or not
Ahmad 2003 There was no comparison of whether cancer was present or not
Ainsworth 2010 There was no comparison of whether cancer was present or not
Aithal 2001 There was no comparison of whether cancer was present or not
Aithal 2002 There was no comparison of whether cancer was present or not
Akahoshi 1998 This study was not included as no pancreatic mass was present in the patient(s) tested
Akwei 2011 There was no comparison of whether cancer was present or not
Al-Haddad 2007 There was no comparison of whether cancer was present or not
Al-Haddad 2010a This study was not included as no pancreatic mass was present in the patient(s) tested
Al-Haddad 2010b There was no comparison of whether cancer was present or not
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(Continued)
Al-Haddad 2014 There was no comparison of whether cancer was present or not
Al-Jebreen 2004 There was no comparison of whether cancer was present or not
Al-Najami 2015 This study was not included as no pancreatic mass was present in the patient(s) tested
Alizadeh 2014 There was no comparison of whether cancer was present or not
Aljebreen 2007 Inadequate reference standard (nature of follow-up not stated)
Alsohaibani 2008 This study was not included as no pancreatic mass was present in the patient(s) tested
Alsohaibani 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Alston 2014 There was no comparison of whether cancer was present or not
Amin 2006 This study was not included as no pancreatic mass was present in the patient(s) tested
Andersen 1994 This study was not included as no pancreatic mass was present in the patient(s) tested
Antonini 2015 There was no comparison of whether cancer was present or not
Arabul 2012 There was no comparison of whether cancer was present or not
Ardengh 2007a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities were used for reference standard (either positive or negative), not accepted unless
all patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ardengh 2007b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ardengh 2008a There was no comparison of whether cancer was present or not
Ardengh 2008b There was no comparison of whether cancer was present or not
Ardengh 2013 Inadequate reference standards
Argimak 2009 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
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(Continued)
Arikawa 2007 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Arlt 2013 The study was not classed as primary research (i.e. not a review or editorial or comment)
Asagi 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Aslanian 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Asnacios 2003 There was no comparison of whether cancer was present or not
Atef 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Attasaranya 2007 There was no comparison of whether cancer was present or not
Awadallah 2008 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Azizi 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Baba 2004 Although this study provides diagnostic accuracy data for pancreatic lesions, it presents information
on branch type and non-branch type first, then presents the diagnostic test accuracy only for branch
type and not for the overall cohort. This is therefore not a representative population
Baek 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Baghbanian 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Baiocchi 2008 Overlap with Baiocchi 2012
Baiocchi 2010 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Baiocchi 2012 Inadequate reference standard (criteria for diagnosing malignancy during clinical follow-up not stated)
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Bali 2011 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Bang 2012a There was no comparison of whether cancer was present or not
Bang 2012b There was no comparison of whether cancer was present or not
Bang 2013a There was no comparison of whether cancer was present or not
Bang 2013b The study was not classed as primary research (i.e. not a review or editorial or comment)
Bang 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Barber 2011 There was no comparison of whether cancer was present or not
Bares 1994 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Barkin 1977 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Baron 1997 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Barral 2013a There was no comparison of whether cancer was present or not
Barral 2013b There was no comparison of whether cancer was present or not
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Barresi 2014 There was no comparison of whether cancer was present or not
Barron 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Bartsch 1998 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Basir 2003 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Bassi 2003 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Beal 2015a Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Beal 2015b Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Becker 2001 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Beliao 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Bentz 1998 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Bergeron 2015 There was no comparison of whether cancer was present or not
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Bernstein 2013 There was no comparison of whether cancer was present or not
Berzosa 2015 There was no comparison of whether cancer was present or not
Bhutani 1995 There was no comparison of whether cancer was present or not
Bhutani 1997 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Bick 2015 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Bighi 1989 This study was not included as no pancreatic mass was present in the patient(s) tested
Binmoeller 1998a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Binmoeller 1998b This study was not included as no pancreatic mass was present in the patient(s) tested
Bluen 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Bournet 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Bournet 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Bournet 2012 There was no comparison of whether cancer was present or not
Bournet 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Boutros 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Brand 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
Brand 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Brenin 1995 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Brimiene 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Brugge 2000 The study was not classed as primary research (i.e. not a review or editorial or comment)
Brugge 2004a The study was not classed as primary research (i.e. not a review or editorial or comment)
Brugge 2004b There was no comparison of whether cancer was present or not
Bruno 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Buchholz 2005 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
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Buchs 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Butt 2015a There was no comparison of whether cancer was present or not
Butt 2015b Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Caglar 2013 There was no comparison of whether cancer was present or not
Cahn 1996 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Caldelari 2011 There was no comparison of whether cancer was present or not
Camellini 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Cantley 2014 There was no comparison of whether cancer was present or not
Carbognin 2006 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Carlinfante 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Carroll 1997 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Casneuf 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Catanzaro 2003 There was no comparison of whether cancer was present or not
Catanzaro 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Cermak 2012 There was no comparison of whether cancer was present or not
Chai 2013 There was no comparison of whether cancer was present or not
Chang 1994 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Chang 1997 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Chang 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Chaudhari 2007 There was no comparison of whether cancer was present or not
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Chaudhari 2008 There was no comparison of whether cancer was present or not
Chaya 2006 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Chebib 2014 There was no comparison of whether cancer was present or not
Chen 2001 There was no comparison of whether cancer was present or not
Chen 2003 There was no comparison of whether cancer was present or not
Chen 2007 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Chen 2014 There was no comparison of whether cancer was present or not
Cheng 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Cheng 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Chiu 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
Chiu 2006 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Cho 2005 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Cho 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Choi 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Choi 2013 There was no comparison of whether cancer was present or not
Choi 2016 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Chung 2009 Inappropriate index test
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Cizginer 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Clave 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
Cocieru 2011 There was no comparison of whether cancer was present or not
Collins 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Collins 2013 There was no comparison of whether cancer was present or not
Collins 2015 There was no comparison of whether cancer was present or not
Cone 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Corominas-Cishek 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Cosgrove 2015 The study was not classed as primary research (i.e. not a review or editorial or comment)
Crippa 2010 The study was not classed as primary research (i.e. not a review or editorial or comment)
Cuillerier 1996 There was no comparison of whether cancer was present or not
D’Onofrio 2007 There was no comparison of whether cancer was present or not
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D’Onofrio 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Dadabhai 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Dadds 2012 There was no comparison of whether cancer was present or not
Dani 2000 There was no comparison of whether cancer was present or not
Dawwas 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Dawwas 2013 The study was not classed as primary research (i.e. not a review or editorial or comment)
De Jong 2010 Should be included under de Jong 2012
de Jong 2011 There was no comparison of whether cancer was present or not
De Tejada 2008 There was no comparison of whether cancer was present or not
Decalan 1995 There was no comparison of whether cancer was present or not
Del Vecchio 2016 Inadequate reference standards
Delbeke 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
DelMaschio 1991 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
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negative, patients must have been followed for at least 6 months
Deng 2008 This study was not included as no pancreatic mass was present in the patient(s) tested
Deshpande 2008 There was no comparison of whether cancer was present or not
DeWitt 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
DeWitt 2005 The study was not classed as primary research (i.e. not a review or editorial or comment)
DeWitt 2008 This study was not included as no pancreatic mass was present in the patient(s) tested
Di Cataldo 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Diederichs 2000 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Diehl 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Dietrich 2008 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Dim 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
DiMagno 1977 This study was not included as no pancreatic mass was present in the patient(s) tested
Dinkel 1990 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Do 2014 There was no comparison of whether cancer was present or not
Draganov 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Eguia 2013 There was no comparison of whether cancer was present or not
Elmas 1996 Inadequate reference standards
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Eloubeidi 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2003a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2003b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2006a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2006b This study was not included as no pancreatic mass was present in the patient(s) tested
Eloubeidi 2006c Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
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Eloubeidi 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2008a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2008b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Eloubeidi 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Ergul 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Erickson 1997 This study was not included as no pancreatic mass was present in the patient(s) tested
Erickson 2000 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Erickson 2001 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Ernst 1998 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Erturk 2006a The study was not classed as primary research (i.e. not a review or editorial or comment)
Erturk 2006b This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Fabbri 2013 There was no comparison of whether cancer was present or not
Fabbri 2015a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fabbri 2015b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Faigel 1997 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fan 2013 There was no comparison of whether cancer was present or not
Fan 2015 There was no comparison of whether cancer was present or not
Fanning 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Faravelli 1990 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Felgueroso 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fernandez-Esparrach 2007a There was no comparison of whether cancer was present or not
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Fernandez-Esparrach 2007b There was no comparison of whether cancer was present or not
Figueiredo 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fischer 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
Fischer 2009 There was no comparison of whether cancer was present or not
Fisher 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fisher 2011 There was no comparison of whether cancer was present or not
Frampton 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Friess 1995 This study was not included as no pancreatic mass was present in the patient(s) tested
Fritscher-Ravens 1998 This study was not included as no pancreatic mass was present in the patient(s) tested
Fritscher-Ravens 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fritscher-Ravens 2000 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
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during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fritscher-Ravens 2001a This study was not included as no pancreatic mass was present in the patient(s) tested
Fritscher-Ravens 2001b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Fritscher-Ravens 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
Frossard 2003 There was no comparison of whether cancer was present or not
Fugazzola 1991 There was no comparison of whether cancer was present or not
Furuhashi 2015 There was no comparison of whether cancer was present or not
Furuhata 2012 There was no comparison of whether cancer was present or not
Fusari 2010 There was no comparison of whether cancer was present or not
Fusaroli 2010 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Fusaroli 2014 The study was not classed as primary research (i.e. not a review or editorial or comment)
Gaa 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Gambitta 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Ganc 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Ganc 2015 Inadequate reference standards
Gaspar 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Gill 2008 The study was not classed as primary research (i.e. not a review or editorial or comment)
Gimeno-Garcia 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Giorgetti 2010 Inadequate reference standard (nature of follow-up not stated)
Giovannini 1995 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Giovannini 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Glasbrenner 2000 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Goh 2006a The study was not classed as primary research (i.e. not a review or editorial or comment)
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Goh 2008 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Gomez 2006 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Gomez 2008 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Gong 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
Gordon 2014 Inadequate reference standards
Gowland 1981 This study was not included as no pancreatic mass was present in the patient(s) tested
Green 2002 The study was not classed as primary research (i.e. not a review or editorial or comment)
Grenacher 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
Gress 1997 This study was not included as no pancreatic mass was present in the patient(s) tested
Gress 2001 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Grieser 2013 There was no comparison of whether cancer was present or not
Guo 2008 There was no comparison of whether cancer was present or not
Gupta 1995 This study was not included as no pancreatic mass was present in the patient(s) tested
Gupta 2008 There was no comparison of whether cancer was present or not
Haba 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Haba 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
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not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hammel 1995 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Hammel 1998 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Han 2016 Inadequate reference standards
Hanada 2009 There was no comparison of whether cancer was present or not
Hanninen 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
Hanninen 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
Harewood 2001a The study was not classed as primary research (i.e. not a review or editorial or comment)
Harewood 2001b This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Harewood 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hasan 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Hasenberg 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hasyagar 2004 There was no comparison of whether cancer was present or not
Hayashi 2013 There was no comparison of whether cancer was present or not
Hebert-Magee 2015 The study was not classed as primary research (i.e. not a review or editorial or comment)
Heinrich 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
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not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Henkes 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Heo 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Herman-Sucharska 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
Hernandez 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Herrmann 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Higashi 2002a The study was not classed as primary research (i.e. not a review or editorial or comment)
Higashi 2002b Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Higashi 2003 The study was not classed as primary research (i.e. not a review or editorial or comment)
Hijioka 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Hikichi 2009 Inadequate reference standard (details of clinical follow-up not stated)
Hilendarov 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hilendarov 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
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imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hilendarov 2012 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Hilendarov 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Ho 1996 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ho 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hocke 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hocke 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hollerbach 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Holt 2008 There was no comparison of whether cancer was present or not
Holt 2014 The study was not classed as primary research (i.e. not a review or editorial or comment)
Hong 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Honselmann 2016 Inadequate reference standards
Horatagis 2003 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Horwhat 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
Horwhat 2006 This study was not included as no pancreatic mass was present in the patient(s) tested
Hou 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Hu 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Huang 2010 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Huang 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
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Hunt 2009 There was no comparison of whether cancer was present or not
Hussain 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Hwang 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Hwang 2011 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Ibrahim 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ichikawa 2001 There was no comparison of whether cancer was present or not
Iftimia 2012 The study was not classed as primary research (i.e. not a review or editorial or comment)
Iglesias 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2009a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
221Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2009b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2010 There was no comparison of whether cancer was present or not
Iglesias-Garcia 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2013a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iglesias-Garcia 2013b The study was not classed as primary research (i.e. not a review or editorial or comment)
Iguchi 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ikeura 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Ikeura 2015a This study was not included as no pancreatic mass was present in the patient(s) tested
Ikeura 2015b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
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not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Imazu 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Imdahl 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
Inokuma 1995 This study was not included as no pancreatic mass was present in the patient(s) tested
Iordache 2016 Inadequate reference standards
Ippolito 2015 There was no comparison of whether cancer was present or not
Irie 2002 There was no comparison of whether cancer was present or not
Ironside 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ishigami 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Ishii 2012 There was no comparison of whether cancer was present or not
Ishikawa 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Itoh 2005 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Itoi 2005a This study was not included as no pancreatic mass was present in the patient(s) tested
Itoi 2005b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Itoi 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
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during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Itokawa 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Itokawa 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Iwashita 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Iwashita 2015 This study was not included as no pancreatic mass was present in the patient(s) tested
Izuishi 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Jabbar 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Jadvar 2001 This study was not included as no pancreatic mass was present in the patient(s) tested
Jahng 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Jahromi 2014 There was no comparison of whether cancer was present or not
Jang 2012 There was no comparison of whether cancer was present or not
Jang 2015 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Jani 2006 The study was not classed as primary research (i.e. not a review or editorial or comment)
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Jani 2008 There was no comparison of whether cancer was present or not
Janssen 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Jayasekeran 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Jeong 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Jhala 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Jin 2013b This study was not included as no pancreatic mass was present in the patient(s) tested
Jing 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Johnson 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kadayifci 2014 The study was not classed as primary research (i.e. not a review or editorial or comment)
Kadayifci 2016 Inadequate reference standards
Kaffes 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Kaimakliotis 2015 Inappropriate index test
Kalb 2013 There was no comparison of whether cancer was present or not
Kalra 2003 The study was not classed as primary research (i.e. not a review or editorial or comment)
Kamata 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kamata 2016b Inadequate reference standards
Kamin 1980 This study was not included as no pancreatic mass was present in the patient(s) tested
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Kamisawa 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kanazawa 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Kang 2013 Reference to be included under Kim 2015.
Kang 2014 There was no comparison of whether cancer was present or not
Kang 2016 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Katanuma 2013 There was no comparison of whether cancer was present or not
Katz 2007 The study was not classed as primary research (i.e. not a review or editorial or comment)
Kauhanen 2009a This study was not included as no pancreatic mass was present in the patient(s) tested
Kauhanen 2009b This study was not included as no pancreatic mass was present in the patient(s) tested
Kauhanen 2015 Inadequate reference standards
Kawada 2012 There was no comparison of whether cancer was present or not
Kawada 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Kawada 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kawada 2016 Inappropriate target condition
Kawamoto 2006 There was no comparison of whether cancer was present or not
Keil 2008 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
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+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Keswani 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Khalid 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Khalid 2006 Same as Kim 2015
Khan 2010 There was no comparison of whether cancer was present or not
Khashab 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Khashab 2013 There was no comparison of whether cancer was present or not
Khodadadian 2001 This study was not included as no pancreatic mass was present in the patient(s) tested
Khurana 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Khurana 2014 There was no comparison of whether cancer was present or not
Kida 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Kim 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kim 2009 There was no comparison of whether cancer was present or not
Kim 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
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patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kim 2012a There was no comparison of whether cancer was present or not
Kim 2012b There was no comparison of whether cancer was present or not
Kim 2012c This study was not included as no pancreatic mass was present in the patient(s) tested
Kim 2013a There was no comparison of whether cancer was present or not
Kim 2013b This study was not included as no pancreatic mass was present in the patient(s) tested
Kim 2013c This study was not included as no pancreatic mass was present in the patient(s) tested
Kim 2013d There was no comparison of whether cancer was present or not
Kim 2014a This study was not included as no pancreatic mass was present in the patient(s) tested
Kim 2014b This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Kim 2014c This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Kim 2014d There was no comparison of whether cancer was present or not
Kim 2015a Inappropriate index test
Kin 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kitano 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Klapman 2003 This study was not included as no pancreatic mass was present in the patient(s) tested
Klapman 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
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Klapman 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
Kliment 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kliment 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kokhanenko 2001 This study was not included as no pancreatic mass was present in the patient(s) tested
Kongkam 2015 Inadequate reference standards
Kopelman 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Koranda 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Korenblit 2016 Inadequate reference standards
Koyama 2001 This study was not included as no pancreatic mass was present in the patient(s) tested
Kriger 2011 This study was not included as the index test was not performed to distinguish between cancerous,
precancerous, and benign lesions
Krishna 2009a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Krishna 2009b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Krishna 2009c This study was not included as no pancreatic mass was present in the patient(s) tested
Krishna 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Krishna 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Krishna 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Krishnan 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Kubiliun 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kubo 2009 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
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Kudo 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kula 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kumon 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Kumon 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Kumon 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Kung 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Kursawa 1991 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kwong 2015 Inadequate reference standards
Kyokane 1996 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Kysucan 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Lackner 1980 The study was not classed as primary research (i.e. not a review or editorial or comment)
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Larghi 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Larino-Noia 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Le Baleur 2009 There was no comparison of whether cancer was present or not
Le Baleur 2011b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
LeBlanc 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
LeBlanc 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2005a There was no comparison of whether cancer was present or not
Lee 2005b This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Lee 2006 There was no comparison of whether cancer was present or not
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Lee 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2008a There was no comparison of whether cancer was present or not
Lee 2008b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Lee 2010a Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Lee 2010b This study was not included as no pancreatic mass was present in the patient(s) tested
Lee 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2013a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2013b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
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not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2013c This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2013d This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Lee 2014b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2014c This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lee 2014d This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Leeds 2013 There was no comparison of whether cancer was present or not
Legmann 1998 This study was not included as no pancreatic mass was present in the patient(s) tested
Lehmann 1998 This study was not included as no pancreatic mass was present in the patient(s) tested
Lemke 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
234Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
negative, patients must have been followed for at least 6 months
Levy 1995 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Levy 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Levy 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Levy 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Lightdale 1994 The study was not classed as primary research (i.e. not a review or editorial or comment)
Lim 2005 There was no comparison of whether cancer was present or not
Lim 2013 There was no comparison of whether cancer was present or not
Lin 2003 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lin 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lin 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Linder 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
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imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Liu 2010a Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Liu 2010b This study was not included as no pancreatic mass was present in the patient(s) tested
Liu 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lopez 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lozano 2011 There was no comparison of whether cancer was present or not
Lu 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lu 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Lytras 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
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Mackie 1979 This study was not included as no pancreatic mass was present in the patient(s) tested
Madan 2012 There was no comparison of whether cancer was present or not
Madura 1997 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Maguchi 2006 The study was not classed as primary research (i.e. not a review or editorial or comment)
Maire 2003 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Makaiova 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
Malak 2016 Inadequate reference standards
Malleo 2012 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Mallery 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Maluf 2005 There was no comparison of whether cancer was present or not
Maluf-Filho 2007 There was no comparison of whether cancer was present or not
Mamoon 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Manfredi 2009 There was no comparison of whether cancer was present or not
Mansoor 2012 There was no comparison of whether cancer was present or not
Mansour 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Mao 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Marchevsky 2003 This study was not included as no pancreatic mass was present in the patient(s) tested
Marotta 1991 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
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Martin 1998 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Martinez 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Marzioni 2015 Inadequate reference standards; details of clinical follow-up not available
Matsubara 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Matsubayashi 2015 The study was not classed as primary research (i.e. not a review or editorial or comment)
Matsuda 2012 There was no comparison of whether cancer was present or not
Matsumoto 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Matsumoto 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Matsumoto 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Maurea 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Mavrogenis 2015 This study was not included as no pancreatic mass was present in the patient(s) tested
Mayerle 2016 Inadequate reference standards
McClellan 2003 This study was not included as no pancreatic mass was present in the patient(s) tested
McDowell 1997 There was no comparison of whether cancer was present or not
Mehan 2009 There was no comparison of whether cancer was present or not
Mehmood 2015 This study was not included as no pancreatic mass was present in the patient(s) tested
Meijer 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Meijer 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Mera 1999 There was no comparison of whether cancer was present or not
Mertz 2000 This study was not included as no pancreatic mass was present in the patient(s) tested
Mesihovic 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
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Micames 2007 The study was not classed as primary research (i.e. not a review or editorial or comment)
Michaels 2006 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Midwinter 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
Mishra 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Mitsuhashi 2006 There was no comparison of whether cancer was present or not
Miyabe 2015 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Moehler 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Moparty 2007 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Moris 2016 Inappropriate target population
Morozova 2014 There was no comparison of whether cancer was present or not
Morozova 2015 Inappropriate target population
Murayama 2011 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Nadig 2012 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Nagamachi 2013 Inadequate reference standards
Nagula 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Nakai 2015 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
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Nakamoto 2000 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Nakamoto 2003 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Napoleon 2010a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Napoleon 2010b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Napoleon 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Nattermann 1995 There was no comparison of whether cancer was present or not
Nayar 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
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negative, patients must have been followed for at least 6 months
Nayar 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Nguyen 1998 This study was not included as no pancreatic mass was present in the patient(s) tested
Nguyen 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Nguyen 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Nicaud 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Nieto 2007 Details of clinical follow-up not available
Nijhawan 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Nikiforova 2013 There was no comparison of whether cancer was present or not
Nishihara 1996 Inappropriate target condition
Nitzsche 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
Nobrega 1994 This study was not included as no pancreatic mass was present in the patient(s) tested
Noda 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Noma 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Noone 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
Norton 2001 This study was not included as no pancreatic mass was present in the patient(s) tested
Nougaret 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
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during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
O’Toole 2004 There was no comparison of whether cancer was present or not
Ogawa 2008b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ogura 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Oguz 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ohno 2009 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Ohta 2012 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Ohtsuka 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Okada 1979 This study was not included as no pancreatic mass was present in the patient(s) tested
Okada 1981 This study was not included as no pancreatic mass was present in the patient(s) tested
Okasha 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
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not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Okasha 2015 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Olson 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Ooi 1998 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Ootaki 2012 There was no comparison of whether cancer was present or not
Opacic 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Oppong 2015 Inadequate reference standards
Osman 2016 Inadequate reference standards
Othman 2011 The study was not classed as primary research (i.e. not a review or editorial or comment)
Ozkan 2016 Inadequate reference standards
Paik 2015 This study was not included as no pancreatic mass was present in the patient(s) tested
Palacios-Gerona 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Palaniappan 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Palazzo 1993 This study was not included as no pancreatic mass was present in the patient(s) tested
Palazzo 2011 The study was not classed as primary research (i.e. not a review or editorial or comment)
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Pan 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Panaro 1978 This study was not included as no pancreatic mass was present in the patient(s) tested
Papanikolaou 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Papos 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Papos 2002a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Papos 2002b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Park 2014a There was no comparison of whether cancer was present or not
Park 2014b This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Park 2016a Inadequate reference standards
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Park 2016b Inadequate reference standards
Pasanen 1992 This study was not included as no pancreatic mass was present in the patient(s) tested
Pasanen 1993 This study was not included as no pancreatic mass was present in the patient(s) tested
Patoureaux 2013 There was no comparison of whether cancer was present or not
Paye 2000 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Pedrazzoli 2005 The study was not classed as primary research (i.e. not a review or editorial or comment)
Pellise 2003 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Perri 2012 The study was not classed as primary research (i.e. not a review or editorial or comment)
Perrone 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Petrone 2012 There was no comparison of whether cancer was present or not
Pezzilli 2013 There was no comparison of whether cancer was present or not
Pitman 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Pitman 2013a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
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negative, patients must have been followed for at least 6 months
Pitman 2013b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Pitman 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Pomerri 1991 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Pongpornsup 2011 There was no comparison of whether cancer was present or not
Qian 2003 There was no comparison of whether cancer was present or not
Qian 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Qin 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Quentin 2005 There was no comparison of whether cancer was present or not
Qureshi 2013 There was no comparison of whether cancer was present or not
Raddaoui 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
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Rajput 1998 This study was not included as no pancreatic mass was present in the patient(s) tested
Raman 2013 There was no comparison of whether cancer was present or not
Ramesh 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Ramesh 2015 There was no comparison of whether cancer was present or not
Ramesh 2016 Inadequate reference standards
Ramirez-Luna 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Rana 2011 There was no comparison of whether cancer was present or not
Ranney 2012 There was no comparison of whether cancer was present or not
Rao 2011 There was no comparison of whether cancer was present or not
Rasmussen 2001 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Rasmussen 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Raut 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
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Raut 2003 This study was not included as no pancreatic mass was present in the patient(s) tested
Redelman 2014 This study was not included as no pancreatic mass was present in the patient(s) tested
Reicher 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Repak 2009 There was no comparison of whether cancer was present or not
Ribeiro 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Richter 1996 This study was not included as no pancreatic mass was present in the patient(s) tested
Richter 2001 This study was not included as no pancreatic mass was present in the patient(s) tested
Ridtitid 2015 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Rocca 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Roch 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Rodriguez 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Rodriguez 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Rodriguez-D’Jesus 2013 There was no comparison of whether cancer was present or not
Rogart 2011 There was no comparison of whether cancer was present or not
Romagnuolo 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Rong 2012 There was no comparison of whether cancer was present or not
Rosch 1990a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Rosch 1990b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Rosch 1991a There was no comparison of whether cancer was present or not
Rosch 1991b This study was not included as no pancreatic mass was present in the patient(s) tested
Rosch 2000 This study was not included as no pancreatic mass was present in the patient(s) tested
Rose 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
Rosique 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Rudolph 2001 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
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negative, patients must have been followed for at least 6 months
Ruf 2006 This study was not included as no pancreatic mass was present in the patient(s) tested
Ryozawa 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
Saftoiu 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Saftoiu 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Saftoiu 2010a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Saftoiu 2010b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Saftoiu 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Saftoiu 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
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patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Saftoiu 2013 The study was not classed as primary research (i.e. not a review or editorial or comment)
Saftoiu 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sahai 2012 The study was not classed as primary research (i.e. not a review or editorial or comment)
Sahani 2006b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sahani 2011 There was no comparison of whether cancer was present or not
Sai 2003 There was no comparison of whether cancer was present or not
Sakamoto 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sakamoto 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Salvia 2012 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Sandrasegaran 2011 There was no comparison of whether cancer was present or not
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Santhosh 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sarbia 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sariya 2003 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Savides 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Savides 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Savoy 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Saxena 2014 There was no comparison of whether cancer was present or not
Schick 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
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during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Schima 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Schmidt 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Schneider 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Schrader 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Schraibman 2011 There was no comparison of whether cancer was present or not
Scott 2000 There was no comparison of whether cancer was present or not
Seicean 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Seicean 2016 Inadequate reference standards
Sendino 2010 There was no comparison of whether cancer was present or not
Sendler 2000 Inadequate reference standards
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Serikawa 2006 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Shah 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Shen 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Shimizu 2010 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Shimizu 2013a This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Shimizu 2013b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Shimizu 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Shimizu 2015 Inappropriate index test
Shin 2002 This study was not included as no pancreatic mass was present in the patient(s) tested
Shin 2010 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Siddiqui 2009 There was no comparison of whether cancer was present or not
Siddiqui 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Siddiqui 2011 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Siddiqui 2012 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Siddiqui 2013 There was no comparison of whether cancer was present or not
Siech 1998 There was no comparison of whether cancer was present or not
Simon 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sina 2014 The study was not classed as primary research (i.e. not a review or editorial or comment)
Singer 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Singhi 2014 There was no comparison of whether cancer was present or not
Singhi 2016 Inadequate reference standards
Singu 2008 There was no comparison of whether cancer was present or not
Soares 2015a Inadequate reference standards
Soares 2015b Inadequate reference standards
Sole 2005 There was no comparison of whether cancer was present or not
Song 2007 There was no comparison of whether cancer was present or not
Song 2010 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Sperti 1994 There was no comparison of whether cancer was present or not
Sperti 2001 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sperti 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sperti 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sreenarasimhaiah 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sreenarasimhaiah 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sreenarasimhaiah 2013 The study was not classed as primary research (i.e. not a review or editorial or comment)
Sreenarasimhaiah 2015 There was no comparison of whether cancer was present or not
Staib 1997 This study was not included as no pancreatic mass was present in the patient(s) tested
256Imaging modalities for characterising focal pancreatic lesions (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Starkov 2008 This study was not included as no pancreatic mass was present in the patient(s) tested
Stelow 2003 There was no comparison of whether cancer was present or not
Storch 2006 This study was not included as no pancreatic mass was present in the patient(s) tested
Storch 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Story 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Strand 2014 There was no comparison of whether cancer was present or not
Strauss 2016 Inadequate reference standards
Strobel 2013 The study was not classed as primary research (i.e. not a review or editorial or comment)
Strohm 1984 This study was not included as no pancreatic mass was present in the patient(s) tested
Su 2007 There was no comparison of whether cancer was present or not
Sugimoto 2015 Inadequate reference standards
Sugiyama 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Suits 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
Sun 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sur 2015 Inadequate reference standards
Suzuki 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
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not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Suzuki 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Sverko 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Swobodnik 1983 This study was not included as no pancreatic mass was present in the patient(s) tested
Szafranska 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Tada 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Tadic 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Takahashi 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
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Talar-Wojnarowska 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Tallini 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Taouli 2002 The study was not classed as primary research (i.e. not a review or editorial or comment)
Tarantino 2014a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Tarantino 2014b There was no comparison of whether cancer was present or not
Tarantino 2014c There was no comparison of whether cancer was present or not
Tatsumi 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Tatsuta 1985 This study was not included as no pancreatic mass was present in the patient(s) tested
Taylor 2007 The study was not classed as primary research (i.e. not a review or editorial or comment)
Tervahartiala 1997 This study was not included as no pancreatic mass was present in the patient(s) tested
Tessler 2006 This study was not included as no pancreatic mass was present in the patient(s) tested
Theruvath 2010 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Thomas 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
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negative, patients must have been followed for at least 6 months
Thomas 2010a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Thomas 2010b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Tlostanova 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Togliani 2015 This study was not included as no pancreatic mass was present in the patient(s) tested
Touchefeu 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Trifunovic 2004 This study was not included as no pancreatic mass was present in the patient(s) tested
Tummala 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Turowska 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
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Uehara 2011 This study was not included as no pancreatic mass was present in the patient(s) tested
Uehara 2015 Inadequate reference standards
Uekitani 2016 Inadequate reference standards
Valinas 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
van Gulik 1999 This study was not included as no pancreatic mass was present in the patient(s) tested
van Kouwen 2004 The study was not classed as primary research (i.e. not a review or editorial or comment)
van Kouwen 2005 This study was not included as no pancreatic mass was present in the patient(s) tested
Vanbiervliet 2014 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Varadarajulu 2004a There was no comparison of whether cancer was present or not
Varadarajulu 2004b This study was not included as no pancreatic mass was present in the patient(s) tested
Varadarajulu 2014a There was no comparison of whether cancer was present or not
Varadarajulu 2014b There was no comparison of whether cancer was present or not
Vasile 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Verzola 2000 This study was not included as no pancreatic mass was present in the patient(s) tested
Vilgrain 1989 There was no comparison of whether cancer was present or not
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Vilgrain 1995 There was no comparison of whether cancer was present or not
Vilmann 1995 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Virtue 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Visser 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Visser 2008 There was no comparison of whether cancer was present or not
Voss 2000 There was no comparison of whether cancer was present or not
Votrubova 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Vullierme 2007 There was no comparison of whether cancer was present or not
Wachs 2010 There was no comparison of whether cancer was present or not
Wakabayashi 2008 This study was not included as no pancreatic mass was present in the patient(s) tested
Wakatsuki 2004 There was no comparison of whether cancer was present or not
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Wakatsuki 2005 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Walter 2015 Inadequate reference standards
Wang 2005 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Wang 2007a There was no comparison of whether cancer was present or not
Wang 2007b This study was not included as no pancreatic mass was present in the patient(s) tested
Wang 2009 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Wang 2011a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wang 2011b This study was not included as no pancreatic mass was present in the patient(s) tested
Wang 2012 There was no comparison of whether cancer was present or not
Wani 2011 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wani 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Warda 2015 Inadequate reference standards
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Watanabe 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Waters 2008 There was no comparison of whether cancer was present or not
Waxman 2001 The study was not classed as primary research (i.e. not a review or editorial or comment)
Wegener 1995 There was no comparison of whether cancer was present or not
Wiersema 1994 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wiersema 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wiesenauer 2003 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Will 2007 This study was not included as no pancreatic mass was present in the patient(s) tested
Will 2008 This study was not included as no pancreatic mass was present in the patient(s) tested
Will 2010 This study was not included as no pancreatic mass was present in the patient(s) tested
Williams 1999 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wilson 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Winner 2015 There was no comparison of whether cancer was present or not
Wittmann 2006 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
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during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Woolf 2013 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wright 2014 There was no comparison of whether cancer was present or not
Wu 2007a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wu 2007b This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Wu 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Wu 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Wyse 2009 This study was not included as no pancreatic mass was present in the patient(s) tested
Xiao 2009 There was no comparison of whether cancer was present or not
Xu 2012 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Xu 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Xu 2014 There was no comparison of whether cancer was present or not
Yamada 2010a There was no comparison of whether cancer was present or not
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Yamada 2010b This study was not included as no pancreatic mass was present in the patient(s) tested
Yamaguchi 1990 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yamao 2003 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yamashita 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yan 2014 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Yang 2014 There was no comparison of whether cancer was present or not
Yang 2015a This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yang 2015b Inadequate reference standards
Yantiss 2008 There was no comparison of whether cancer was present or not
Yao 2012 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Yeh 1999 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
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Yim 2005 There was no comparison of whether cancer was present or not
Yin 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yin 2015 Inadequate reference standards
Ylagan 2002 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yoshioka 2015 There was no comparison of whether cancer was present or not
Yuan 2007 There was no comparison of whether cancer was present or not
Yun 2007 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Yusuf 2009 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Zamboni 2012 This study was not included as no pancreatic mass was present in the patient(s) tested
Zaruba 2013 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
Zdanyte 2004 There was no comparison of whether cancer was present or not
Zeiderman 1991 This study did not use an index test such as CT, MRI, PET, EUS-FNA, and EUS elastography
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Zhang 2010a There was no comparison of whether cancer was present or not
Zhang 2010b This study was not included as no pancreatic mass was present in the patient(s) tested
Zhang 2010c This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Zhang 2010d There was no comparison of whether cancer was present or not
Zhang 2011 Diagnostic accuracy data were not available for this study.We classed any of the following as acceptable
forms of data: (2 x 2 table OR sensitivity + specificity + number with and without disease OR positive
+ negative predictive values + number of positive and negative tests) OR total test positive + total test
negative + total disease positive + total disease present + total disease absent + accuracy percentage
Zhang 2012 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Zhang 2015 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Zhong 2012 There was no comparison of whether cancer was present or not
Zhu 2008 There was no comparison of whether cancer was present or not
Zhu 2013 This study was not included as no pancreatic mass was present in the patient(s) tested
Ziak 2011 There was no comparison of whether cancer was present or not
Zimny 1997 This study was not included as no pancreatic mass was present in the patient(s) tested
Zimny 1998 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
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patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Zimny 1999 The study was not classed as primary research (i.e. not a review or editorial or comment)
Zubarik 2004 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
Zyrek-Betts 2008 This study included an inadequate reference standard. Our criteria for a reference standard included
the following: all surgery, or with negative follow-up of at least 6 months; if EUS-FNA or other
imaging modalities used for reference standard (either positive or negative), not accepted unless all
patients (positive and negative) were followed up for at least 6 months. Clear evidence of metastases
during follow-up in patients with positive diagnosis (an increase in size is not sufficient). Biopsy (but
not EUS-FNA cytology) is acceptable for positive results (< 6 months) but not for negative results - if
negative, patients must have been followed for at least 6 months
CT: computed tomography
EUS: endoscopic ultrasound
FNA: fine-needle aspiration
MRI: magnetic resonance imaging
PET: positron emission tomography
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Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Cancerous versus benign or
precancerous - EUS-FNA
(cytology)
1 45
2 Cancerous versus benign or
precancerous - EUS-FNA
(CEA > 500 ng/mL)
1 24
3 Cancerous versus benign or
precancerous - PET
1 76
4 Cancerous versus benign - EUS 2 133
5 Cancerous versus benign -
EUS-FNA
3 147
6 Cancerous versus benign - PET 3 99
7 Cancerous versus benign - PET
(SUVmax > 3.5)
1 80
8 Cancerous versus benign - CT 2 123
9 Cancerous versus benign - MRI 1 29
10 Precancerous or cancerous
versus benign - EUS
1 34
11 Precancerous or cancerous
versus benign - EUS-FNA
3 52
12 Precancerous or cancerous
versus benign - EUS-FNA
(CEA > 50 ng/mL)
1 11
13 Precancerous or cancerous
versus benign - PET (SUVmax
> 2.4)
1 32
14 Precancerous or cancerous
versus benign - CT
1 48
15 Precancerous or cancerous
versus benign - MRI
1 27
16 Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
- EUS
5 156
17 Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
- EUS-FNA
3 158
18 Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
- EUS-FNA (CEA > 200
ng/mL)
1 41
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19 Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
- CT
6 326
20 Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
- MRI
1 32
21 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
EUS
4 196
22 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
EUS-FNA
3 310
23 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
EUS-FNA (CEA > 200 ng/mL)
3 160
24 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
EUS-FNA (CA 19-9 > 1000
U/mL)
1 41
25 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia)
- EUS-FNA (CEA > 692.8
ng/mL)
1 20
26 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
PET (SUVmax 2 to 2.5)
4 124
27 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
CT
3 139
28 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia) -
MRI
3 189
29 Cancerous (invasive carcinoma)
versus precancerous (low-grade
dysplasia) - EUS
1 51
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30 Cancerous (invasive carcinoma)
versus precancerous (low-grade
dysplasia) - CT
1 46
31 Precancerous or cancerous
(intermediate- or high-grade
dysplasia or invasive carcinoma)
versus precancerous (low-grade
dysplasia) - CT
3 106
32 Precancerous or cancerous
(intermediate- or high-grade
dysplasia or invasive carcinoma)
versus precancerous (low-grade
dysplasia) - MRI
2 71
33 Cancerous (high-grade
dysplasia or invasive carcinoma)
versus precancerous (low- or
intermediate-grade dysplasia)
or benign - EUS
1 70
34 Cystic lesion subgroup analysis
- Cancerous versus benign -
EUS-FNA
1 26
35 Cystic lesion subgroup analysis
- Cancerous versus benign -
PET
1 80
36 Cystic lesion subgroup analysis
- Precancerous or cancerous
versus benign - EUS-FNA
2 34
Test 1. Cancerous versus benign or precancerous - EUS-FNA (cytology).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 1 Cancerous versus benign or precancerous - EUS-FNA (cytology)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McHenry 2002 19 0 5 21 0.79 [ 0.58, 0.93 ] 1.00 [ 0.84, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Cancerous versus benign or precancerous - EUS-FNA (CEA > 500 ng/mL).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 2 Cancerous versus benign or precancerous - EUS-FNA (CEA > 500 ng/mL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kalha 2003 14 6 1 3 0.93 [ 0.68, 1.00 ] 0.33 [ 0.07, 0.70 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Cancerous versus benign or precancerous - PET.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 3 Cancerous versus benign or precancerous - PET
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jafarimehr 2010 46 2 8 20 0.85 [ 0.73, 0.93 ] 0.91 [ 0.71, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Cancerous versus benign - EUS.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 4 Cancerous versus benign - EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brand 2000 77 16 4 18 0.95 [ 0.88, 0.99 ] 0.53 [ 0.35, 0.70 ]
Harrison 1999 15 1 1 1 0.94 [ 0.70, 1.00 ] 0.50 [ 0.01, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Cancerous versus benign - EUS-FNA.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 5 Cancerous versus benign - EUS-FNA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brandwein 2001 - Cystic 3 0 3 20 0.50 [ 0.12, 0.88 ] 1.00 [ 0.83, 1.00 ]
Brandwein 2001 - Solid 22 0 15 6 0.59 [ 0.42, 0.75 ] 1.00 [ 0.54, 1.00 ]
Cherian 2010 65 0 2 11 0.97 [ 0.90, 1.00 ] 1.00 [ 0.72, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Cancerous versus benign - PET.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 6 Cancerous versus benign - PET
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Erkan 2012 30 4 3 4 0.91 [ 0.76, 0.98 ] 0.50 [ 0.16, 0.84 ]
Higashi 1997 26 2 2 4 0.93 [ 0.76, 0.99 ] 0.67 [ 0.22, 0.96 ]
Kato 1995 14 2 1 7 0.93 [ 0.68, 1.00 ] 0.78 [ 0.40, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Cancerous versus benign - PET (SUVmax > 3.5).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 7 Cancerous versus benign - PET (SUVmax > 3.5)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hu 2013 52 10 2 16 0.96 [ 0.87, 1.00 ] 0.62 [ 0.41, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Cancerous versus benign - CT.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 8 Cancerous versus benign - CT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Grieser 2010 70 7 0 28 1.00 [ 0.95, 1.00 ] 0.80 [ 0.63, 0.92 ]
Harrison 1999 8 2 8 0 0.50 [ 0.25, 0.75 ] 0.0 [ 0.0, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Cancerous versus benign - MRI.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 9 Cancerous versus benign - MRI
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Klau 2011 16 1 4 8 0.80 [ 0.56, 0.94 ] 0.89 [ 0.52, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. Precancerous or cancerous versus benign - EUS.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 10 Precancerous or cancerous versus benign - EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sedlack 2002 22 4 2 6 0.92 [ 0.73, 0.99 ] 0.60 [ 0.26, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. Precancerous or cancerous versus benign - EUS-FNA.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 11 Precancerous or cancerous versus benign - EUS-FNA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fischer 2009 - Cystic 7 1 5 4 0.58 [ 0.28, 0.85 ] 0.80 [ 0.28, 0.99 ]
Fischer 2009 - Solid 12 1 0 4 1.00 [ 0.74, 1.00 ] 0.80 [ 0.28, 0.99 ]
Sedlack 2002 3 0 8 7 0.27 [ 0.06, 0.61 ] 1.00 [ 0.59, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 12. Precancerous or cancerous versus benign - EUS-FNA (CEA > 50 ng/mL).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 12 Precancerous or cancerous versus benign - EUS-FNA (CEA > 50 ng/mL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sedlack 2002 2 3 5 1 0.29 [ 0.04, 0.71 ] 0.25 [ 0.01, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. Precancerous or cancerous versus benign - PET (SUVmax > 2.4).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 13 Precancerous or cancerous versus benign - PET (SUVmax > 2.4)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Otomi 2014 17 1 1 13 0.94 [ 0.73, 1.00 ] 0.93 [ 0.66, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Precancerous or cancerous versus benign - CT.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 14 Precancerous or cancerous versus benign - CT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fisher 2008 21 5 13 9 0.62 [ 0.44, 0.78 ] 0.64 [ 0.35, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 15. Precancerous or cancerous versus benign - MRI.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 15 Precancerous or cancerous versus benign - MRI
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jang 2014a 13 2 1 11 0.93 [ 0.66, 1.00 ] 0.85 [ 0.55, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 16 Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cellier 1998 7 3 2 9 0.78 [ 0.40, 0.97 ] 0.75 [ 0.43, 0.95 ]
de Jong 2012 2 2 2 26 0.50 [ 0.07, 0.93 ] 0.93 [ 0.76, 0.99 ]
Nakagawa 2009 17 4 4 9 0.81 [ 0.58, 0.95 ] 0.69 [ 0.39, 0.91 ]
Yamao 2001 6 1 5 36 0.55 [ 0.23, 0.83 ] 0.97 [ 0.86, 1.00 ]
Zhan 2011 12 0 0 9 1.00 [ 0.74, 1.00 ] 1.00 [ 0.66, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 17. Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS-FNA.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 17 Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS-FNA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jin 2015 3 5 10 58 0.23 [ 0.05, 0.54 ] 0.92 [ 0.82, 0.97 ]
Pais 2007 16 5 5 48 0.76 [ 0.53, 0.92 ] 0.91 [ 0.79, 0.97 ]
Salla 2007 3 0 0 5 1.00 [ 0.29, 1.00 ] 1.00 [ 0.48, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS-FNA (CEA > 200 ng/mL).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 18 Cancerous (invasive carcinoma) versus precancerous (dysplasia) - EUS-FNA (CEA > 200 ng/mL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maire 2008 5 13 0 23 1.00 [ 0.48, 1.00 ] 0.64 [ 0.46, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 19. Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 19 Cancerous (invasive carcinoma) versus precancerous (dysplasia) - CT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cellier 1998 9 2 4 10 0.69 [ 0.39, 0.91 ] 0.83 [ 0.52, 0.98 ]
Nakagawa 2009 14 3 7 10 0.67 [ 0.43, 0.85 ] 0.77 [ 0.46, 0.95 ]
Nara 2009 25 4 6 88 0.81 [ 0.63, 0.93 ] 0.96 [ 0.89, 0.99 ]
Ogawa 2008 18 5 2 36 0.90 [ 0.68, 0.99 ] 0.88 [ 0.74, 0.96 ]
Taouli 2000 7 2 2 24 0.78 [ 0.40, 0.97 ] 0.92 [ 0.75, 0.99 ]
Yamao 2001 4 0 8 36 0.33 [ 0.10, 0.65 ] 1.00 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 20. Cancerous (invasive carcinoma) versus precancerous (dysplasia) - MRI.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 20 Cancerous (invasive carcinoma) versus precancerous (dysplasia) - MRI
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
de Jong 2012 3 2 1 26 0.75 [ 0.19, 0.99 ] 0.93 [ 0.76, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 21. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - EUS.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 21 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Doi 2002 14 2 3 9 0.82 [ 0.57, 0.96 ] 0.82 [ 0.48, 0.98 ]
Kobayashi 2012 8 2 1 25 0.89 [ 0.52, 1.00 ] 0.93 [ 0.76, 0.99 ]
Lee 2014 12 4 4 64 0.75 [ 0.48, 0.93 ] 0.94 [ 0.86, 0.98 ]
Yamao 2001 37 2 4 5 0.90 [ 0.77, 0.97 ] 0.71 [ 0.29, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - EUS-FNA.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 22 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - EUS-FNA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jin 2013a 15 31 21 96 0.42 [ 0.26, 0.59 ] 0.76 [ 0.67, 0.83 ]
Smith 2016 14 5 15 93 0.48 [ 0.29, 0.67 ] 0.95 [ 0.88, 0.98 ]
Zhan 2013 6 0 4 10 0.60 [ 0.26, 0.88 ] 1.00 [ 0.69, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - EUS-FNA (CEA > 200 ng/mL).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 23 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - EUS-FNA (CEA > 200 ng/mL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Correa-Gallego 2009 8 33 9 22 0.47 [ 0.23, 0.72 ] 0.40 [ 0.27, 0.54 ]
Kucera 2012 11 15 10 11 0.52 [ 0.30, 0.74 ] 0.42 [ 0.23, 0.63 ]
Maire 2008 9 9 1 22 0.90 [ 0.55, 1.00 ] 0.71 [ 0.52, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - EUS-FNA (CA 19-9 > 1000 U/mL).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 24 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - EUS-FNA (CA 19-9 > 1000 U/mL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maire 2008 9 18 1 13 0.90 [ 0.55, 1.00 ] 0.42 [ 0.25, 0.61 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 25. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - EUS-FNA (CEA > 692.8 ng/mL).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 25 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - EUS-FNA (CEA > 692.8 ng/mL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zhan 2013 8 1 2 9 0.80 [ 0.44, 0.97 ] 0.90 [ 0.55, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - PET (SUVmax 2 to 2.5).
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 26 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - PET (SUVmax 2 to 2.5)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hong 2010 16 2 0 13 1.00 [ 0.79, 1.00 ] 0.87 [ 0.60, 0.98 ]
Saito 2013 28 1 4 15 0.88 [ 0.71, 0.96 ] 0.94 [ 0.70, 1.00 ]
Takanami 2011 7 0 2 7 0.78 [ 0.40, 0.97 ] 1.00 [ 0.59, 1.00 ]
Tomimaru 2010 13 0 1 15 0.93 [ 0.66, 1.00 ] 1.00 [ 0.78, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 27. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - CT.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 27 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - CT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hong 2010 15 6 1 9 0.94 [ 0.70, 1.00 ] 0.60 [ 0.32, 0.84 ]
Le Baleur 2011a 10 1 0 49 1.00 [ 0.69, 1.00 ] 0.98 [ 0.89, 1.00 ]
Yamao 2001 15 0 27 6 0.36 [ 0.22, 0.52 ] 1.00 [ 0.54, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 28. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) - MRI.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 28 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) - MRI
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jang 2014b 15 7 4 35 0.79 [ 0.54, 0.94 ] 0.83 [ 0.69, 0.93 ]
Kim 2015 26 2 16 49 0.62 [ 0.46, 0.76 ] 0.96 [ 0.87, 1.00 ]
Ogawa 2014 16 0 6 13 0.73 [ 0.50, 0.89 ] 1.00 [ 0.75, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 29. Cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia) - EUS.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 29 Cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia) - EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kubo 2001 10 4 3 34 0.77 [ 0.46, 0.95 ] 0.89 [ 0.75, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. Cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia) - CT.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 30 Cancerous (invasive carcinoma) versus precancerous (low-grade dysplasia) - CT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Takeshita 2008 4 2 4 36 0.50 [ 0.16, 0.84 ] 0.95 [ 0.82, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) versus
precancerous (low-grade dysplasia) - CT.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 31 Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) versus precancerous (low-grade dysplasia) - CT
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ogawa 2008 29 5 6 21 0.83 [ 0.66, 0.93 ] 0.81 [ 0.61, 0.93 ]
Sahani 2006 12 1 5 7 0.71 [ 0.44, 0.90 ] 0.88 [ 0.47, 1.00 ]
Tan 2009 12 1 0 7 1.00 [ 0.74, 1.00 ] 0.88 [ 0.47, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 32. Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) versus
precancerous (low-grade dysplasia) - MRI.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 32 Precancerous or cancerous (intermediate- or high-grade dysplasia or invasive carcinoma) versus precancerous (low-grade dysplasia) - MRI
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Choi 2003 23 4 4 15 0.85 [ 0.66, 0.96 ] 0.79 [ 0.54, 0.94 ]
Sahani 2006 12 1 5 7 0.71 [ 0.44, 0.90 ] 0.88 [ 0.47, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 33. Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-
grade dysplasia) or benign - EUS.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 33 Cancerous (high-grade dysplasia or invasive carcinoma) versus precancerous (low- or intermediate-grade dysplasia) or benign - EUS
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kamata 2016a 29 24 1 16 0.97 [ 0.83, 1.00 ] 0.40 [ 0.25, 0.57 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. Cystic lesion subgroup analysis - Cancerous versus benign - EUS-FNA.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 34 Cystic lesion subgroup analysis - Cancerous versus benign - EUS-FNA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brandwein 2001 - Cystic 3 0 3 20 0.50 [ 0.12, 0.88 ] 1.00 [ 0.83, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Cystic lesion subgroup analysis - Cancerous versus benign - PET.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 35 Cystic lesion subgroup analysis - Cancerous versus benign - PET
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hu 2013 52 10 2 16 0.96 [ 0.87, 1.00 ] 0.62 [ 0.41, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. Cystic lesion subgroup analysis - Precancerous or cancerous versus benign - EUS-FNA.
Review: Imaging modalities for characterising focal pancreatic lesions
Test: 36 Cystic lesion subgroup analysis - Precancerous or cancerous versus benign - EUS-FNA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fischer 2009 - Cystic 7 0 5 4 0.58 [ 0.28, 0.85 ] 1.00 [ 0.40, 1.00 ]
Sedlack 2002 3 0 8 7 0.27 [ 0.06, 0.61 ] 1.00 [ 0.59, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. QUADAS-2 classification
Domain Signalling
question
Signalling
question
Signalling
question
Risk of bias Concerns for
applicability
1: Patient
sampling
Was a consecutive or
random sample of
patients enrolled?
Was a case-control
design avoided?
Did the study avoid
inappropriate exclu-
sions?
Could the selection
of participants have
introduced bias?
Are there concerns
that the included
participants and set-
ting do not match
the review question?
Yes: all consecutive
patients or random
sample of patients
with focal pancre-
atic lesions were en-
rolled
No: selected pa-
tients were enrolled
Unclear: this was
not clear from the
report
Yes: case-control de-
sign was avoided
No: case-control de-
signwas not avoided
Unclear: this was
not clear from the
report
Yes: the
study avoided inap-
propriate exclusions
(i.e. difficult-to-di-
agnose patients)
No: the study ex-
cluded patients in-
appropriately
Unclear: this was
not clear from the
report
Low risk: ’yes’ for all
signalling questions
High risk: ’no’ or
’unclear’ for at least
1 signalling ques-
tion
Low concern: the
selected participants
represent the pa-
tients in whom the
tests will be used
in clinical practice
(please see diagnos-
tic pathway (Figure
1))
High concern: there
is high concern that
participant selection
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Table 1. QUADAS-2 classification (Continued)
was performed in
such a way that
the included partic-
ipants did not repre-
sent the patients in
whom the tests will
be used in clinical
practice
2: Index test(s) Were
the index test results
interpreted without
knowledge of the re-
sults of the reference
standard?
If a threshold was
used, was it prespec-
ified?
- Could the conduct
or interpretation of
the index test have
introduced bias?
Are there
concerns that the in-
dex test, its conduct,
or its interpretation
differ from the re-
view question?
Yes: in-
dex test results were
interpreted without
knowledge of the re-
sults of the reference
standard
No: index test re-
sults were inter-
preted with knowl-
edge of the results of
the reference stan-
dard
Unclear: this was
not clear from the
report
Yes: if the criteria for
a positive test were
prespecified
No: if the criteria for
a positive test were
not prespecified
Unclear: this was
not clear from the
report
- Low risk: ’yes’ for all
signalling questions
High risk: ’no’ or
’unclear’ for at least
1 of the 2 signalling
questions
High concern: there
is high concern that
the conduct or in-
terpretation of the
index test differs
from the way it is
likely to be used in
clinical practice
Low concern: there
is low concern that
the conduct or in-
terpretation of the
index test differs
from the way it is
likely to be used in
clinical practice
3: Target condition
and reference stan-
dard(s)
Is the reference stan-
dard likely to classify
the target condition
correctly?
Were the reference
standard results in-
terpreted
without knowledge
of the results of the
index tests?
- Could the reference
standard, its con-
duct, or its inter-
pretation have in-
troduced bias?
Are there concerns
that the target con-
dition as defined by
the reference stan-
dard does not match
the review question?
Yes: histopathologi-
cal examination of
the entire lesion by
surgical resection
No: histopathologi-
cal examination (ir-
respec-
tive of how the tis-
sues were obtained
- Low risk: ’yes’ for all
signalling questions
High risk: ’no’ or
’unclear’ for at least
1 of the 2 signalling
questions
Low con-
cern: histopatholog-
ical examination of
the entire lesion by
surgical resection
High con-
cern: histopatholog-
ical examination (ir-
respec-
-
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Table 1. QUADAS-2 classification (Continued)
for histopathologi-
cal examination) in
patients with posi-
tive test (for cancer-
ous or precancerous
lesions) and clinical
follow-up by a doc-
tor (with or with-
out sequential fol-
low-up with imag-
ing) of all patients
with negative test
for a period of at
least 6 months and
for a maximum pe-
riod of 24 months
Unclear: this was
not clear from the
report. Such studies
will be excluded
Yes: reference stan-
dard results were
interpreted without
knowledge of the re-
sults of the index
test
No: reference stan-
dard results were in-
ter-
preted with knowl-
edge of the results of
the index test
Unclear: this was
not clear from the
report
tive of how the tis-
sues were obtained
for histopathologi-
cal examination) in
patients with posi-
tive test (for cancer-
ous or precancerous
lesions) and clinical
follow-up by a doc-
tor (with or with-
out sequential fol-
low-up with imag-
ing) of all patients
with negative test
for a period of at
least 6 months and
for a maximum pe-
riod of 24 months
4: Flow and timing Was there an appro-
priate interval be-
tween index test and
reference standard?
Did all patients re-
ceive the same refer-
ence standard?
Were all patients in-
cluded in the analy-
sis?
Could the
patient flow have in-
troduced bias?
-
Yes:
histopatho-
logical examination
of the entire le-
sion (gold standard)
- performed within
2 months (chosen
arbitrarily)
Yes: histopathologi-
cal examination of
the entire lesion by
surgical resection
No: histopathologi-
cal examination (ir-
respec-
tive of how the tis-
Yes:
all patients meet-
ing the selection cri-
teria (selected par-
ticipants) were in-
cluded in the anal-
ysis, or data on all
of the selected par-
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Table 1. QUADAS-2 classification (Continued)
Histopatho-
logical examination
(irrespective of how
the tissues were ob-
tained
for histopathologi-
cal examination) in
patients with posi-
tive test (for cancer-
ous or precancerous
lesions) performed
within 2 months
and clinical follow-
up (including se-
quential follow-up
with imaging) of all
patients with nega-
tive test for a period
of at least 6 months
No:
the histopathologi-
cal examination was
performed beyond 2
months of the index
tests
The clinical follow-
up (including se-
quential follow-up
imaging) was per-
formed less than 6
months after the
index test, because
some tumours may
be slow-growing
Unclear: this was
not clear from the
report
sues were obtained
for histopathologi-
cal examination) in
patients with posi-
tive test (for cancer-
ous or precancerous
lesions) and clinical
follow-up by a doc-
tor (with or with-
out sequential fol-
low-up with imag-
ing) of all patients
with negative test
for a period of at
least 6 months and
for a maximum pe-
riod of 24 months
Unclear: this was
not clear from the
report. Such studies
will be excluded
ticipants were avail-
able so that a 2
x 2 table including
all selected partici-
pants could be con-
structed
No: not all patients
meeting the selec-
tion criteria were in-
cluded in the analy-
sis, or the 2 x 2 table
could not be con-
structed using data
on all selected par-
ticipants
Unclear: this was
not clear from the
report
Table 2. Summary sensitivity and specificity of different tests for different target conditions
Comparison Name of test Sensitivity Specificity
Cancerous versus benignor pre-
cancerous
EUS-FNA
(cytology)
0.79 (95% CI 0.60 to 0.91) 1.00 (95% CI 0.85 to 1.00)
Cancerous versus benignor pre-
cancerous
EUS-FNA
(CEA > 500 ng/mL)
0.93 (95% CI 0.70 to 0.99) 0.33 (95% CI 0.12 to 0.65)
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Table 2. Summary sensitivity and specificity of different tests for different target conditions (Continued)
Cancerous versus benignor pre-
cancerous
PET
(criteria unspecified)
0.85 (95% CI 0.73 to 0.92) 0.91 (95% CI 0.72 to 0.97)
Cancerous versus benign EUS 0.95 (95% CI 0.84 to 0.99) 0.53 (95% CI 0.31 to 0.74)
Cancerous versus benign EUS-FNA
(cytology)
0.79 (95% CI 0.07 to 1.00) 1.00 (95% CI 0.91 to 1.00)
Cancerous versus benign PET (criteria unspecified) 0.92 (95% CI 0.80 to 0.97) 0.65 (95% CI 0.39 to 0.85)
Cancerous versus benign PET (SUVmax > 3.5) 0.96 (95% CI 0.87 to 0.99) 0.62 (95% CI 0.43 to 0.78)
Cancerous versus benign CT 0.98 (95% CI 0.00 to 1.00) 0.76 (95% CI 0.02 to 1.00)
Cancerous versus benign MRI 0.80 (95% CI 0.58 to 0.92) 0.89 (95% CI 0.57 to 0.98)
Precancerous or cancerous ver-
sus benign
EUS 0.92 (95% CI 0.74 to 0.98) 0.60 (95% CI 0.31 to 0.83)
Precancerous or cancerous ver-
sus benign
EUS-FNA (cytology) 0.73 (95% CI 0.01 to 1.00) 0.94 (95% CI 0.15 to 1.00)
Precancerous or cancerous ver-
sus benign
EUS-FNA
(CEA > 50 ng/mL)
0.29 (95% CI 0.08 to 0.64) 0.25 (95% CI 0.05 to 0.70)
Precancerous or cancerous ver-
sus benign
PET
(SUVmax 2.4)
0.94 (95% CI 0.74 to 0.99) 0.93 (95% CI 0.69 to 0.99)
Precancerous or cancerous ver-
sus benign
CT 0.62 (95% CI 0.45 to 0.76) 0.64 (95% CI 0.39 to 0.84)
Precancerous or cancerous ver-
sus benign
MRI 0.93 (95% CI 0.69 to 0.99) 0.85 (95% CI 0.58 to 0.96)
Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
EUS 0.78 (95% CI 0.45 to 0.94) 0.91 (95% CI 0.61 to 0.98)
Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
EUS-FNA
(cytology)
0.66 (95% CI 0.03 to 0.99) 0.92 (95% CI 0.73 to 0.98)
Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
EUS-FNA
(CEA > 200 ng/mL)
1.00 (95% CI 0.57 to 1.00) 0.64 (95% CI 0.48 to 0.78)
Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
CT 0.72 (95% CI 0.50 to 0.87) 0.92 (95% CI 0.81 to 0.97)
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Table 2. Summary sensitivity and specificity of different tests for different target conditions (Continued)
Cancerous (invasive carcinoma)
versus precancerous (dysplasia)
MRI 0.75 (95% CI 0.30 to 0.95) 0.93 (95% CI 0.77 to 0.98)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
EUS 0.86 (95% CI 0.74 to 0.92) 0.91 (95% CI 0.83 to 0.96)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
EUS-FNA
(cytology)
0.47 (95% CI 0.24 to 0.70) 0.91 (95% CI 0.32 to 1.00)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
EUS-FNA
(CEA > 200 ng/mL)
0.58 (95% CI 0.28 to 0.83) 0.51 (95% CI 0.19 to 0.81)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
EUS-FNA
(CA 19-9 > 1000 U/mL)
0.90 (95% CI 0.60 to 0.98) 0.42 (95% CI 0.26 to 0.59)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
EUS-FNA
(CEA > 692.8 ng/mL)
0.80 (95% CI 0.49 to 0.94) 0.90 (95% CI 0.60 to 0.98)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
PET
(SUVmax > 2 to 2.5)
0.90 (95% CI 0.79 to 0.96) 0.94 (95% CI 0.81 to 0.99)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
CT 0.87 (95% CI 0.00 to 1.00) 0.96 (95% CI 0.00 to 1.00)
Cancerous (high-grade dyspla-
sia or invasive carcinoma) ver-
sus precancerous (low- or inter-
mediate-grade dysplasia)
MRI 0.69 (95% CI 0.44 to 0.86) 0.93 (95% CI 0.43 to 1.00)
Cancerous (invasive carcinoma)
versus precancerous (low-grade
dysplasia)
EUS 0.77 (95% CI 0.50 to 0.92) 0.89 (95% CI 0.76 to 0.96)
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Table 2. Summary sensitivity and specificity of different tests for different target conditions (Continued)
Cancerous (invasive carcinoma)
versus precancerous (low-grade
dysplasia)
CT 0.50 (95% CI 0.22 to 0.78) 0.95 (95% CI 0.83 to 0.99)
Precancerous or cancerous (in-
termediate- or high-grade dys-
plasia or invasive carcinoma)
versus precancerous (low-grade
dysplasia)
CT 0.83 (95% CI 0.68 to 0.92) 0.83 (95% CI 0.64 to 0.93)
Precancerous or cancerous (in-
termediate- or high-grade dys-
plasia or invasive carcinoma)
versus precancerous (low-grade
dysplasia)
MRI 0.80 (95% CI 0.58 to 0.92) 0.81 (95% CI 0.53 to 0.95)
Precancerous or cancerous (in-
termediate- or high-grade dys-
plasia or invasive carcinoma)
versus precancerous (low-grade
dysplasia) or benign
EUS 0.97 (95% CI 0.83 to 0.99) 0.40 (95% CI 0.26 to 0.55)
Cystic lesion subgroup analysis Cancerous versus benign -
EUS-FNA (cytology)
0.50 (95% CI 0.19 to 0.81) 1.00 (95% CI 0.84 to 1.00)
Cystic lesion subgroup analysis Cancerous versus benign - PET
(SUVmax > 3.5)
0.96 (95% CI 0.87 to 0.99) 0.62 (95% CI 0.43 to 0.78)
Cystic lesion subgroup analysis Precancerous or cancerous ver-
sus benign - EUS-FNA
(cytology)
0.43 (95% CI 0.19 to 0.71) 1.00 (95% CI 0.74 to 1.00)
CA 19-9: carbohydrate antigen 19-9
CEA: carcinoembryonic antigen
CI: confidence interval
CT: computed tomography
EUS: endoscopic ultrasound
FNA: fine-needle aspiration
MRI: magnetic resonance imaging
PET: positron emission tomography
SUVmax: maximum standardised uptake values
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A P P E N D I C E S
Appendix 1. Glossary of terms
Ablation: destruction of tissue.
Adenocarcinoma: cancer arising from cells that secrete digestive enzymes (proteins that help with the breakdown of food into simple
substances that the gut can absorb).
Algorithm: order in which diagnostic tests are performed and actions taken depending upon the results of the tests (in this context).
Asymptomatic: not showing any signs of disease or illness.
Benign: non-cancerous (in this context).
Biomarkers: substances in an organism that indicate disease or illness.
Chemotherapy: medication used to treat or control cancer (in this context).
Contraindication: something that causes a specific treatment or procedure to be withheld because it would cause harm.
Cystic: related to an abnormal enclosed sac found within the body that is filled with a fluid or semifluid substance.
Cytology: the study of cells obtained from a tissue to determine whether the cell is cancerous (in this context).
Density: the measure of how compact something is (in this context).
Diffuse: spread out.
Disseminated: spread of cancer (in this context).
Dysplasia: abnormal growth or development of cell; precancerous (in this context).
Focal: characterised as being a specific or limited area of disease (in this context).
Gastrointestinal: related to the stomach and intestines.
Histological: examination of tissues under a microscope.
Histopathological: examination of tissues under a microscope to determine the changes related to a disease or illness.
Hormone: a chemical substance secreted by the body’s cells that acts on other cells of the body, stimulating them to perform their role
or suppressing the functions of the cells. Hormones are generally transported in the blood or other body fluids (e.g. stomach juice)
from the cell that secretes the hormones to the cell on which they act.
Immunocytochemistry: examination of tissues under a microscope using special stains that bind to specific types of cells or tissues.
Ionising radiation: radiation consisting of particles, X-rays, or gamma rays with sufficient energy to cause ionisation in the medium
through which it passes, thereby damaging cells (in this context).
Laparoscopy: a surgical procedure in which an instrument is inserted through a small incision in the abdomen to view the organs or
permit a surgical procedure using small instruments.
Lesions: abnormal changes in the structure of all or part of an organ due to disease (in this context).
Malignancies: cancers.
Metastases: the spread of cancer beyond its original source.
Modality: method.
Morphological: related to structure.
Mortality: death.
Peptic: related to stomach or the upper part of the intestine.
Percutaneous: performed through the skin.
Perioperative: around the time of surgery.
Prognosis: outcomes resulting from disease or illness or related to the treatment of disease or illness.
Proteomic: related to the study of proteins.
Radiological: related to X-rays or ultrasound.
Resection: removal of all or part of an organ.
Steatorrhoea: excessive fat in stools.
Surveillance: close observation.
Vascularity: the degree of vessels (tubes that carry blood in humans).
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Appendix 2. Cochrane search strategy
#1 (pancreas OR pancreatic)
#2 (CTOR tomodensitometry OR PETORMRI ORNMRIOR zeugmatogra* OR ((computed OR computerised OR computerized
OR emission OR positron OR magneti* OR MR OR NMR OR proton OR acoustic OR ARFI) AND (tomogra* OR scan OR
scans OR imaging)) OR endosonogra* OR EUS OR ((echogra* OR ultrason* OR ultrasound) AND endoscop*) OR elastogr* OR
sonoelastogr* OR acoustogra*)
#3 #1 AND #2
Appendix 3. MEDLINE search strategy
1. exp Pancreas/
2. exp Pancreatic Neoplasms/di [Diagnosis]
3. exp Pancreatitis, Chronic/di [Diagnosis]
4. exp Pancreatic Cyst/di [Diagnosis]
5. (pancreas or pancreatic).ti,ab.
6. 1 or 2 or 3 or 4 or 5
7. (sensitiv: or diagnos:).mp. or di.fs.
8. 6 and 7
9. (CT or tomodensitometry or PET or MRI or NMRI or zeugmatogra* or ((computed or computerised or computerized or emission
or positron or magneti* or MR or NMR or proton or acoustic or ARFI) and (tomogra* or scan or scans or imaging))).ti,ab.
10. exp Tomography, X-Ray Computed/ or Positron-Emission Tomography/ or exp Magnetic Resonance Imaging/
11. 9 or 10
12. exp Endosonography/
13. (endosonogra* or EUS).ti,ab.
14. 12 or 13
15. exp Ultrasonography/
16. (echogra* or ultrason* or ultrasound).ti,ab.
17. 15 or 16
18. exp Endoscopy, Gastrointestinal/
19. endoscop*.ti,ab.
20. 18 or 19
21. 17 and 20
22. 14 or 21
23. exp Elasticity Imaging Techniques/
24. (elastogr* or sonoelastogr* or acoustogra*).ti,ab.
25. 23 or 24
26. 11 or 22 or 25
27. 8 and 26
Appendix 4. Embase search strategy
1. exp pancreas/
2. exp pancreas tumor/di [Diagnosis]
3. exp chronic pancreatitis/di [Diagnosis]
4. exp pancreas cyst/di [Diagnosis]
5. (pancreas or pancreatic).ti,ab.
6. 1 or 2 or 3 or 4 or 5
7. sensitiv:.tw. or diagnostic accuracy.sh. or diagnostic.tw.
8. 6 and 7
9. (CT or tomodensitometry or PET or MRI or NMRI or zeugmatogra* or ((computed or computerised or computerized or emission
or positron or magneti* or MR or NMR or proton or acoustic or ARFI) and (tomogra* or scan or scans or imaging))).ti,ab.
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10. exp computer assisted tomography/ or positron emission tomography/ or exp nuclear magnetic resonance imaging/
11. 9 or 10
12. endoscopic echography/
13. (endosonogra* or EUS).ti,ab.
14. 12 or 13
15. exp ultrasound/
16. (echogra* or ultrason* or ultrasound).ti,ab.
17. 15 or 16
18. exp gastrointestinal endoscopy/
19. endoscop*.ti,ab.
20. 18 or 19
21. 17 and 20
22. 14 or 21
23. exp elastography/
24. (elastogr* or sonoelastogr* or acoustogra*).ti,ab.
25. 23 or 24
26. 11 or 22 or 25
27. 8 and 26
Appendix 5. Science Citation Index Expanded search strategy
#1 TS=(pancreas OR pancreatic)
#2 TS=(CT OR tomodensitometry OR PET OR MRI OR NMRI OR zeugmatogra* OR ((computed OR computerised OR com-
puterized OR emission OR positron OR magneti* OR MR OR NMR OR proton OR acoustic OR ARFI) AND (tomogra* OR scan
OR scans OR imaging)) OR endosonogra* OR EUS OR ((echogra* OR ultrason* OR ultrasound) AND endoscop*) OR elastogr*
OR sonoelastogr* OR acoustogra*)
#3 TS=(sensitiv* or “predictive value” or diagnostic or accuracy)
#4 #1 AND #2 AND #3
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. We have included sensitivity-maximising diagnostic filters for searching MEDLINE and Embase databases because the original
searches without the filters retrieved more than 50,000 references (Haynes 2004; Wilczynski 2005). We also made some
modifications to the search strategy because we needed to balance the possibility of missing some studies against the risk of not being
able to complete the review. We decided that it is useful to have evidence from major studies rather than having no information at all.
2. We did not search the Cochrane Register of Diagnostic Test Accuracy Studies, as we believe it is no longer maintained.
3. We have performed the related search function through MEDLINE (OvidSP) rather than MEDLINE (PubMed) and also
performed a cited reference search in MEDLINE (via OvidSP).
4. We have reworded the Statistical analysis and data synthesis section to bring this in line with our recent reviews. There were no
material differences to the plan of statistical analysis except that we also planned to perform a bivariate analysis, which takes into
account the correlation between sensitivity and specificity for tests with explicit thresholds as well. We did this because the summary
sensitivity and specificity (and hence the positive likelihood ratio and negative likelihood ratio from which the post-test probabilities
can be calculated) are available from the bivariate model.
5. We have simplified the analysis in the presence of sparse data based on the article by Takwoingi and colleagues (Takwoingi 2015).
6. We have presented the post-test probabilities only for the median prevalence in the comparison to avoid presenting readers with
an overwhelming amount of data.
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